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1 ABSTRACT 
Sorafenib represents the current standard of care for patients with advanced-stage hepatocellular 
carcinoma (HCC). Nonetheless, its use is hampered by the frequent occurrence of drug resistance 
and up to 80% of patients treated with sorafenib suffer from side effects necessitating dose reduction, 
“drug holidays” or treatment termination. This study aimed to extend the current knowledge on the 
mechanism of sorafenib resistance with focus on a potential relapse of tumor growth after sorafenib 
withdrawal. Tumor growth resumption essentially contributes to a poor therapy outcome of 
sorafenib, but to date there is no therapeutic strategy to address this problem.  
Herein, a robust sorafenib resistance HCC cell model was established and characterized by mass 
spectrometry (MS)-based proteomics and lipidomics, in order to reveal targets for a potential 
second-line therapy after sorafenib failure. The impact of continuous sorafenib exposure and drug 
withdrawal on cellular metabolism and mitochondrial functionality was then specified by glycolytic 
stress tests, high resolution respirometry and transmission electron microscopy (TEM).  
We found that acquired chemoresistance of HCC is accompanied by severe mitochondrial damage 
and impairment of the electron transport chain (ETC). These sorafenib-resistant cells, fail to maintain 
their cellular redox homeostasis and obtain broad chemotherapeutic cross-resistance. In fact, 
sorafenib withdrawal leads to a rapid resumption of tumor cell proliferation, while cells resensitize 
towards chemotherapeutic treatment. Upon this tumor “rebound” growth, regeneration of the 
mitochondrial integrity and a boost of oxidative phosphorylation were observed. Inhibition of 
mitochondrial biogenesis by bacterial translation-inhibiting antibiotics, such as tigecycline (TGC), 
decreases the renewal of critical ETC subunits and limits the regeneration of reducing equivalents. 
Thereby, TGC efficiently blocks the oxidative glutamine metabolism of the tricarboxylic acid (TCA) 
cycle, which fuels rapid tumor regrowth. Importantly, TGC prevents the therapy-limiting tumor 
relapse after sorafenib withdrawal in vitro and in ectopic murine HCC xenografts in vivo.  
Approved bacterial translation inhibiting antibiotics are generally characterized by favorable safety 
profiles with low incidence of adverse side-effects and good experience on dosing schedules, 
therefore holding tremendous promise for clinical translation. With regard to the clinical potential of 
the approved antibiotic TGC, we present a novel promising second-line therapeutic approach for 
HCC patients with progressive disease during sorafenib therapy, but also for patients who need a 
treatment interruption due to severe adverse events. Our study encourages a clinical evaluation of 
TGC for a new designation in advanced-stage HCC, to prevent the tumor growth resumption after 
therapy termination and prolong the patient’s life expectancy after sorafenib failure. 
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2 INTRODUCTION 
2.1 Hepatocellular carcinoma (HCC) 
HCC ranks as the third leading cause of cancer-related mortality in the human population and the 
most common primary cancer of the liver (Njei et al., 2015; WHO, 2012). In addition, HCC is 
nowadays reported to be one of the fastest growing causes of death with increasing incidence in the 
western population and poses, especially in the United States (US), an underestimated economic 
burden on the healthcare system (Ghouri et al., 2017). The tumorigenesis of HCC comprises 
angiogenesis, chronic inflammation, as well as alterations in the tumor macro- and micro-
environment. Thereby, both the intrinsic genetic background and extrinsic risk factors, such as viral 
infections and the western lifestyle, have a decisive impact on the development of HCC. 
2.1.1 Epidemiology and etiology 
Since the 1970s, the epidemic of HCC has spread beyond Eastern Asia with a growing number of 
cases reported in the US, Canada and Western Europe (Ghouri et al., 2017). Thereby, the incidence 
has more than quadrupled from 1973 (1.51 cases/ 100.000 population) to 2011 (6.20 cases/ 
100.000 population). Thus, HCC emerged to be the fifth most abundant malignancy worldwide with 
745.000 reported deaths in 2012 (Njei et al., 2015). In high-risk countries, liver cancer can arise 
before the age of 20 years, whereas in countries at low risk, liver cancer is rare before the age of 
50 years, classifying liver cancer as one of the seven most common age-adjusted malignancies in the 
human population (WHO, 2012). In its worldwide distribution, rates of liver cancer in men 
(523,000 cases/year, 7.9% of all cancers) are typically two to three times higher than in women 
(226,000 cases/year, 6.5% of all cancers) (Parkin et al., 2005). Further, regional differences have 
been noted with more than 80% of HCC cases occurring in sub-Saharan Africa and in Eastern Asia 
(>20 cases/100.000 population). Mid-incidence levels are reported in Southern European countries 
(10-20 cases/100.000 population) and comparable few cases (<5 cases/ 100.000 population) are 
known in the United States, Canada, and in Scandinavia (Bosch et al., 2004; El-Serag, 2012). The 
pathogenesis of HCC varies based on the underlying etiological background with cirrhosis being the 
most common risk factor, as found in 80%-90% of patients. Cirrhosis is essentially promoted by 
infections with the hepatitis B (HBV) (contributes to 44% of all HCC cases) and hepatitis C virus 
(HCV) (contributes to 21% of all HCC cases), resulting in a 5-year cumulative risk of HCC 
development between 5% and 30%, depending on the incidence of further risk factors, region, 
ethnicity and the stage of cirrhosis (Baecker et al., 2018; El-Serag, 2012). Besides, the intoxication 
by alcohol and aflatoxins, metabolic disorders, the non-alcoholic fatty liver disease and 
immune-related disorders contribute to the rising numbers of cirrhosis and HCC development 
(Baecker et al., 2018; Bugianesi, 2007; Parikh and Hyman, 2007).   
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2.1.2 Current treatment strategies 
The development of new treatment strategies for HCC is a highly dynamic and research-intensive 
field since the approval of sorafenib in 2007. As a consequence of earlier diagnosis and a more 
frequent use of curative treatment modalities, the outcome for patients improved significantly. 
Remarkably, between 1975 and 2005 the 5-year survival trend in the US increased by more than 60% 
(Altekruse et al., 2009). In general, therapy allocation depends on variables known to impact 
prognosis including tumor burden, liver function, and the performance status (PS) of the patient.  
2.1.2.1 The Barcelona Clinic Liver Cancer (BCLC) staging system 
Staging is of high importance in the management of HCC, in order to apply the best individual 
treatment strategy. For this purpose, the Barcelona Clinic Liver Cancer (BCLC) system is the most 
commonly used staging approach and has been widely accepted in clinical practice. The BCLC 
system determines the cancer stage and the patient’s prognosis alongside an established criteria 
catalog (Figure 1) (Bruix et al., 2016; Bruix, 2011; Llovet et al., 1999). Thereby, patients are 
classified into very early, early, intermediate, advanced, and terminal stage HCC, depending on the 
size and number of nodules (N), macrovascular invasion or extrahepatic spread by metastasis (M) 
and the outcome of the patient’s performance status test (PST) (Forner et al., 2010).  
 
Figure 1. The BCLC staging system for HCC. CLT, cadaveric liver transplantation; LDLT, living donor 
liver transplantation; M, metastasis classification; N, node classification; OS, overall survival; PEI, 
percutaneous ethanol injection; PST, performance status test; RF(A), radiofrequency (ablation); TACE, 
transarterial chemoembolization; *, Stage C with PST 1-2 and/ or vascular invasion/ extrahepatic spread. 
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Very early and early-stage patients (BCLC 0 or BCLC A) exhibit a solitary lesion or up to 3 nodules 
≤3 cm with preserved liver function. These patients can benefit from potentially curative therapies 
such as resection, transplantation and ablation (Bruix et al., 2016). Hepatic resection is often 
performed in non-cirrhotic patients, resulting in an overall low morbidity. However, strict screening 
for the presence of cirrhosis is required as cirrhosis potentiates the risk of post-operative 
complications and hepatic failure (Bismuth and Majno, 2000). Liver transplantation (CLT/ LDLT) 
eliminates HCC together with potential preexisting illnesses, providing the best outcome for patients, 
but is highly limited by the availability of organs (Schlachterman et al., 2015). For early stage 
patients, a comparable shorter recovery period can be achieved by minimally invasive percutaneous 
radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) (Schlachterman et al., 
2015). Patients with intermediate stage HCC (BCLC B) are free of symptoms, but have large, 
multifocal tumors, rendering them poor candidates for curative therapies. Among those, patients with 
preserved liver function can benefit from transarterial chemoembolization (TACE), a treatment 
modality that combines obstruction of the hepatic artery with embolizing particles and intraarterial 
injection of cytotoxic agents, such as doxorubicin or cisplatin (Bruix, 2011; Marelli et al., 2007; 
Schlachterman et al., 2015). However, most patients are still diagnosed with advanced-stage HCC 
(BCLC C) with tumors that have spread beyond the liver, vascular invasion and cancer-related 
symptoms (Bruix et al., 2016). They cannot benefit from curative therapies and are standardly treated 
with the multikinase inhibitor sorafenib. Patients with end stage HCC (BCLC D) have an impaired 
liver function and marked cancer-related symptoms (PST >2). Those patients have a poor prognosis 
and require palliative care (Forner et al., 2010). 
2.1.2.2 A glance on recent clinical trials 
Within the past decade, a large variety of therapeutic agents has been developed and tested in clinical 
trials aiming to increase efficiency or safety to the standard of care sorafenib (Table 1).  
2.1.2.2.1 Phase III trials on first-line alternatives to sorafenib 
Despite increasing mechanistic insights, phase III trials for advanced-stage HCC conducted with the 
alternative first-line agents sunitinib (Cheng et al., 2013), brivanib (Johnson et al., 2013) and linifanib 
(Cainap et al., 2015) were reported as negative and also combination therapies of sorafenib with 
erlotinib (Zhu et al., 2015b) and doxorubicin (Abou-Alfa et al., 2010) failed. Further, first-line 
minimal invasive approaches including hepatic arterial infusion chemotherapy (HAIC) (Kudo et al., 
2018b) as well as selective internal radiation therapy (SIRT) with yttrium-90 (90Y) resin microsphere 
radio-embolization were shown to be non-superior to sorafenib in the treatment of advanced-stage 
HCC (Chow et al., 2018; Vilgrain et al., 2017). The amount of negative first-line trials indicates a 
clear difficulty of newly developed agents to meet the predefined clinical study endpoints in terms 
of superiority to sorafenib in the overall survival (OS) of patients. Only a recent phase III first-line 
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trial of the multi‑targeted tyrosine kinase inhibitor lenvatinib (REFLECT) was announced positive, 
showing non-inferiority to sorafenib in the OS of advanced-stage HCC patients (Kudo et al., 2018a). 
Differences, however, occurred in the safety profile, as lenvatinib accompanied with a high incidence 
of hypertension, anorexia, and fatigue, whereas sorafenib predominantly caused hand-foot skin 
reaction (HFSR) (chapter 6.3.4.1). Further, immunotherapy evoked as a promising first-line 
alternative with ongoing phase III trials of tislelizumab, atezolizumab with bevacicumab 
(IMbrave150) and durvalumab with tremelimumab as mono- or combination-therapies (Raoul et al., 
2018). In 2019, preliminary study endpoints of the IMbrave150 trial indicated a promising outcome 
in terms of OS and accelerated approval of this drug combination was sought in 2020 (chapter 
6.3.4.1). To date, despite the numerous advents of new agents, sorafenib maintains its role as gold 
standard and remains favorable in the systemic first-line therapy of advanced-stage HCC with regard 
to the overall OS benefit and the good experience on the safety profile and dosing schedules.  
2.1.2.2.2 Phase III trials on second-line therapies after sorafenib failure 
Similar to the phase III trials on first-line alternatives to sorafenib, a number of trials have failed in 
the second-line setting. Among those, brivanib (Llovet et al., 2013), everolimus (Zhu et al., 2014), 
ramucimurab (Zhu et al., 2015a), a regional trial with S-1 (tegafur/gimeracil/oteracil) (Hsieh et al., 
2015), tivantinib (Rimassa et al., 2018) and the arginine depleting enzyme conjugate ADI-PEG 20 
(Abou-Alfa et al., 2018b) were non-beneficial to placebo. Importantly, in 2017 the agents regorafenib 
(Bruix et al., 2017) and nivolumab (Finkelmeier et al., 2018) have been approved for patients who 
progressed under sorafenib treatment. Regorafenib demonstrated a significantly improved OS from 
10.6 months compared to 7.8 months of the placebo group and an increase of the progression-free 
survival (PFS) and time to progression (TTP). However, due to its high structural similarity to 
sorafenib, a comparable toxicity profile was obtained with regorafenib. Therefore, unlike other 
studies, the RESOURCE trial investigated regorafenib solely in patients refractory but tolerant to 
sorafenib. The PD-1 targeting antibodies nivolumab and pembrolizumab received accelerated FDA 
approval as second-line therapies because of promising tumor response rates of phase I/II trials (El-
Khoueiry et al., 2017; Finkelmeier et al., 2018). However, phase III trials of both nivolumab and 
pembrolizumab failed to meet their predefined endpoints (Finn et al., 2020; Liu et al., 2019). More 
recently, also the small molecule cabozantinib (CELESTRIAL) reported improved OS, but the 
majority of patients of the cabozantinib-treated arm experienced severe adverse events necessitating 
treatment termination (Abou-Alfa et al., 2018a). Further, the therapeutic benefit of ramucirumab 
(anti-VEGFR-2) second-line to sorafenib is limited to patients with high alpha-fetoprotein (AFP) 
levels (≥ 400 ng/ml) as revealed by the REACH-2 phase III trial (Zhu et al., 2018b). Thus, despite 
the successful approval of regorafenib, cabozantinib, ramucirumab and the fast developing treatment 
landscape with new immunotherapeutic, an effective second-line therapy with reliable safety profile 
for sorafenib-intolerant patients remains an urgent need (see also: chapter 6.3.4.2).  
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Table 1. Phase III clinical trials of HCC targeting agent. 
BCLC staging  Clinical trial Status 
Early-stage 
(adjuvant) 
peretinoin vs. placebo (NIK-333) Negative 
sorafenib vs. placebo (STORM) Negative 
Intermediate-stage 
(Combination with 
TACE) 
sorafenib (Post TACE/ TACE2) Negative 
brivanib (BRISK-TA) Terminated 
orantinib (TSU-68) (ORIENTAL) Terminated 
Advanced-stage 
(first-line) 
 
sunitinib vs. sorafenib (SUN1170) Negative 
brivanib vs. sorafenib (BRISK-FL) Negative 
linifanib vs. sorafenib (LiGHT) Negative 
sorafenib + erlotinib vs. sorafenib (SEARCH) Negative 
sorafenib + doxorubicin vs. sorafenib (CALGB808028) Negative 
sorafenib ± HAIC (SILIUS) Negative 
lenvatinib vs. sorafenib (REFLECT) Positive 
SIRT vs. sorafenib (SARAH/ SIRveNIB/SORAMIC) Negative 
nivolumab vs. sorafenib (CheckMate-459) Negative 
tislelizumab vs. sorafenib (BGB-A317) Ongoing 
atezolizumab + bevacicumab vs. sorafenib (IMbrave150) Ongoing 
durvalumab + tremelimumab vs. sorafenib (HIMALAYA) Ongoing 
Advanced-stage 
(second-line) 
 
brivanib vs. placebo (BRISK-PS) Negative 
everolimus vs. placebo (EVOLVE-1) Negative 
ramucirumab vs. placebo (REACH/ REACH-2) Neg./ Pos. 
S-1 vs. placebo (S-CUBE) Negative 
tivantinib vs. placebo (METIV-HCC, JET-HCC) Negative 
regorafenib vs. placebo (RESOUCE) Positive 
cabozantinib vs. placebo (CELESTRIAL) Positive 
ADI-PEG 20 vs. placebo (ADI-PEG 20) Negative 
DT vs. placebo (ReLive) Negative 
 pembrolizumab vs. placebo (KEYNOTE-240) Negative 
*DT: doxorubicin loaded nanoparticels; HAIC, hepatic arterial infusion chemotherapy; Neg., negative; Pos., 
positive; SIRT, selective internal radiation therapy (table updated: 05/2020).  
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2.2 The multikinase inhibitor sorafenib 
To date, in highly developed countries 30% of HCC patients are diagnosed at initial stages when 
curative treatments can be optimally applied. But still, with 40% of all reported cases, most patients 
remain to be diagnosed with advanced-stage HCC (Bruix and Llovet, 2002). For those patients, 
curative treatment modalities have a poor outcome and medical interventions, such as resection, 
chemotherapy, RFA and TACE, show tumor recurrence with rapid progression, vascular invasion 
and multiple intrahepatic metastases. Thus, the 5-year relative survival of advanced-stage HCC 
patients amounts to only 7% (Bosch et al., 2004). As a consequence of the poor OS, big effort has 
been ongoing for many years to find new targeted therapies for advanced-stage HCC, finally leading 
to the development of the multikinase inhibitor sorafenib in 1990 (Daher et al., 2018).   
Table 2. Key efficacy results of the SHARP and AP phase III trials. 
Study SHARP trial AP trial 
Treatment sorafenib placebo sorafenib placebo 
Group size n = 299  n = 303 n = 150 n = 76 
Median OS (95% CI)* 10.7 (9.4–13.3) 7.9 (6.8–9.1) 6.5 (5.6–7. 6) 4.2 (3.8–5.6) 
P-value OS <0.001% 0.014% 
Median TTP (95% CI)* 5.5 (4.1–6.9) 2.8 (2.7–3.9) 2.8 (2.6–3.6) 1.4 (1.4–1.6) 
P-value TTP <0.001% 0.0005% 
*AP, Asia-Pacific; CI, confidence interval; SHARP, Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol; TTP, time to progression; median OS and TTP are shown in months (Raoul et al., 2018). 
In 2007, sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals–Onyx Pharmaceuticals) became the 
first worldwide approved systemic therapy and until today the standard of care first-line treatment 
for patients with unresectable HCC. Its approval was based on the phase III randomized placebo-
controlled SHARP (Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol) trial 
(Llovet et al., 2008) and a study conducted in the Asia-Pacific (AP) region (Cheng et al., 2009). 
Thereby, sorafenib achieved a significantly prolonged OS in both the SHARP and the AP phase III 
trial (Table 2). These results were confirmed later by the GIDEON (Global Investigation of 
therapeutic decisions in HCC and of its treatment with sorafenib) (Raoul et al., 2018), a prospective, 
open-label, cohort study, that evaluated sorafenib safety and HCC treatment practices in 3202 
patients across 39 countries (Lencioni et al., 2014; Marrero et al., 2016). 
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2.2.1 Mechanism of action 
Sorafenib is an orally administered multikinase inhibitor that exerts antiproliferative, antiangiogenic 
and proapoptotic effects. It inhibits the serine-threonine kinases Raf-1 and B-Raf, the receptor 
tyrosine kinase activity of the vascular endothelial growth factor receptors (VEGFRs) 1, 2, 3, the 
platelet-derived growth factor receptor-β (PDGFR-β), the FMS-like tyrosine kinase-3 (Flt-3), Ret 
and c-Kit (Chang et al., 2007; Wilhelm et al., 2004). The Raf proteins are integral components of the 
Ras/Raf/mitogen-activated protein kinase (MAPK)/extracellular signaling-regulated kinase (ERK) 
(RAF/MEK/ERK) signaling cascade. The MAPK/ERK pathway consists of three sequentially 
activated protein kinases, which promote cell proliferation and survival. In contrast, the sorafenib-
targeted tyrosine kinase receptors VEGFR and PDGFR are predominantly involved in angiogenesis, 
whereas Flt-3, Ret and c-Kit enhance tumorigenesis and therefore contribute to the broad-spectrum 
activity of sorafenib in several cancers (Cervello et al., 2012; Wilhelm et al., 2006). It has been 
demonstrated that sorafenib dose-dependently decreases the activation of the hypoxia-inducible 
factor-1α (HIF-1α) protein, playing a potential role in mediating its antiangiogenetic effect (Liu et 
al., 2012). In addition, sorafenib treatment associates with a reduced expression of the antiapoptotic 
myeloid cell leukemia 1 (Mcl-1) protein, which may increase the proapoptotic therapeutic efficacy 
in combination therapies with alternative chemotherapeutic compounds and signal transduction 
inhibitors (Wilhelm et al., 2004) (Figure 2).  
 
Figure 2. Mechanism of action and chemical structure of the multikinase inhibitor sorafenib. ERK, 
extracellular signaling-regulated kinase; Flt-3, FMS-like tyrosine kinase-3; ERK, extracellular signaling-
regulated kinase; HIF-1α, hypoxia-inducible factor-1α; MAPK, Ras/Raf/mitogen-activated protein kinase; 
Mcl-1, myeloid cell leukemia 1; MEK, MAPK-ERK kinase; PDGFR-β, platelet-derived growth factor 
receptor-β; VEGFR, vascular endothelial growth factor receptor. 
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2.2.2 Clinical limitations of sorafenib 
The use of sorafenib is hampered by the frequent occurrence of drug-related serious adverse events, 
as reported in around 80% of patients (Llovet et al., 2008). In addition, only 2% of patients obtain 
partial responses and many show tumor progression later on. Thus, sorafenib resistance essentially 
limits the OS and time to symptomatic progression of those patients (Zhai and Sun, 2013). 
2.2.2.1 Adverse events and dosing recommendations 
Sorafenib therapy is associated with severe side-effects, such as hand-foot skin reaction (HFSR), 
diarrhea, abdominal pain and weight loss, necessitating dose-reduction (26%), therapy interruptions 
(44%) or complete sorafenib retraction (38%) (Llovet et al., 2008). Notably, sorafenib-related 
adverse events have been identified as clinical biomarkers for sorafenib efficacy, rendering a 
persistent side-effect management inevitable (Raoul et al., 2018). In general, the treatment regimen 
of sorafenib is limited by its dose-dependent toxicity, with higher tolerance in longer treatment 
intervals, allowing dosing up to 600 mg twice daily in a 7 days on/7 days off study (Strumberg et al., 
2007). Nowadays, patients are standardly treated with the maximal tolerated dose of 400 mg 
sorafenib, twice daily on a continuous dosing-schedule (Al-Rajabi et al., 2015). However, drug levels 
were found to be insufficiently low in some patients, indicating the presence of intrinsic 
pharmacokinetic resistance, which results in approximately 50% interindividual variability in 
sorafenib exposure (Boudou-Rouquette et al., 2012; Strumberg et al., 2007). Inadequate target 
inhibition by underdosing, acquired sorafenib resistance and tumor growth resumption might be the 
consequence (Kuczynski et al., 2015). In addition, sorafenib plasma levels have been shown to 
significantly decline over time. These drug level changes might involve the induction of cytochrome 
P450 3A4 (CYP3A4) metabolism and can only be managed by long-term dosage adjustments, which 
limit the survival due to excessive body weight loss (Kuczynski et al., 2015). 
2.2.2.2 Acquired therapy resistance 
The genetic heterogeneity of HCC results in initial sorafenib resistance of some patients and has led 
to the identification of predictive biomarkers for therapy responsiveness, such as basal phospho-ERK 
-, JNK- and VEGF-A- levels (Zhu et al., 2017). To date, a variety of mechanisms accounting for the 
development of chemotherapeutic drug resistance have been described. They comprise 
compensatory pathway activation, epithelial-to-mesenchymal transition (EMT), disabling of pro-
apoptotic signaling and the establishment of an hypoxic environment (Zhai and Sun, 2013). 
However, the exact mechanism of acquired sorafenib resistance has not yet been fully elucidated. 
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2.2.2.2.1 Epithelial-to-mesenchymal transition (EMT)  
EMT is a highly conserved developmental process that governs morphogenesis and cell migration in 
multicellular organisms. However, in tumorigenesis, EMT contributes to dedifferentiation and gives 
rise to the dissemination of single carcinoma cells from the sites of the primary tumors (Thiery, 
2002). Several ligands and pathways have been implicated to trigger EMT in physiological and 
pathological conditions, such as transforming growth factor beta (TGF-β), fibroblast growth factor 
(FGF), PDGF, Wnt-signaling and activation of the mammalian target of rapamycin (mTOR) (Thiery, 
2002). Upon EMT the activation of these pathways leads to the stabilization of the Snail protein, 
which mediates silencing of the cell adhesion molecule E-cadherin (Batlle et al., 2000). In addition, 
the protein expression of mesenchymal cell markers, such as vimentin and N-cadherin is elevated, 
resulting in the remodeling of the cellular actin cytoskeleton with loss of polarity, cell-to-cell contacts 
and increased tumor cell migration (Zhu et al., 2017). In patients, EMT is associated with poor 
survival, the development of invasive tumor growth and metastasis (Marcucci and Rumio, 2018). 
Increasing evidence is given that long-term sorafenib exposure triggers EMT with loss of E-cadherin 
expression, conveying a high invasive potential (van Malenstein et al., 2013). 
2.2.2.2.2 Evasive PI3K/AKT pathway activation 
A crucial signaling node that contributes to the induction of EMT is the phosphatidylinositol 3-kinase 
(PI3K)/AKT-signaling pathway, which works in parallel to the sorafenib-targeted MAPK/ERK axis 
and is involved in cell apoptosis as well as chemotherapeutic drug resistance (Zhai and Sun, 2013). 
The serine/threonine kinase mTOR, which acts downstream of PI3K and AKT, is modulated by 
extracellular stimulants and interacts with several proteins to form the active unit mTOR complex 
(mTORC) 1 and 2 (Marcucci and Rumio, 2018). Besides promoting EMT, mTORC1 inhibits the 
cytoprotective formation of autophagosomes (He and Klionsky, 2009). Sorafenib-resistant HCC has 
been shown to increase the abundance of phosphorylated AKT protein (p-Akt) in response to therapy 
and inhibition of AKT expression or activation sensitizes tumor cells to sorafenib-induced apoptosis 
(Chen et al., 2011). Thus, evasive PI3K/AKT-signaling might contribute to acquired sorafenib 
resistance of advanced-stage HCC in the course of therapy. 
2.2.2.2.3 Controversial role of stress-induced autophagy 
Tumor cells have evolved two distinct mechanisms in order to respond to stress from the tumor 
microenvironment: EMT (chapter 2.2.2.2.1) and macroautophagy (Marcucci and Rumio, 2018). 
Autophagy is referred to as a self-digestion process by which cytoplasmic contents are sequestered 
in autophagosomes and delivered to lysosomes for degradation (Pickles et al., 2018). However, the 
role of autophagy in tumorigenesis and chemotherapeutic resistance is discussed controversially. In 
addition to the well-established pro-survival functions during nutrient-deprivation, it is suggested 
that cytotoxicity follows excessive autophagy through digestion of essential cellular components. 
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Hence, autophagy-mediated cytotoxicity is classified as programmed cell death type II (Abdel-Aziz 
et al., 2017; Maiuri et al., 2007). In line with this controversy, autophagy modulation contributes to 
both resistance and cytotoxicity of several chemotherapeutics with a suspected impact on sorafenib 
responsiveness. It was shown that sorafenib treatment led to an accumulation of autophagosomes 
and activation of the autophagic flux, indicated by increased LC3 lipidation and a reduction of the 
autophagy substrate sequestosome 1 (SQSTM1, p62) in HCC cells (Shimizu et al., 2012). 
2.2.2.3 Tumor growth resumption in antiangiogenic treatment breaks 
Angiogenesis has long been associated with aggressive tumor growth and inhibition of the VEGF 
axis is the basis of most antiangiogenic drugs (Bagri et al., 2010). Besides preventing the formation 
of new tumor vessels, VEGF inhibitors eliminate many existing tumor vessels and normalize the 
phenotype of those that survive treatment (Jain, 2001). This approach was substantiated in 2004 with 
the approval of the anti-VEGF monoclonal antibody bevacizumab as combination therapy for the 
treatment of metastatic colorectal cancer. In addition, tyrosine kinase inhibitors (TKIs) with 
antiangiogenic activity such as sunitinib, sorafenib, and pazopanib have been approved as stand-
alone chemotherapy (Bagri et al., 2010; Hurwitz  et al., 2004). VEGF pathway inhibitors have 
achieved objective clinical success over the past decade, however, uncertainty remains about whether 
vascular and tumor regrowth occurs when therapy is stopped.   
Previously, preclinical models have shown that halting antiangiogenic therapy can lead to rapid 
revascularization (Mancuso et al., 2006) and evidence is accumulating that tumors can quickly 
resume after therapy withdrawal (Levashova et al., 2010; Nagengast et al., 2011). Further, 
administering antiangiogenic agents, such as sunitinib, on a discontinuous treatment schedule might 
involve a certain risk of tumor regrowth in drug-free break periods (Ebos and Pili, 2012). Still, tumor 
vascular rebound or tumor growth resumption following treatment discontinuation has not been 
confirmed in all cases (di Tomaso et al., 2011). In case of selective VEGF pathway inhibition by 
bevacizumab, quantification of tumor growth during and after treatment with anti-VEGF found no 
evidence of altered tumor proliferation (Bagri et al., 2010). While the underlying mechanisms for 
this growth resumption remain elusive, microenvironmental changes and hypoxia-induced 
autophagy are speculated to condition cancer cells for tumor extravasation upon sustained 
antiangiogenic treatment (Abdel-Aziz et al., 2017). Further, recent work shed light on hypoxic and 
glycolytic adaptions of the cancer cell metabolism upon antiangiogenic therapy with sunitinib or 
sorafenib. However, treatment withdrawal led to tumor regrowth, restored angiogenesis, a metabolic 
shift to enhanced lipid synthesis and a drastic increase in metastatic dissemination (Sounni et al., 
2014). To date, sparse research has been done to investigate metabolic adaptions in tumor growth 
resumption, the impact on the OS and to extrapolate a targeted therapeutic response. 
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2.3 Targeting mitochondria for anticancer therapy 
Mitochondria are the cells' powerhouse mediating metabolic reprogramming, which is described as 
a central feature of cancer cells. In general, mitochondria exert both vital and lethal functions, making 
them the Achilles' heel for anticancer therapy. On the one hand, they are indispensable for energy 
production upon fast proliferation, precursor metabolite biosynthesis and signaling, but on the other 
hand they are also crucial regulators of the intrinsic apoptosis program (Warburg, 1956; Weinberg 
and Chandel, 2015). Most chemotherapeutic agents interfere with signaling pathways upstream of 
mitochondria in order to trigger intrinsic apoptosis, whereas drugs that directly target the 
mitochondrial metabolism are discussed as tools to bypass drug resistance (Fulda et al., 2010). 
2.3.1 Mitochondria-targeting chemotherapeutics 
Mitochondria contribute to multiple steps of oncogenesis, such as malignant transformation, tumor 
progression and the modulation of treatment responsiveness, thus constituting a promising target for 
the development of novel anticancer agents (Vyas et al., 2016). Importantly, acquired drug resistance 
is frequently related to alterations in the intrinsic apoptosis pathway and preventing these 
mitochondrial adaptions appears to be essential for therapeutic resensitization (Fulda et al., 2010; 
Hanahan and Weinberg, 2011). This new understanding of mitochondria and their role in conferring 
chemoresistance led to the clinical approval of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax, 
which prevents apoptosis evasion and is nowadays in clinical use for the treatment of chronic 
lymphocytic leukemia (Ashkenazi et al., 2017). Besides regulating intrinsic apoptosis, mitochondria 
attracted attention from a metabolic perspective, as evidence was increasing that distinct 
mitochondrial metabolites are capable of driving oncogenesis (Dang et al., 2009). In addition, cancer 
cells adapt biosynthetic circuits to obtain metabolic flexibility, which confers chemoresistance and 
provides intermediates for aggressive tumor growth (Fendt et al., 2013). Thus, various preclinical 
studies are ongoing, assessing the anticancer potential of hexokinase inhibitors, thiol redox inhibitors, 
voltage-dependent anion-selective channel/adenine nucleotide translocase (VDAC/ANT) inhibitors, 
lipophilic cations targeting the mitochondrial membrane as well as agents affecting the tricarboxylic 
acid (TCA) cycle, the mitochondrial DNA (mtDNA) or the electron transport chain (ETC) (Porporato 
et al., 2017; Sborov et al., 2015). However, most clinical studies are pending or still in early stages 
and therapies maintain yet unavailable for clinical application. 
2.3.2 The metabolic contribution of mitochondria to tumor growth 
Pioneering work in the quantitative investigation of cancer cell metabolism was done in the 1920s 
by Otto Warburg, showing that under aerobic conditions tumor tissue fermentates approximately 
tenfold more glucose to lactate compared to normal tissues, a phenomenon known as the Warburg 
effect (Warburg, 1956). The increased glucose turnover of cancer cells was initially misinterpreted 
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as an evidence of mitochondrial dysfunctionality. In contrast, current evidence suggests that 
glycolysis in cancer cells is promoted by altered growth factor signaling that exerts a direct 
stimulatory effect on glucose uptake and metabolism, rather than by a low energy status (Ward and 
Thompson, 2012). Further, the role of proto-oncogenes and tumor suppressors has been extended 
from the ability to regulate the cell cycle by sustaining respectively evading proliferative signaling, 
to a key function in reprogramming cancer cell metabolism (Hanahan and Weinberg, 2011). Whereas 
the tumor suppressor p53 promotes the pentose phosphate pathway (PPP) and oxidative 
phosphorylation, the proto-oncogene MYC is known to enhance the glucose and glutamine turnover 
in order to fuel cell proliferation (Koppenol et al., 2011). According to the current understanding, 
cancer cells do not replace the mitochondrial metabolism, but exhibit the Warburg effect while 
retaining oxidative phosphorylation (OXPHOS) (Koppenol et al., 2011). However, in proliferating 
cells the production of adenosine triphosphate (ATP) by respiration was shown to appear secondary 
to the synthesis of anabolic precursor metabolites (Ward and Thompson, 2012).  
2.3.2.1 Mitochondrial biosynthesis of amino acids, lipids and nucleotides 
The mitochondrial TCA cycle, which is mostly fueled by the abundant nutrients glucose and 
glutamine, generates intermediates and building blocks used to provide proliferating cells with 
macromolecules for the synthesis of amino acids, lipids and nucleotides (Ahn and Metallo, 2015).  
 
Figure 3. Biosynthetic nodes within mitochondria. Illustration of the metabolic pathways within 
mitochondria that contribute to the biosynthesis of building blocks in proliferating cells. The TCA cycle and 
folate one-carbon metabolism (FOCM) enable cells to convert glucose, glutamine and amino acids to lipids, 
non-essential amino acids, nucleotides, glutathione, purines, pyrimidines and other cellular components. 
Enzymatic reactions that are dependent on redox-sensitive cofactors are depicted in red. ALA, alanine; AKG, 
α-ketoglutarate; ASP, aspartate; GLU, glutamine; GLY, glycine; OAA, oxaloacetate; PCA, pyruvate 
carboxylase; PDH, pyruvate dehydrogenase; SER, Serine; SUC, succinate; THF, tetrahydrofolate. 
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As previously mentioned, cancer cells are known to consume increased amounts of glucose, which 
are metabolized to pyruvate and either excreted as lactate or transported into the mitochondria 
(Warburg, 1956). Thus, upon conditions of limited glutamine availability or turnover, cancer cells 
tend to increasingly rely on glucose carbon flux through pyruvate carboxylase (PCA) to maintain 
oxaloacetate (OAA) production and the biosynthesis of downstream TCA cycle intermediates (Ahn 
and Metallo, 2015). Beyond flux through the PCA, mitochondrial pyruvate is oxidized by the 
pyruvate dehydrogenase (PDH) complex to form acetyl-coenzyme A (ACoA) (Ahn and Metallo, 
2015). ACoA is subsequently converted to citrate via condensation with OAA, which is then either 
further oxidized to isocitrate in the TCA cycle or transported out of the mitochondria to yield 
cytosolic ACoA. Extramitochondrial ACoA is the main substrate for de novo lipogenesis and 
acetylation reactions (Wellen et al., 2009) (Figure 3). Recently it was shown that during hypoxia or 
when mitochondrial respiration is impaired, reductively metabolized glutamine can also serve as a 
carbon source for fatty acid synthesis (Fendt et al., 2013; Mullen et al., 2011).  
For entering into the TCA cycle, glutamine is sequentially converted to glutamate (GLU) by 
glutaminases and into α-ketoglutarate (AKG) by glutamate dehydrogenases or aminotransferases 
(Weinberg and Chandel, 2015). Glutamine essentially provides the cell with nitrogen through 
transamination reactions, contributing to de novo purine synthesis and the formation of non-essential 
amino acids, such as alanine (ALA) and aspartate (ASP). In turn, ASP acts as a nitrogen donor and 
is a precursor for the amino acid asparagine (Altman et al., 2016). In general, backbone synthesis of 
purine nucleotides requires nitrogen from ASP, GLU, glycine (GLY) and formate, all precursors 
primarily derived from the mitochondrial metabolism. In detail, serine (SER), which is derived from 
glycolysis intermediates by glutamate-dependent transamination, is substrate to the serine 
hydroxymethyltransferase of the folate one-carbon metabolism (FOCM). The FOCM generates GLY 
and 5,10-methyl (CHO)-tetrahyfrofolate (THF), thereby providing the educts for purine, thymidine 
and glutathione (GSH) synthesis (Ahn and Metallo, 2015; Altman et al., 2016) (Figure 3). Further, 
pyrimidine ring synthesis requires glutamine, ASP, as well as the activity of the dihydroorotate 
dehydrogenase, a mitochondrial enzyme that converts dihydroorotate to orotate coupled with the 
reduction of ubiquinone (Coenzyme CoQ, CoQ) to ubiquinol in the ETC. Importantly, oxidation of 
ubiquinol is necessary to maintain an adequate supply of CoQ and is therefore impaired in cells that 
lack a functional ETC (Ahn and Metallo, 2015; Mullen et al., 2014).  
2.3.2.2 Control of the mitochondrial reduction-oxidation (redox) balance 
It is suggested that fast proliferating cells possess an equally important need for the maintenance of 
redox balance as for the biogenesis of macromolecular building blocks (Cairns et al., 2011; Sullivan 
et al., 2015). Thus, beyond its role in providing anabolic precursors, glutamine oxidation is essential 
for the TCA cycle-mediated reduction of the redox-active cofactors nicotinamide adenine 
dinucleotide (NAD+) and flavin adenine dinucleotide (FAD). In their reduced state NADH and 
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FADH2 are metabolized by the ETC, which couples nutrient oxidation to ATP production (Weinberg 
and Chandel, 2015). Another glutamine-dependent redox-mediator is reduced nicotinamide adenine 
dinucleotide phosphate (NADPH), which provides reducing power in a variety of biosynthetic 
enzymatic reactions and essentially contributes to lipid synthesis. NADPH is mostly generated by 
electron transfer to NADP+ in the course of extramitochondrial conversation of malate to pyruvate 
(Weinberg and Chandel, 2015). Malate is thereby directly exported from mitochondria to the cytosol 
or obtained by reduction of OAA, which is exported into the cytoplasm by the malate-aspartate 
shuttle (DeBerardinis et al., 2007). Besides, mitochondrial NADP+ is reduced by the isocitrate 
dehydrogenase 2 (IDH2), whereas cytosolic NADP+ is recycled to NADPH by isocitrate 
dehydrogenase 1 (IDH1) or the oxidative PPP. The PPP was thereby shown to be uniquely required 
for the maintenance of a normal NADP+/NADPH ratio, the enzymatic hydrogenation of folic acid to 
THF and nucleotide biosynthesis by the FOCM (Chen et al., 2019). Importantly, NADPH keeps the 
antioxidant GSH, a tripeptide consisting of the amino acids GLU, GLY and cysteine (CYS), in its 
reduced state for the defence against reactive oxygen species (ROS) (Panieri and Santoro, 2016). 
Mitochondria are the most prominent source of intracellular ROS, which are byproducts of the ETC 
and, at physiologic levels, mediate important signaling events necessary for cell proliferation (Cairns 
et al., 2011). However, at high abundance due to impaired electron transport or disturbed cellular 
redox balance, ROS may damage cellular components, promote genetic instability and lead to cell 
death (Wellen and Thompson, 2010). 
2.3.3 Shaping the mitochondrial bioenergetic function 
Mitochondria are involved in multiple anabolic processes by supplying cells with both ATP and 
reduction equivalents. Thus, modulators of the mitochondrial metabolism and, especially, of the ETC 
activity are frequently applied for experimental analysis of the mitochondrial functionality and 
respiratory capacity as they shape the oxygen consumption, which is measurable in intact cells. 
2.3.3.1 The electron transport system (ETS) 
The mitochondrial ETS consists of the F1F0-ATPase (complex V, ATP synthase) and the electron-
transporting complexes (I-IV), which are embedded in the inner mitochondrial membrane (IMM) 
and electrically connected by the electron carriers CoQ and cytochrome C (CytC) (Figure 5). Among 
those, the complexes I, III and IV are transmembrane proton pumps, required to establish an 
electrochemical gradient (ΔH+) for ATP production (Mitchell, 1961). Thereby, the respective 
enzymatic subunits catalyze the electron (e-) transfer of the reducing equivalents NADH and FADH2 
to oxygen (O2) (Chen, 1988). The energy released from this series of redox-reactions is coupled to 
the proton (H+) flux through the F1F0-ATPase across the IMM, which harasses this protonmotive 
force to drive ATP synthesis, membrane transport and thermogenesis (LeBleu et al., 2014; Mitchell, 
1961). The adenine nucleotide translocator (ANT), which is localized in the contact sites between 
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inner and outer mitochondrial membrane, can export ATP in exchange for adenosine diphosphate 
(ADP) and relies therefore not only on the activity of the ETS, but also on the abundance of 
cytoplasmic ATP generated by glycolysis (Kalbacova et al., 2003).  
2.3.3.2 Mitochondrial superoxide production 
Superoxides (O2-) are ROS of mitochondrial origin, which are generated through the interaction of 
one-electron donors with local O2 in the mitochondria as a consequence of electron leakage from 
redox centres of the ETC (Turrens, 2003). Thereby, both the complexes I and III, but also electron-
transferring dehydrogenase complexes are known sites of O2- production (Drose and Brandt, 2012) 
(Figure 5). In general, the complex I-mediated O2- production is increased in cells that have a high 
protonmotive force respectively a reduced CoQ-pool due to an insufficient ATP-production or a low 
NAD+/NADH ratio (Murphy, 2009). Excessive ROS production or insufficient antioxidant defence 
can lead to oxidative damage of mitochondrial proteins, membranes and DNA. Further, as a 
consequence of oxidative damage, mitochondrial ATP production and a wide range of metabolic 
functions such as the TCA cycle, fatty acid oxidation and amino acid synthesis may be disturbed 
(Murphy, 2009). Importantly, increased ROS abundance has been shown to promote tumor growth 
and malignant progression, whereas chemotherapeutic sensitization has been reported upon 
impairment of the antioxidant defense by NADPH or GSH (Panieri and Santoro, 2016). 
2.3.3.3 The NADH-ubiquinone oxidoreductase (NDUF) 
The mitochondrial multisubunit enzyme complexes I-V act successively in transferring electrons 
from the electron donating cofactors NADH and FADH2 to oxygen, which is reduced to water. The 
first enzyme in the ETC, the NDUF (complex I), removes electrons from NADH and passes them 
via a series of enzyme-bound flavin mononucleotide (FMN) and iron–sulphur (Fe-S) redox centres 
to CoQ (Larosa and Remacle, 2018) (Figure 4). The NDUF consists of 36 subunits whereby 7 of 
those represent the enzymatic core, which resembles the bacterial complex I and is, thus, conserved 
in all eukaryotes (Scarpulla, 2006; Taanman, 1999). Given that the NDUF is involved in the majority 
of electron uptake and O2- production, it represents a sensitive target of the ETS and is inhibited by 
rotenoids, metformin and a variety of antibiotics (Degli Esposti, 1998; Wheaton et al., 2014).   
 
Figure 4. Electron flux through the respiratory complexes I-V. CoQ, Coenzyme Q; CytC, cytochrome C; 
FAD, flavin adenine dinucleotide; Fe-S, iron–sulphur redox center; FMN, flavin mononucleotide; IMM, inner 
mitochondrial membrane; NAD, nicotinamide adenine dinucleotide. 
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2.3.3.4 Experimental modulators of the mitochondrial metabolism 
Inhibition of the electron transport across the ETC results in a reduced electrochemical gradient, 
which is required for ATP production by the complex V. Thereby, inhibition of the complex I, which 
is targeted by rotenone, appears to be the most sensitive target of the ETS (Sullivan et al., 2015; 
Wheaton et al., 2014). In addition, inhibition of the complex III by antimycin A or disruption of the 
protonmotive force by uncouplers, such as carbonyl cyanide 3-chlorophenylhydrazone (CCCP), 
decrease the oxygen consumption of the complex IV (Kalbacova et al., 2003). CCCP is a lipid-
soluble ionophore, which enters in protonated form as a weak acid into intact mitochondria. It 
discharges the electrochemical gradient and uncouples the proton flow back into the mitochondria 
from the ATP production by the F1F0-ATPase. In order to maintain the mitochondrial membrane 
potential, CCCP stimulates mitochondria to increasingly translocate electron across the complexes 
I, III and IV, thus elevating the measured oxygen consumption (Benz and McLaughlin, 1983). In 
contrast, inhibition of the mitochondrial F0F1-ATPase by oligomycin prevents the proton flux out of 
the mitochondria and increases the mitochondrial membrane potential. Nowadays, oligomycins are 
extensively used to examine the activity of ETC subunits and to assess the dependency of tumor cells 
on mitochondrial respiration (Kalbacova et al., 2003; Nagle and Zhou, 2010). In contrast, the 
antimetabolite 2-deoxy-D-glucose (2-DG) competitively inhibits the generation of glucose-6-
phosphate and reveals glycolytic dependency (Barban and Schulze, 1961), whereas the amino-thiol 
N-acetyl cysteine (NAC) scavenges free cellular radicals (Sun, 2010) (Figure 5). 
  
Figure 5. Modulators of the mitochondrial metabolism used for experimental analysis. 2-DG, 
2-deoxy-D-glucose; CCCP, carbonyl cyanide 3-chlorophenylhydrazone; CytC, cytochrome C; IMM/OMM, 
inner/ outer mitochondrial membrane; NAC, N-acetyl cysteine; O2-, superoxides; Q, Coenzyme Q (CoQ). 
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2.4 Aim of the study 
Acquired sorafenib resistance occurs frequently during therapy for advanced-stage HCC and 
contributes to a poor outcome for these patients. In addition, the therapeutic benefit of sorafenib is 
limited by a rapid resumption of tumor growth upon sorafenib withdrawal, which might be necessary 
due to the occurrence of drug-related serious adverse events. However, a multitude of phase III trials 
have failed to prolong the OS of patients in the systemic first-line and second-line setting of 
advanced-stage HCC and, until today, sorafenib remains the standard of care therapy.   
Thus, it is an urgent issue to understand how the majority of patients develop resistance to sorafenib 
and what happens after sorafenib retraction. In order address this question and to extrapolate 
possibilities for therapeutic interventions, we developed a robust sorafenib resistance HCC model. 
We aimed to extend the current knowledge of acquired sorafenib resistance with a focus on the 
mechanistic background of a potential tumor relapse after sorafenib treatment termination, as both 
resistance and tumor relapse contribute to a poor therapy outcome. Importantly, rapid tumor regrowth 
has been previously reported upon withdrawal of TKIs in patients, however, the underlying 
mechanisms remain elusive and, to date, there are no therapeutic strategies to address this problem. 
 
 
In summary, this study aims at: 
1. Characterizing the sorafenib resistance phenotype in a HCC cell model and identifying the 
underlying mechanisms that contribute to sorafenib resistance (chapter 4.1). 
 
2. Elucidating the metabolic and mechanistic background of growth resumption observed after 
sorafenib withdrawal to assess which therapeutic implications ensue (chapter 4.2-4.4).  
 
3. Analyzing emerging therapeutic options, to extrapolate an alternative treatment strategy with 
focus on second-line drug candidates after sorafenib retraction (chapter 4.5-4.6). 
 
4. Presenting an innovative alternative therapeutic approach that can be verified with good 
effectiveness in vivo and that possesses a high potential for clinical translation (chapter 4.7). 
 
 
 
  
MATERIALS AND METHODS 
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3 MATERIALS AND METHODS 
3.1 Materials  
3.1.1 Cells 
Table 3. Cell lines. 
Cell line Supplier or academic partner 
HUH7-R/ RIL175-R Generated from HUH7-WT/ RIL175-WT cells (Meßner, et al., unpublished) 
HUH7-R-LUC Stable lentiviral modification of HUH7-R cells (Meßner, et al., unpublished) 
HUH7-WT (JCRB0403) Japanese Collection of Research Bioresources (JCRB) 
RIL175 (RIL-175) A gift from Prof. S. Rothenfußer, University Hospital, LMU Munich, Germany 
VCR-R CEM M. Kavallaris, University of New South Wales, Sydney, Australia 
The generation of sorafenib-resistant HUH7 (HUH7-R) and RIL175 (RIL175-R) cells (chapter 
3.2.1.2) as well as the genetic modification to luciferase expressing HUH7-R cells (HUH7-R-LUC) 
(chapter 3.2.2.1) will be subsequently described. The establishment and profiling of RIL175 
(Kapanadze et al., 2013) and of vincristine-resistant CEM cells (VCR-R CEM) (Haber et al., 1989) 
was previously done and VCR-R CEM cells were kindly provided by the group of M. Kavallaris. 
3.1.2 Compounds and Reagents 
Table 4. Clinical approved chemotherapeutic and antibiotic compounds. 
Compound  CAS Number Producer 
ABT888 912445-05-7 Enzo Life Sciences, Lörrach, Germany 
Chloramphenicol 56-75-7 Sigma-Aldrich, Taufkirchen, Germany 
Cisplatin 15663-27-1 Sigma-Aldrich, Taufkirchen, Germany 
Doxorubicin 25316-40-9 Sigma-Aldrich, Taufkirchen, Germany 
Everolimus 159351-69-6 Selleckchem, Munich, Germany 
Gefitinib 184475-35-2 Selleckchem, Munich, Germany 
Linezolid 165800-03-3 Sigma-Aldrich, Taufkirchen, Germany 
SN38 86639-52-3 Tocris Bioscience, Abingdon, UK 
Sorafenib 284461-73-0 Enzo Life Sciences, Lörrach, Germany 
Tigecycline  1229002-07-6 Sigma-Aldrich, Taufkirchen, Germany 
Tivantinib 905854-02-6 Selleckchem, Munich, Germany 
Vincristine 2068-78-2 Sigma-Aldrich, Taufkirchen, Germany 
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Table 5. Chemicals and Reagents. 
Reagent Producer 
2,2,2-Trichlorethanol (TCE) Sigma-Aldrich, Taufkirchen, Germany 
2,4,6-Tris-(dimethylaminomethyl)phenol SE, Heidelberg, Germany 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent Roti® Quant Bio-Rad, Munich, Germany 
Complete® Roche Diagnostics, Penzberg, Germany 
Coumaric acid Fluka, Buchs, Switzerland 
Crystal violet Carl Roth, Karlsruhe, Germany 
DharmaFECT Transfection Reagent 1 Thermo Scientific, Waltham, MA, USA 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
D-luciferin sodium salt Biomol GmbH, Hamburg, Germany 
Dodecenylsuccinic anhydride SE, Heidelberg, Germany 
ECL Plus WB Detection reagent GE Healthcare, München, Germany 
FluorSave® reagent mounting medium Merck, Darmstadt, Germany 
Glutaraldehyde (2.5%) in sodium cacodylate buffer EMS, Hatfield, PA, USA 
Glycerol Applichem¸ Darmstadt, Germany 
Glycidether 100 SE, Heidelberg, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
HEPES Carl Roth, Karlsruhe, Germany 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
Isoflurane CP-Pharma®, Burgdorf, Germany 
Lead citrate, 3% Leica, Wetzlar, Germany 
Methylnadicanhydride SE, Heidelberg, Germany 
N,N,N',N'-Tetramethylethylendiamin (TEMED) VWR, Radnor, PA, USA 
Osmium tetroxide, 4% EMS, Hatfield, PA, USA 
Page Ruler™ Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Paraformaldehyde solution, 4% Polysciences, Warrington, PA, USA 
Penicillin – Streptomycin (Pen/Strep) PAN Biotech, Aidenbach, Germany 
Polyacrylamide Carl Roth, Karlsruhe, Germany 
Porcine trypsin Promega, Madison, WI, USA 
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PowerUp™ SYBR® Green Master Mix Applied Biosystems, Waltham, USA 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Propylene oxide SE, Heidelberg, Germany 
Pyronin Y Sigma-Aldrich, Taufkirchen, Germany 
Sodium cacodylate buffer, pH 7.4, 0.1 M EMS, Hatfield, PA, USA 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodiumdodecylsulfate (SDS) Carl Roth, Karlsruhe, Germany 
TransIT-X2® Transfection Reagent Mirus Bio LLC, Madison, WI, USA 
Tricine Sigma-Aldrich, Taufkirchen, Germany 
Tris base Sigma-Aldrich, Taufkirchen, Germany 
Trisodium citrate Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Tween 20 Sigma-Aldrich, Taufkirchen, Germany 
UranyLess EM Stain EMS, Hatfield, PA, USA 
*EMS: Electron Microscopy Sciences, SE: Serva Electrophoresis GmbH. 
 
Table 6. Assay Kits. 
Assay Name Producer 
CellTiterBlue® reagent Promega, Mannheim, Germany 
CellTiterGlo® reagent Promega, Mannheim, Germany 
CyQUANT® Cell Proliferation Assay Kit Life Technologies, Eugene, USA 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems, Waltham, USA 
L-Lactate Assay Kit Cayman Chemical, Michigan, USA 
Multi-Drug Resistance Assay Kit (Calcein AM) Cayman Chemical, Michigan, USA 
NAD/NADH Glo™ Promega, Mannheim, Germany 
NADP/NADPH Glo™ Promega, Mannheim, Germany 
RNeasy® Mini Kit (250) QIAGEN, Hilden, Germany 
ROS Detection Cell-Based Assay Kit (DCFDA) Cayman Chemical, Michigan, USA 
Seahorse XF Glycolysis Stress Test Kit Agilent Technologies, Santa Clara, USA 
Materials and Methods 
24 
 
Table 7. Inhibitors, metabolites and antimetabolites. 
Inhibitor Producer 
1,4-Dithioerythritol (DTE) Sigma-Aldrich, Taufkirchen, Germany 
2-deoxy-D-glucose (2-DG) Sigma-Aldrich, Taufkirchen, Germany 
3-methyladenine (3-MA) Sigma-Aldrich, Taufkirchen, Germany 
Acetyl-Coenzyme A (ACH) Sigma-Aldrich, Taufkirchen, Germany 
Antimycin-A Sigma-Aldrich, Taufkirchen, Germany 
Aspartate (ASP) Sigma-Aldrich, Taufkirchen, Germany 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) Sigma-Aldrich, Taufkirchen, Germany 
Citrate (CIT) Sigma-Aldrich, Taufkirchen, Germany 
Complete® mini EDTA free Roche diagnostics, Penzberg, Germany 
Concanamycin A Sigma-Aldrich, Taufkirchen, Germany 
Cyclosporine A Enzo Life Sciences, Lörrach, Germany 
Cysteine (CYS) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen, Germany 
L-Glutamine Sigma-Aldrich, Taufkirchen, Germany 
Malate (MAL) Sigma-Aldrich, Taufkirchen, Germany 
MitoBlock-6 (MB6) Focus Biomolecules, Plymouth, USA 
N-acetyl cysteine (NAC) Cayman Chemical, Michigan, USA 
Oligomyclin Sigma-Aldrich, Taufkirchen, Germany 
Oxaloacetate (OAA) Sigma-Aldrich, Taufkirchen, Germany 
Phenymethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Taufkirchen, Germany 
Pyruvate (PYR) Sigma-Aldrich, Taufkirchen, Germany 
Rotenone Sigma-Aldrich, Taufkirchen, Germany 
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) ICN, Biomedicals, Aurora, OH, USA 
Verapamil Enzo Life Sciences, Lörrach, Germany 
α-ketobutyrate (AKB) Sigma-Aldrich, Taufkirchen, Germany 
α-ketoglutarate (AKG) Sigma-Aldrich, Taufkirchen, Germany 
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3.1.3 Antibodies and Dyes 
3.1.3.1 Antibodies for Western blot 
Table 8. Primary antibodies for immunoblotting. 
Antigen Source Dilution Cat. No. Producer 
Akt rabbit 1:1,000 #9272 CST 
AMPK mouse 1:1,000 # 2793 CST 
Bak rabbit 1:1,000 #ab32371 Abcam 
Bax rabbit 1:500 #sc-493 Santa Cruz 
Bcl-2 rabbit 1:1,000 #2872 CST 
Drp-1 rabbit 1:1,000 #8570 CST 
E-Cadherin rabbit 1:1,000 #3195 CST 
Erk rabbit 1:1,000 #9102 CST 
GADD153/CHOP rabbit 1:500 #sc-793 Santa Cruz 
IDH2 rabbit 1:500 #22166SS Novus Biologicals 
LC3 rabbit 1:1,000 #4108 CST 
Mfn-1 rabbit 1:1,000 #14739 CST 
MMP-2 rabbit 1:1,000 #4022 CST 
MMP-9 rabbit 1:1,000 #3852 CST 
NFΚBp65 goat 1:500 sc-372-G Santa Cruz  
OGDH rabbit 1:1,000 #19622 Novus Biologicals 
OxPhos WB Antibody Cocktail mouse 1:250 #45-8099 Thermo Scientific 
p38MAPK rabbit 1:1,000 #9212 CST 
PGC-1α rabbit 1:1,000 #ab54481 Abcam 
phospho-Akt (Ser473) rabbit 1:500 #9271 CST 
phospho-AMPK (Thr172) rabbit 1:1,000 #2535 CST 
phospho-Erk (Thr202/Tyr204) rabbit 1:1,000 #9106 CST 
phospho-NFΚBp65 (Ser536) rabbit 1:1,000 #3031 CST 
phospho-p38MAPK (Thr180/182) rabbit 1:1,000 #9211 CST 
TFE3 rabbit 1:1,000 #PA5-35210 Thermo Scientific 
TFEB rabbit 1:1,000 #4240 CST 
Vimentin rabbit 1:1,000 #5741 CST 
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Table 9. Secondary antibodies for immunoblotting. 
Antibody Dilution Cat. No. Producer 
Goat-anti-rabbit IgG(H+L)-HRP conjugate 1:1,000 #172-1019 Bio-Rad 
Goat-anti-mouse IgG1-HRP conjugate 1:1,000 #ab97240 Abcam 
Donkey-anti-goat IgG-HRP conjugate 1:10,000 #ab97120 Abcam 
For Western blot analysis all antibodies were diluted in 5% BSA in PBS before use. 
3.1.3.2 Antibodies for Immunostaining 
Table 10. Primary antibodies for immunostaining. 
Antigen Source Dilution Cat. No. Producer 
E-Cadherin (HECD1) mouse 1:1,000 #131700 Invitrogen 
N-Cadherin rabbit 1:200 #4061 CST 
PGC-1α rabbit 1:300 #ab54481 Abcam 
*CST: Cell Signaling Technologies. 
 
Table 11. Secondary antibodies and dyes for immunostaining. 
Antibody/Dye Dilution Cat. No. Producer 
Alexa Fluor 488 goat anti-rabbit  1:400 #A-11008 Invitrogen 
Alexa Fluor 488 goat-anti-mouse 1:400 #A-11001 Invitrogen 
Alexa Fluor 546 donkey-anti-rabbit 1:400 #A-10040 Invitrogen 
Hoechst (bisBenzimide H 33342) 1:100 #23491-52-3 Sigma Aldrich 
For immunostaining all antibodies were diluted in 0.2% BSA in PBS before use. 
3.1.3.3 Fluorescent Dyes 
Table 12. Staining dyes for live cell imaging and flow cytometry. 
Fluorescent Dye Ex/Em [nm] Dilution Cat. No. Producer 
 2-NBDG  488/530 100 µM N13195 Invitrogen 
Cal-520 AM 488/530 10 µM 21131 AAT Bioquest 
LysoTracker™ Red DND-99 577/590 1:3,000 L7528 Invitrogen 
MitoSOX™ Red 488/575 5 µM M36008 Invitrogen 
MitoTracker™ Green FM 490/516 1:9,000 M7514 CST 
*2-NBDG, 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose. 
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3.1.4 Primers 
Table 13. Primer sequences for quantitative real-time PCR. 
Target Type Sequence Producer 
E-Cadherin  forward 5′-CAG CAC GTA CAC AGC CCT AA-3′ Metabion 
 reverse 5′-AAG ATA CCG GGG GAC ACT CA-3′ Metabion 
PGC-1α TaqMan PPARGC1A (Hs00173304_m1) Thermo Scientific 
 
3.1.5 Small interfering RNAs 
For transient transfections siRNAs were used in an initial concentration of 50 nM with 0.08% 
transfection reagent DharmaFECT 1 (T-2001-02, Dharmacon) per well. After stimulation the final 
concentration per well was reduced to 25 nM siRNA and 0.04% DharmaFECT 1 to avoid toxicity. 
Table 14. siRNAs used for transient gene silencing. 
Target Cat. No. Transfection reagent Producer 
LUC (nt) D 001206-14-05 Dharmafect 1 Dharmacon 
IDH2 M 004013-00-0005 Dharmafect 1 Dharmacon 
OGDH M 009679-02-0005 Dharmafect 1 Dharmacon 
 
3.1.6 Technical equipment 
Table 15. Instruments. 
Name Producer 
Acquity Ultraperformance LC system Waters, Eschborn, Germany 
Cell Homogenizer Potter S Sartorius AG, Göttingen, Germany 
ChemiDoc™ Touch Imaging System Bio-Rad, Munich, Germany 
Climate chamber for live cell microscopy Ibidi GmbH, Martinsried, Germany 
Digital Caliper Emil Lux, Wermelskirchen, Germany 
DMi1 microscope Leica, Wetzlar, Germany 
EASY-nLC 1000 chromatography system Thermo Scientific, Waltham, MA, USA 
FACSCalibur Becton Dickinson, Heidelberg, Germany 
FACSCantoII Becton Dickinson, Heidelberg, Germany 
IVIS®spectrum CLS, Rüsselsheim, Germany 
JEOL-1200 EXII transmission electron microscope JEOL GmbH, Freising, Germany 
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Leica EM AC20 contrasting system Reichert und Jung, Germany 
Leica SP8 confocal laser scanning microscope Leica Microsystems, Wetzlar, Germany 
MC120 HD camera Leica, Wetzlar, Germany 
Mikro 22R centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® Spectrophotometer PEQLAB Biotechnologie GmbH 
Orbitrap XL instrument Thermo Scientific, Waltham, MA, USA 
Orion II microplate luminometer BDS, Pforzheim, Germany 
OROBOROS Oxygraph-2k Oroboros Instruments, Innsbruck, Austria 
QTRAP 5500 mass spectrometer Sciex, Darmstadt, Germany 
QuantStudio™ 3 Real-Time PCR System Applied Biosystems, Foster City, CA 
Seahorse XFe96 Analyzer Agilent Technologies 
Sonoplus GM3200 with BR30 cup booster Bandelin, Berlin, Germany 
Spark® multimode microplate reader Tecan, Crailsheim, Germany 
SpectraFluor®PLUS Tecan, Männedorf, Switzerland 
Sunrise® Tecan, Männedorf, Switzerland 
Ultramicrotome Ultracut E Reichert und Jung, Germany 
Vi-Cell® CR Beckmann Coulter, Fullerton, CA, USA 
xCELLigence® instrument Roche Diagnostics, Penzberg, Germany 
*CLS, Caliper Life Sciences GmbH, BDS, Berthold Detection Systems. 
 
Table 16. Assay Materials. 
Name Producer 
1 ml syringes Hartenstein GmbH, Würzburg, Germany 
27 G needles Hartenstein GmbH, Würzburg, Germany 
BEEM capsules, 0.95 ml Plano GmbH, Wetzlar, Germany 
Column Acquity UPLC BEH C18 1.7 µM, 2.1×50 mm Waters, Milford, MA, USA 
Column Acquity UPLC BEH C8 1.7 µm, 1×100 mm Waters, Milford, MA, USA 
Column PepMap RSLC C18, 75 µm x 50 cm, 2 µm Thermo Scientific, Waltham, MA, USA 
Column PepMap100 C18, 75 µm x 2 cm, 3 µm Thermo Scientific, Waltham, MA, USA 
Culture flasks, plates and dishes TPP, Trasadingen, Switzerland 
E-Plate® Roche Diagnostics, Penzberg, Germany 
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FACS tubes Thermo Scientific, Waltham, MA, USA 
Ibidi® µ-slide Ibidi GmbH, Martinsried, Germany 
Immun-Blot® PVDF membrane (0.2 µM) Bio-Rad, Munich, Germany 
Kolliphor EL (Solutol) Sigma-Aldrich, Taufkirchen, Germany 
MicroAmp® Fast Optical 96-Well Plate, 0.1 ml Applied Biosystems, Waltham, USA 
MicroAmp® Optical Adhesive Film Applied Biosystems, Waltham, USA 
Microplate 96-well transparent/ black/ white Greiner Bio-One, Kremsmünster, Austria 
Nitrocellulose membrane (0.2 µM), Hybond-ECLTM AmershamBioscience, Freiburg, Germany 
QIA-Shredder columns Qiagen, Hilden, Germany 
Seahorse XFe96 FluxPaks (inc. mini) Agilent Technologies, Santa Clara, USA 
XFe96 microplate Agilent Technologies, Santa Clara, USA 
 
3.1.7 Software 
Table 17. Software tools for data analysis. 
Software name and version Supplier 
Analyst 1.6 Sciex, Darmstadt, Germany 
FlowJo 7.6 Tree Star, Ashland, OR, USA 
Glycolysis Stress Test Report Generator Agilent Technologies, Santa Clara, USA 
GraphPad Prism 7 GraphPad Software, San Diego, CA, USA 
GSEA 3.0 The Broad Institute, Massachusetts, USA 
Image Lab 5.2 Bio-Rad, Hercules, CA, USA 
Leica LAS X Leica, Wetzlar, Germany 
Living Image 4.4 CLS, Rüsselsheim, Germany 
MaxQuant Max Planck Institute of Biochemistry, Munich 
Microsoft Office 2010 Microsoft, Redmont, WA, USA 
Perseus 1.5.4.1. Max Planck Institute of Biochemistry, Munich 
RTCA Roche Diagnostics, Penzberg, Germany 
Wave 2.3.0 Agilent Technologies, Santa Clara, CA 
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3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Cell culture buffers and solutions 
For the cultivation of HUH7 and RIL175 cells, DMEM medium (PAN Biotech GmbH, Aidenbach, 
Germany) was used. CEM/VCR-R cells were cultured in RPMI 1640 medium with 2 mM glutamine 
(PAN Biotech GmbH, Aidenbach, Germany). Both media were supplemented with 10% FCS (PAA 
Laboratories GmbH, Pasching, Austria) and a combination of 100 U/ml penicillin and 100 µg/ml 
streptomycin (Pen/Strep). All cells were cultured at 37 °C with 5% CO2 in constant humidity. Before 
seeding of adherent HUH7 and RIL175 cells, culture flasks, multiwell-plates and dishes were coated 
with collagen G (0.001% in PBS, Biochrom AG, Berlin, Germany). The buffers and solutions that 
were used for the cultivation of HUH7, RIL175 and CEM/VCR-R cells are listed below (Table 18).  
Table 18. Buffers and solutions used for cell culture. 
 
 
PBS 
PBS 
+ Ca2+/Mg2+ 
 
 
 
Growth 
medium 
Freezing 
medium 
NaCl 132.2 mM 137 mM  DMEM/ RPMI 500 ml 70% 
Na2HPO4 10.4 mM 8.10 mM  FCS 50 ml 20% 
KH2PO4 3.2 mM 1.47 mM  DMSO - 10% 
KCl - 2.68 mM  Trypsin/EDTA (T/E) 
MgCl2 - 0.25 mM  Trypsin  0.05% 
H2O add add  EDTA  0.02% 
pH 7.4 7.4  PBS  add 
 
3.2.1.2 Generation of the sorafenib-resistant cell lines HUH7-R and RIL175-R 
The sorafenib-resistant cell line HUH7-R was generated from HuH7 (JCRB0403) cells (indicated as 
HUH7-WT), which were purchased from the Japanese Collection of Research Bioresources (JCRB). 
Sorafenib-resistant RIL175-R cells were generated from RIL-175 cells (Kapanadze et al., 2013) 
(indicated as RIL175-WT) and used to confirm the key-findings obtained by the sorafenib-resistant 
HUH7-R cell model. Sorafenib resistance was obtained through continuous exposure of HUH7-WT 
respectively RIL175-WT cells to sorafenib (BAY 43-9006, Enzo Life Sciences GmbH, Lörrach, 
Germany) just below their IC50-value. Over several weeks, the sorafenib dose was slowly increased 
with 0.5 µM per time up to a tolerated sorafenib concentration of 10 µM in the growth medium. After 
establishment, the HUH7-R and RIL175-R cell lines were alternating cultured in growth medium 
Materials and Methods 
31 
 
with and without supplementation of 10 µM sorafenib, as described below, and used for the 
sorafenib-resistant rebound growth model (chapter 3.2.1.3). The IC50-values of HUH7-R and 
RIL175-R cells in comparison to their parental cell lines HUH7-WT and RIL175-WT were 
determined by the CellTiter-Blue® (CTB) viability assay as subsequently described (chapter 3.2.9.1). 
Cells were cultured in constant humidity at 37 °C and 5% CO2 in an incubator.  
3.2.1.3 The sorafenib-resistant rebound growth model 
HUH7-R and RIL175-R cells that were cultured in the presence of 10 µM sorafenib for at least 7 days 
are indicated as HUH7-R(+) and RIL-175-R(+) cells. For the generation of the rebound growth cell 
types HUH7-R(-) and RIL175-R(-), sorafenib was withdrawn from R(+) cells for 72 h before 
seeding. In general, HUH7-R and RIL175-R cells were seeded in growth medium in the respective 
multiwall-plates and dishes 24 h before performing experiments. Consequently, R(-) cells were 
cultured without sorafenib for a total of 96 h if not otherwise mentioned. In order to maintain a 
constant sorafenib resistance phenotype with standardized treatment conditions, R(-) cells were 
reseeded in the presence of 10 µM sorafenib for another 7 days and used as R(+) cells in the following 
week. For experiments including a rebound growth time series, R(+) cells were seeded as described 
above and sorafenib was withdrawn for the specified time (in hours), as indicated in brackets. 
3.2.1.4 Passaging 
Adherent HUH7 and RIL175 cells were passaged every 3-5 days, when grown to 80-90% of 
confluence. For passaging, the medium was removed and cells were washed with pre-warmed PBS 
(Table 18). Subsequently, cells were detached with trypsin/ethylene-diamine-tetraacetic acid 
(EDTA) (Table 18) and the enzymatic reaction was stopped by adding growth medium (Table 18). 
Cells were then either re-cultured in a 75cm2 flask or seeded for experimental analysis. The growth 
and plating medium of HUH7-R(+) and RIL175-R(+) cells was supplemented with 10 µM sorafenib. 
Growth medium was changed twice per week for HUH7-WT and RIL175-WT cells and three times 
per week for R(+) cells, due to strong lactate production. The suspension cell line VCR-R CEM was 
maintained at a cell density of 0.1-1.0 x 106 cells/ml by passaging twice per week. Before seeding, 
the cell density of all cell lines was determined using the cell viability analyzer ViCell XR. 
3.2.1.5 Freezing and thawing 
For freezing, confluent HUH7 and RIL175 cells were trypsinized as described above, counted, 
centrifuged (1,000 rpm, 5 min, 20 °C) and resuspended in 1.5 ml ice-cold freezing medium  
(Table 18). For all cell lines 1-3 x 106 cells were snap frozen at -80 °C and the cryovials were 
transferred to nitrogen tanks (-196 °C) for long-term storage. For thawing, cells were immediately 
resuspended in culture medium and excessive DMSO was separated by centrifugation. The cell pellet 
was resuspended in culture medium and cells were grown in a 25 cm² flask until passaging. 
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3.2.2 Stable and transient transfection 
3.2.2.1 Stable lentiviral transfection 
The stably luciferase-expressing HUH7-R cells (HUH7-R-LUC) were generated by lentiviral 
transduction. Therefore, virus supernatant from HEK 293T cells that had been transfected with the 
plasmids pCDH-eFFLuc-T2A-eGFP (Rabinovich et al., 2008) (a gift from Prof. Jeremias, Helmholtz 
Zentrum München, Germany), pCMV-VSV-G and pCMV-dR8.2 were used.  
3.2.2.1.1 Production of lentiviral supernatant 
The generation and concentration of virus supernatant was performed by the group of Prof. Dr. med. 
Rothenfusser (University Hospital, LMU Munich, Germany). Prior to transfection, 4 x 106 293T cells 
were plated onto a 10 cm dish in 10 ml pre-warmed DMEM medium, supplemented with 10% FCS, 
Pen/Strep and L-Glutamine. After reaching a confluence of 60-70%, cells were transfected with the 
respective plasmids. Therefore, a transfection solution was prepared with OptiMEM (486 µl) and 
TransIT-X2 solution (15 µl). After an incubation of 15 min at room temperature, 2.5 µg of the 
pCDH-eFFLuc-T2A-eGFP plasmid DNA and 1.25 µg each of the packaging plasmids 
pCMV-VSV-G and PCMV-dR8.2 were added, carefully mixed and incubated for 15 min more. 
Meanwhile, the medium from 293T cells was removed from the 10 cm dishes and 5 ml fresh, 
pre-warmed growth medium together with the transfection solution was added. After 24 h of 
incubation, 5 ml of fresh growth medium were added. Subsequently, the virus containing supernatant 
was harvested 48 h post transfection and filtrated through 0.45 µm filters. For concentration, the 
supernatant was centrifuged, the pellet resuspended in 500 µl growth medium and the virus 
containing supernatant stored at -80 °C until transduction.  
3.2.2.1.2 Transduction of HUH7-R cells 
For lentiviral transduction, 2 x 106 HUH7-R cells were plated in growth medium into a 6-well plate 
and grown overnight to 60-70% of confluence. Thereafter, 2 ml of virus supernatant and 3.8 µg/ml 
polybrene were added per well. Polybrene enhances the fusion of viral particles with the target cells. 
Cells were washed in PBS and the polybrene containing transduction mixture was replaced by fresh 
growth medium after 16 h due to cytotoxicity. The transduced cells were expanded after three 
passaging cycles and FACS-sorted for the eGFP-positive HUH7-R-LUC population, which was used 
for the in vivo assessment of tumor size by bioluminescence imaging (chapter 3.2.12.3). 
3.2.2.2 Transient gene silencing and overexpression 
Transient siRNA-gene silencing experiments were performed with siRNA pools targeting the 
mitochondrial enzymes isocitrate dehydrogenase 2 IDH2 (siIDH2) and oxoglutarate dehydrogenase 
OGDH (siOGDH). A non-targeting siRNA for luciferase (siLUC) was thereby used as a negative 
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control (Table 14). For transfection, the respective siRNA was applied in an initial concentration of 
50 nM per well with 0.08% transfection reagent DharmaFECT 1 (chapter 3.1.5). The cells were 
incubated with the transfection solution for 1.5 h and either left untreated or stimulated as indicated 
for the experiment, with a final concentration of 25 nM siRNA and 0.04% DharmaFECT 1 per well. 
All experiments were carried out 72 h post transfection and the gene silencing efficiency was 
monitored by Western blot analysis of the OGDH and IHD2 protein abundance (chapter 3.2.4). For 
transient transfection with the Rab-9-GFP plasmid (Figure S8 C), cells were seeded in ibidi®-µslides 
and grown overnight to 80-90% of confluence. The plasmid DNA was diluted 1:100 in DMEM and 
1.75% DharmaFECT1 was used as a transfection reagent as described above. Cells were incubated 
with the transfection solution for 4 h, fresh growth medium was added and live cell imaging was 
performed after 24 h, as subsequently described (chapter 3.2.5.3). 
3.2.3 Proliferation assays 
3.2.3.1 Crystal violet staining 
For sensitivity testing of cells towards a variety of compounds, as well as lactate assay (chapter 
3.2.9.2) and ROS assay (chapter 3.2.11.2) normalization, a crystal violet proliferation assay was 
performed. Therefore, the cells were seeded in triplicates at a density of 10,000 cells/well (40,000 
cells/well for HUH7-R(+)) in a transparent, flat-bottom 96-well plate. The cells were grown for 24 h 
before stimulation. After incubation respectively sorafenib withdrawal for 72 h, cells were stained 
with 100 μM crystal violet solution for 10 min at room temperature and washed with distilled water. 
In order to quantify proliferation, the bound dye was solubilized by adding 200 μl dissolving buffer 
and the absorbance at 550 nm was measured in a SpectraFluor®PLUS plate-reading photometer. 
Table 19. Buffers and solutions for crystal violet staining. 
Crystal violet solution   Dissolving buffer  
Crystal violet 0.5%  Trisodium citrate 50 mM 
Methanol 20%  Ethanol 50% 
H2O add  H2O add 
 
3.2.3.2 Impedance measurement 
The real-time proliferation of HCC cells was assessed by impedance measurements using the 
xCELLigence system. The cells were seeded at a density of 2,500 cells/well in triplicates in 
equilibrated 16-well E-plates. Cells were grown in growth medium for 24 h before treatment or 
sorafenib withdrawal for 72 h. The cell index, which is proportional to the cell count per well, was 
assessed every hour and normalized to the start point of treatment respectively sorafenib withdrawal. 
The growth rate was calculated by the RTCA software as slope of the cell-index curve.  
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3.2.4 Western blot 
3.2.4.1 Cell lysis and sample preparation 
The protein levels of interest were examined by Western blot analysis. Therefore, cells were seeded 
in a 6-well culture dish and grown overnight to confluence. The next day, cells were washed once 
with ice-cold PBS, 100 μl lysis buffer was added and cells were frozen at -80 °C for at least 20 min. 
In order to load equal amounts of protein of all samples onto the polyacrylamide gel electrophoresis 
(PAGE), protein concentrations were determined by Bradford assay (Bradford, 1976). Therefore, 
10 μl re-diluted protein samples were incubated with 190 μl 1:5-diluted Bradford reagent Roti® 
Quant for 5 min. The absorbance of each sample, which correlates with the respective protein 
concentration, was measured at 592 nm on a SpectraFluor®PLUS plate reading photometer and 
linear regression was performed using a BSA dilution series. The protein concentrations were 
adjusted by adding 1x sodium dodecyl sulfate (SDS) sample buffer to a total of 80 µl per sample. In 
order to optimize protein denaturation for obtaining an equal protein size-to-charge ratio, 20 µl 
5x SDS sample buffer were added per 80 µl of adjusted sample prior to denaturation at 95 °C for 
5 min. Exclusively samples for analysis of the respiratory chain (OxPhos WB Antibody Cocktail) 
were heated to 37 °C for 1 h, as the complex I signal decreases at temperatures above 50 °C. 
Table 20. Lysis and SDS sample buffer for Western blot sample preparation. 
Lysis buffer premixture   Add to Lysis buffer before use 
Tris/HCl 50 mM  Complete®EDTAfree 4 mM 
NaCl 150 mM  PMSF 1 mM 
Nonidet NP-40 1%  H2O2 600 μM 
Sodium deoxycholate 0.25%  5x SDS sample buffer 
SDS 0.10%  Tris/HCl pH 6.8 3.125 M 
activated Na2VO4 300 μM  Glycerol 50% 
NaF 1 mM  SDS 5% 
β-glycerophosphate 3 mM  DTT 2% 
pyrophosphate 10 mM  Pryonin Y 0.025% 
H2O add  H2O add 
 
3.2.4.2 Polyacrylamide gel electrophoresis (PAGE) 
An equal amount of protein was separated via one of both SDS electrophoretic techniques, 
Glycine-SDS-Page or Tricine-SDS-PAGE. Protein separation was performed on discontinuous 
polyacrylamide gels, consisting of a separation and a stacking gel (Table 21). 
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Table 21. Polyacrylamide gels for PAGE. 
 
 
Stacking gel 
Separation gel 
10% 12% 15% 
Rotiophorese™ Gel 30 17% 33% 40% 50% 
Tris base (pH 6.8) 125 mM - - - 
Tris base (pH 8.8) -  375 mM 375 mM 375 mM 
SDS 0.1% 0.1% 0.1% 0.1% 
TEMED 0.2% 0.1% 0.1% 0.1% 
APS 0.1% 0.05% 0.05% 0.05% 
TCE - 0.5% 0.5% 0.5% 
H2O add add add add 
 
3.2.4.2.1 Glycine-SDS-PAGE 
The Glycine-SDS-PAGE (Laemmli, 1970) uses a glycine-tris buffer system and is the most 
commonly applied electrophoretic technique, with optimal separation for proteins larger than 
30 kDa. The concentration of acrylamide in the gel can be varied, in order to adapt the separation 
capacity to higher or lower protein mass ranges. In the following, 10%, 12% and 15% 1.5 mm 
separation gels were used (Table 21), which are defined by the total percentage concentration of 
acrylamide monomers and the cross linker Ammonium persulfate (APS), in relation to the total gel 
volume (Hjertén, 1962). An equal amount of protein was separated in electrophoresis buffer  
(Table 22) at a constant voltage (100 V, 21 min for stacking gel/ 200 V, 43 min for separation gel). 
Table 22. Buffers for Glycine-SDS-PAGE and Tricine-SDS-PAGE. 
 
 
(Laemmli, 1970) (Schagger, 2006) 
Electophoresis buffer Anode buffer Cathode buffer 
Tris base 4.9 mM 100 mM 100 mM 
Glycine 38 mM  - - 
Tricine - - 100 mM 
SDS 0.1% - 0.1% 
HCl - 22.5 mM  
H2O add add add 
pH 8.3 8.9 ~ 8.25 
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3.2.4.2.2 Tricine-SDS-PAGE 
The Tricine-SDS-PAGE (Schagger, 2006) is based on a tricine-tris buffer system and is currently the 
recommended electrophoretic system for the separation of proteins with a molecular weight below 
30 kDa. In the following, a modified protocol with 12% 1.0 mm polyacrylamide gels (Table 21) was 
used. In this electrophoretic technique, the maximal protein load is limited by large amounts of 
neutral detergent and lipids in the sample. Therefore, the protein concentration was kept at 
approximately 20 µg per 10-15 µl of SDS sample buffer. A low SDS ratio has been previously 
reported to facilitate the electrophoretic separation of peptides from the bulk SDS (Schagger, 2006). 
The Tricine-SDS electrophoresis was performed with an anode/ cathode buffer system (Table 22) at 
a constant voltage (30 V, 21 min for stacking gel/ 150 V, 60 min for separation gel). 
3.2.4.3 Tank blotting and protein detection 
After electrophoretic protein separation, the total protein load of the trichloroethanol (TCE) 
supplemented polyacrylamide gels was determined for subsequent normalization. Therefore, the 
polyacrylamide gels were UV-activated on the ChemiDoc™ Touch Imaging System and the antibody 
band intensities were normalized to the respective protein load, using the Stainfree™ technology 
(Bio-Rad). Thereafter, the PVDF-membranes were activated in methanol for 5 min and the proteins 
were transferred via tank blotting (Table 23) at a constant voltage (100 V, 90 min, 4 °C). In order to 
prevent non-specific antibody binding, the membrane was blocked secondary to protein transfer for 
1 h in 5% BSA in PBS. The membrane was incubated with the first, antigen binding antibody 
overnight at 4 °C (Table 8) on an orbital shaker. The next day, the membrane was washed 4x5 min 
in 1xTBS-T (Table 23) and the secondary, HRP-coupled antibody was added for 2 h at room 
temperature (Table 9). After a final 4x5 min washing step, membranes were shortly incubated with 
a freshly prepared ECL-solution (Table 23), activated with 17 µM H2O2 and the chemiluminescence 
was detected with the ChemiDoc™ Touch Imaging System. The received bands were evaluated by 
comparing the molecular weight of the proteins to the pre-stained protein ladder PageRuler™ and 
the protein expression was quantified with the Image Lab™ Software. 
Table 23. Buffers for tank blotting, washing of membranes and Western blot detection. 
Tank buffer   1x TBS-T   ECL-solution 
Tris base 48 mM  Tris/HCl 50 mM  Tris base (pH 8.5) 0.1 M 
Glycine 39 mM  NaCl 150 mM  Luminol 2.5 mM 
Methanol 20%  Tween 20 0.05%  Coumaric acid 1 mM 
H2O add  pH 7.6  H2O  
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3.2.5 Microscopy 
3.2.5.1 Phase contrast microscopy 
The morphology of HUH7 and RIL175 cells was assessed under standardized culture conditions as 
described above (chapter 3.2.1). Therefore, a Leica DMi1 microscope with a Leica MC120 HD 
camera was used. The cellular diameter D was assessed by the Vi-Cell™ XR cell counter and used 
for the calculation of the cellular volume V with the formula: V = 4/3 x π x D/2. 
3.2.5.2 Immunostaining 
For cell immunostaining and subsequent confocal microscopy, cells were seeded in ibidi®-µslides 
(HUH7-WT: 15,000 cells/well, HUH7-R(+): 30,000 cells/well, HUH7-R(-): 20,000 cells/well) and 
grown overnight. After 24 h, the cells were washed with Ca2+/Mg2-containing PBS (Table 18), fixed 
with 4% paraformaldehyde (PFA), permeabilized with 1% Triton X-100 and incubated with 1% BSA 
solution for 30 min in order to block unspecific antibody binding. Thereafter, cells were incubated 
with the respective primary antibody solution overnight (4 °C) (Table 10). Cells were washed with 
PBS and incubated with the secondary antibody (Table 11) together with the DNA-staining Hoechst 
reagent (1:100) diluted in 0.2% BSA for 1 h. After washing with PBS, fluorescent stainings were 
sealed with one drop of FluorSaveTM Reagent mounting medium and a cover slip. Samples were 
kept at 4 °C for longer storage and imaged using a Leica SP8 confocal laser scanning microscope. 
Subsequent image analysis was performed with the Leica LAS X software. 
3.2.5.3 Live Cell imaging 
Mitochondrial morphology and lysosomal mass distributions were assessed in living, unfixed cells 
in a climate chamber (37 °C, 5% CO2, constant humidity) (Ibidi GmbH). Therefore, cells were seeded 
in ibidi®-µslides (HUH7-WT: 15,000 cells/well, HUH7-R(+): 30,000 cells/well, HUH7-R(-): 
20,000 cells/well) and grown overnight. After 24 h, cells were washed with PBS and incubated with 
the respective staining dye for 30 min protected from light. In detail, cells were stained with 
200 µl/well of the MitoTracker™ Green FM (1:9,000) or LysoTracker™ Red DND-99 (1:3,000) 
staining solution (Table 12). Images were obtained using a Leica TCS SP8 confocal laser scanning 
microscope and image analysis was performed with the Leica LAS X software. 
3.2.5.4 Transmission electron microscopy (TEM) 
Cells for TEM were detached, 0.5 x 106 cells centrifuged (200 g, 5 min, RT) and resuspended in 
300 µl PBS. Thereafter, cells were transferred into 0.95 ml BEEM capsules, centrifuged (410 g, 
10 min, RT) and fixed in 600 µl glutaraldehyde (2.5%) in sodium cacodylate buffer (Electron 
Microscopy Sciences) for at least 24 h. After fixation, glutaraldehyde was removed and samples were 
washed three times with 0.1 M sodium cacodylate buffer (Electron Microscopy Sciences). 
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Postfixation and prestaining was done for 45 to 60 min with 1% osmium tetroxide (Table 24). 
Samples were washed three times with ddH2O and dehydrated with an ascending ethanol series (once 
15 min with 30%, 50%, 70%, 90%, 96%, twice 10 min with 100%) and twice 30 min with propylene 
oxide. Subsequently, samples were embedded in Epon (Table 24). For microscopy, ultrathin sections 
were sliced with an Ultracut E Ultramicrotome and automatically stained with UranyLess EM Stain 
and 3% lead citrate using the contrasting system Leica EM AC20. For analysis, the samples were 
examined with a JEOL-1200 EXII transmission electron microscope. 
Table 24. Buffers and solutions for transmission electron microscopy. 
Osmium tetroxide 1%   Epon  
Osmium tetroxide 4% 10 ml  Glycidether 100 3.61 M 
Sodium chloride 3.4% 10 ml  Methylnadicanhydride 1.83 M 
Potassium dichromate 4.46% 10 ml  Dodecenylsuccinic anhydride 0.92 M 
H2O 10 ml  Tris(dimethylaminomethyl)phenol 5.53 mM 
pH (adjusted with KOH) 7.2  H2O add 
 
3.2.6 Quantitative real-time PCR analysis 
3.2.6.1 Isolation of mRNA 
For the isolation of mRNA from cell culture samples, the Qiagen RNeasy Mini Kit was used 
according to the manufacturer’s protocol. Therefore, cells were seeded in a density of 
0.6 x 106 cells/well in a 6-well plate and grown over night to 80-90% of confluence. Prior to mRNA-
isolation, tumor tissues were homogenized in lysis buffer provided by the manufacturer, using the 
Cell Homogenizer Potter S. The mRNA concentration of each sample was determined with the 
NanoDrop® ND 1000 spectrophotomer and normalized among the samples.  
3.2.6.2 Reverse transcription and RT-PCR 
For the creation of cDNA templates by reverse transcription, the High-Capacity cDNA Reverse 
Transcription Kit was used as described by the manufacturer. The Real-Time-Polymerase chain 
reaction (RT-PCR) was performed with the QuantStudio™ 3 Real-Time PCR System. The SYBR 
Green Mix I was used for the amplification of E-Cadherin. For the RT-PCR of PGC-1α, the 
TaqMan® Gene Expression Master Mix together with the TaqMan® Gene Expression Assay 
PPARGC1A (Hs00173304_m1) were used according to the manufacturer’s protocol. Changes in 
mRNA levels were assessed by the ΔΔCT method as previously described (Fleige et al., 2006). 
Materials and Methods 
39 
 
3.2.7 Flow Cytometry 
Table 25. Isotonic buffers for flow cytometry. 
HBSS (Hank's Balanced Salt Solution), HHBS (Hank's Buffer with Hepes)* 
CaCl2 1.26 mM  KH2PO4 0.44 mM  NaCl 137.9 mM 
D-glucose 5.56 mM  MgCl2 x 6 H2O 0.49 mM  *HEPES 20 mM 
NaHCO3 4.17 mM  MgSO4 x 7 H2O 0.41 mM  H2O add 
KCl 5.33 mM  Na2HPO4 0.34 mM  pH 7.2 
 
3.2.7.1 Calcein assay 
For assessment of the multidrug resistance (MDR) transporter activity by flow cytometry, 
HUH7-WT, HUH7-R(+) and HUH7-R(-) cells were seeded at a density of 3 x 105 cells in duplicates 
in a 12-well plate and grown for 24 h. The Multi-Drug Resistance Assay Kit (Calcein AM) was used 
according to the manufacturer’s instructions. Thereby, the cells of the positive control were 
stimulated with Cyclosporine A (25 µM) respectively Verapamil (50 µM) and incubated for 30 min 
in an incubator. The calcein solution provided by the manufacturer was added in a final concentration 
of 250 nM to the culture medium. Thereafter, the samples were incubated for 30 min protected from 
light. The cells were detached with trypsin/EDTA and transferred to FACS tubes for centrifugation 
(400 g, 5 min, 25 °C). The cell pellet was resuspended in 300 µl PBS and fluorescence was assessed 
on a FACSCanto II flow cytometer (Ex 488 nm, Em 530 nm). 
3.2.7.2 Glucose uptake 
For quantification of the cellular glucose uptake, cells were seeded as described above 
(chapter 3.2.7.1), washed with PBS and stained with 100 µM of the fluorescent glucose analogue 
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). The cells were 
incubated with 2-NBDG for 30 min protected from light. Thereafter, cells were detached with 
trypsin/EDTA, washed with PBS and transferred to FACS tubes for centrifugation (400 g, 5 min, 
25 °C). The cell pellet was resuspended in 300 µl PBS and fluorescence was assessed on a 
FACSCanto II (Ex 488 nm, Em 530 nm). For analysis, the cell debris was excluded and the 
fluorescence intensity median normalized to the control using the FlowJo™ 7.6 analysis software. 
3.2.7.3 Cellular superoxides 
The cellular abundance of mitochondrial reactive oxygen species (ROS) was assessed for 
HUH7-WT, HUH7-R(+) and HUH7-R(-) cells, seeded as described above (chapter 3.2.7.1). Cells 
were incubated with a 5 µM working solution of the MitoSOX™ Red Mitochondrial Superoxide 
Indicator for live-cell imaging diluted in HBSS (Table 25). Cells were incubated for 30 min protected 
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from light. Subsequently, cells were detached with trypsin/EDTA, culture medium was added and 
cells were pipetted in FACS tubes for centrifugation (400 g, 5 min, 4 °C). Cells were washed in 
HBSS (Table 25), centrifuged and kept on ice until flow cytometric measurement on a FACSCalibur 
(Ex 488 nm, Em 575 nm). The cell debris was excluded and the fluorescence intensity median 
normalized to the respective control using the FlowJo™ 7.6 analysis software. 
3.2.7.4 Mitochondrial and lysosomal mass 
Cells were seeded as previously described (chapter 3.2.7.1), washed with PBS and incubated with 
the MitoTracker™ Green FM (1:9,000) or LysoTracker™ Red DND-99 (1:3,000) dye diluted in 
DMEM. Cells were incubated for 30 min protected from light and subsequently resuspended in 
300 µl PBS for analysis on a FACSCanto II (Ex 490 nm, Em 516 nm for mitochondrial mass and 
Ex 577 nm, Em 590 nm for lysosomal mass). The cell debris was excluded and the fluorescence 
intensity median normalized to the respective control using the FlowJo™ 7.6 analysis software. 
3.2.7.5 Intracellular Calcium 
Cytosolic calcium levels were determined using the calcium indicator Cal-520 AM according to the 
manufacturer’s protocol. Cells were seeded as previously described (chapter 3.2.7.1), grown for 24 h 
and incubated with 10 μM of the Cal-520 AM dye. Cells were incubated (90 min, 37 °C, then 30 min, 
RT), detached and centrifuged (400 g, 5 min, RT). The cell pellet was washed and resuspended in 
HHBS (Table 25) to remove excess dye. The fluorescence intensity was analyzed on a FACSCanto II 
(Ex 488 nm, Em 530 nm). The cell debris was excluded and the fluorescence intensity median 
normalized to the respective control using the FlowJo™ 7.6 analysis software. 
3.2.7.6 Apoptosis 
For the assessment of apoptosis rates, a previously published method (Nicoletti et al., 1991) was 
used. Therefore, cells were seeded as previously described (chapter 3.2.7.1), trypsinized and washed 
twice by centrifugation (600 g, 10 min, 4 °C). After resuspension in ice-cold PBS, cells were 
permeabilized and DNA stained by adding a fluorochrome solution (FS), which contains the DNA-
intercalator propidium iodide (PI) (Table 26). Cells were incubated in the FS buffer overnight at 4 °C 
and analyzed the next day by flow cytometry on a FACSCalibur instrument (Ex 493 nm, 
Em 632 nm). Given, that apoptosis is accompanied by DNA fragmentation, the low-fluorescence 
sub-G1 peak, which accounts for apoptosis, was quantified by the FlowJo™ 7.6 analysis software. 
Table 26. PI containing permealization buffer. 
FS buffer 
Propidium iodide 75 μM  Triton-X 100 0.1% 
Trisodium citrate 0.1%  PBS add 
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3.2.8 LC-MS/MS analysis of the cellular proteome and lipidome 
3.2.8.1 Proteomics analysis 
Mass spectrometry (MS) - based proteomics analysis of HUH7-WT, HUH7-R(+) and HUH7-R was 
performed and the MaxQuant analysis kindly provided by Dr. T. Fröhlich (Laboratory for Functional 
Genome Analysis, LAFUGA, Gene Centre, LMU, Munich, Germany). 
3.2.8.1.1 Sample preparation 
Cells were seeded in 6-well dishes and grown to confluence for 24 h. Thereafter, cells were washed 
five times with PBS, detached with trypsin/EDTA and centrifuged (1,000 rpm, 5 min, 4 °C). The cell 
pellets were resuspended in 100 µl ice-cold PBS and stored at -80 °C until further processing. Per 
1 x 105 cells, 20 µl of 8 M urea/ 0.4 M NH4HCO3 was added. Cells were lysed using the Sonoplus 
GM3200 ultrasonic device with BR30 cup booster, applying 10,000 kJ. For further homogenization, 
samples were centrifuged through QIA-Shredder devices. Protein concentrations were determined 
by Bradford assays (Bradford, 1976) and adjusted to 0.6 mg/ml with 8 M urea/ 0.4 M NH4HCO3. To 
cleave bisulfide bonds, 25 µg of total protein was incubated with 1,4-Dithioerythritol (DTE) at a 
concentration of 4.5 mM for 30 min and free sulfhydryl residues were blocked with 10 mM 
iodoacetamide for 30 min in the dark. After dilution with water to a concentration of 1 M urea, 0.5 µg 
porcine trypsin was added and samples were incubated overnight at 37 °C. 
3.2.8.1.2 Liquid-chromatography mass spectrometry (LC-MS/MS) 
The chromatography of peptides was performed on an EASY-nLC 1,000 chromatography system 
coupled to an Orbitrap XL instrument. For analysis, 2.5 µg of peptides diluted in 0.1% formic acid 
(FA) were transferred to a trap column (PepMap100 C18, 75 µm x 2 cm, 3 µm particles) and 
separated at a flow rate of 200 nl/min (Column: PepMap RSLC C18, 75 µm x 50 cm, 2 µm particles). 
A 260 min linear gradient from 5% to 25% solvent B (0.1% formic acid, 100% ACN) and a 
consecutive 60 min linear gradient from 25% to 50% solvent B was used. For data acquisition, a top 
five data dependent collision-induced dissociation (CID) method was applied. 
3.2.8.1.3 Data processing 
For quantitative data analysis of the LC-MS/MS-proteomics screening and for subsequent volcano 
blot and gene cluster analysis, the MaxQuant and Perseus software packages were used, respectively. 
The MaxQuant dataset was filtered, in order to exclude incomplete information with less than 3 valid 
values per condition and protein. Further, missing label-free quantification (LFQ) intensities were 
filled with imputation values from the normal distribution. For volcano blot analysis, a two-sampled 
t-test (FDR 0.01, p-value <0.05) was performed and values outside the significance range were 
excluded by a cut-off-curve (setting: s0 = 2). 
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3.2.8.1.4 Gene set enrichment analysis (GSEA) 
The GSEA software (The Broad Institute, Massachusetts, USA) is a computational method that 
determines whether an a priori defined set of genes shows statistically significant differences between 
two biological states. Therefore, gene sets were obtained from the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (C2.cp.keeg.v.5.1.symbols) and the gene ontology (GO) database 
(C5.bp.v.5.1.symbols, C5.cc.v.5.1. symbols, C5.mf.v.5.1.symbols). For subsequent analysis, gene 
set size filters were set to min=15/ max=500 genes per gene set. The primary result of the GSEA is 
the enrichment score (ES), which reflects the degree to which a gene set is overrepresented at the top 
or bottom of a ranked list of genes. The ES reflects the correlation of the gene with one or the other 
phenotype. The normalized enrichment score (NES) accounts for differences in gene set size, 
whereas the False Discovery Rate (FDR) is an analogue to the nominal p-value (NOM p-val), 
adjusted for gene set size and multiple hypothesis testing. For better comparison, gene sets were 
ranked according to their NOM p-val and gene sets with NOM p-val<0.05 were highlighted. 
3.2.8.2 Lipidomics analysis 
MS-based lipidomics analysis of HUH7-R(+) compared to HUH7-WT cells was performed and 
kindly provided by Dr. A. Koeberle together with Dr. H. Pein (Department of Pharmacy, 
Pharmaceutical Chemistry, Friedrich-Schiller-University Jena, Jena, Germany). 
3.2.8.2.1 Analysis of fatty acids and phospholipids 
Fatty acids and phospholipids were extracted and analyzed as previously reported (Koeberle et al., 
2013; Pein et al., 2017). In detail, 1.5 x 106 HUH7-WT and HUH7-R(+) cells were harvested and 
resuspended in 150 µl PBS. Next, 365 µl of a 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
standard (2 µl 0.2 mM DMPC in 363 µl methanol) and 187.5 µl chloroform was added to each sample 
and the tubes were vortexed for 30 seconds. Additionally, 187.5 µl chloroform was added and 
samples were vortexed a second time. Subsequently, 187.5 µl saline solution (0.9% NaCl) was 
added, samples vortexed and centrifuged (4000 rpm, 5 min, RT). The lower chloroform phase was 
transferred to a separate tube and the solvent was evaporated to obtain a dry lipid layer (20 min, 
30 °C). The lipid films were then stored at -20 °C until further analysis.   
Chromatography was carried out on an Acquity UPLC BEH C8 column (1.7 µm, 1×100 mm) using 
an Acquity Ultraperformance LC system. Lipids were detected by a QTRAP 5500 mass spectrometer 
equipped with an electrospray ionization source. The glycerophospholipids of the sample were 
identified and quantified in the negative ion mode based on the detection of both fatty acid anion 
fragments by multiple reaction monitoring (MRM). Sphingomyelins were analyzed after 
fragmentation and identified by the choline head group (m/z = 184) by MRM, and free fatty acids 
were detected by single ion monitoring in the negative ion mode. The absolute amounts of lipids 
Materials and Methods 
43 
 
were normalized to the internal standard DMPC and the cell number. The cellular proportion of 
individual lipid species was calculated as percentage of all lipids within the subgroup (= 100%). 
3.2.8.2.2 Analysis of acyl-CoAs 
For the analysis of the cellular acyl-CoA composition, 4 x 106 HUH7-WT and HUH7-R(+) cells were 
harvested, centrifuged (1,000 rpm, 5 min, RT) and snap frozen. The cells pellets were stored at -80 °C 
until further analysis. Extraction and analysis of acyl-CoAs was performed as previously described 
(Glatzel et al., 2018), using [13C3]-malonyl-CoA as internal standard. In brief, acyl-CoAs were 
separated on an Acquity UPLC BEH C18 column (1.7 µM, 2.1×50 mm) and detected based on the 
neutral loss of 2’-phospho-ADP ([M+H-507]+) in the positive ion mode using the UPLC-coupled 
tandem ESI-MS system described above. Subsequently, mass spectra were processed using the 
Analyst 1.6 software and results were displayed by heatmap analysis. 
3.2.9 Metabolic assays 
3.2.9.1 Cell viability 
Assessment of IC50-values and growth rescue experiments were determined with the CellTiter-Blue® 
(CTB) viability assay. Therefore, HUH7-WT, HUH7-R(-/72 h), RIL175 cells (10,000 cells/well) and 
HUH7-R(+) cells (40,000 cells/well) were seeded in triplicates into 96-well plates, stimulated 24 h 
after seeding and incubated for 72 h. Further, 20 μl CTB reagent was added to each well with a 
culture medium volume of 100 µl. After 4 h of incubation, the metabolic activity was quantified via 
dual fluorescence record at 560/590 nm on a SpectraFluor®PLUS plate reading photometer. 
3.2.9.1.1 Intracellular ATP 
For the assessment of the cellular dependency towards anaerobic glycolysis, HUH7-WT 
(10,000 cells/well), HUH7-R(+) (40,000 cells/well) and HUH7-R(-/72 h) (10,000 cells/well) cells 
were seeded in triplicates in a 96-well plate and grown for 24 h. Cells were stimulated with the 
antimetabolite 2-DG in a concentration ranging from 0 to 200 µM. After 72 h, the microplate was 
equilibrated to room temperature for 20 min and 100 μl of CellTiter-Glo® reagent were added to an 
equal amount of culture medium to each well. Cell lysis was induced on an orbital shaker for 2 min, 
following 10 min of incubation at RT, protected from light. The content of each well was transferred 
to a white walled Greiner CELLSTAR® 96-well plate and luminescence was recorded with an 
Orion II microplate luminometer. Similarly, ATP levels of HUH7-R cells upon rebound growth 
compared to HUH7-WT were assessed. Therefore cells were seeded in a 24-well plate in a density 
dependent on the time of rebound growth (R(-/0): 96,000 cells/well, R(-/24h): 80,000 cells/well, 
R(-/48 h): 48,000 cells/well, R(-/72 h): 24,000 cells/well, R(-/96 h): 16,000 cells/well, R(-/168 h): 
12,000 cells/ well) and sorafenib was withdrawn for the indicated time. HUH7-WT cells were seeded 
in a density of 80,000 cells/well 24 h before assaying. Thereafter, cells were detached with 
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trypsin/EDTA, normalized to the cell number and incubated with an equal amount of CellTiter-Glo® 
reagent. The luminescence intensity was assessed on a luminometer as described above. 
3.2.9.2 Lactate fermentation 
The abundance of extracellular lactate was assessed with the L-Lactate Assay Kit according to the 
manufacturer’s instruction. Thereby, HUH7-R(+) cells were seeded in triplicates in a 96-well plate 
in a density dependent on the time of rebound growth as previously described (chapter 3.2.9.1.1). 
Sorafenib was withdrawn from HUH7-R cells for the indicated time. HUH7-WT cells were seeded 
in a density of 20,000 cells/well 24 h before assaying. For each condition, 200 µl of supernatant were 
collected and deproteinated by adding 200 µl cold 0.5 M metaphosphoric acid (MPA), as provided 
by the manufacturer. The samples were vortexed and placed on ice (5 min). Next, the samples were 
centrifuged (10,000 g, 5 min, 4 °C), in order to pellet the proteins, 360 µl supernatant was removed 
and neutralized with 36 µl of 2.5 M potassium carbonate. In a last centrifugation step (10,000 g, 
5 min, 4 °C) precipitated salts were removed. The supernatant was used for assaying with the 
provided detection reagents, as described by the manufacturer’s protocol. The fluorescence was 
measured on a SpectraFluor®PLUS plate reader (Ex 535 nm, Em 590 nm). 
3.2.10 Functional analysis of glycolysis and oxidative phosphorylation 
3.2.10.1 Glycolytic Stress Test 
The contribution of glycolysis and oxidative phosphorylation to the cellular energy generation was 
analyzed by a glycolytic stress test. Therefore, HUH7-WT, HUH7-R(+) and HUH7-R(-) cells were 
seeded into a XFe96 microplate and grown for 24 h to confluence. The Seahorse Glycolysis Stress 
Test Kit was used in combination with the Seahorse XFe96 Analyzer, as described by the 
manufacturer. In detail, cells were initially incubated in assay medium without glucose or pyruvate 
and subsequently treated with D-glucose (10 mM), oligomycin (1 µM) and 2-DG (50 mM). The 
extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) were measured for 
80 min and the basal ECAR levels and OCR levels were assessed at the plateau after D-glucose 
injection. Results were normalized to the DNA content, which was assessed by CyQuant® GR 
staining, according to the manufacturer’s protocol. Data analysis was performed with the Wave 2.3.0 
software and the Seahorse XF Glycolysis Stress Test Report Generator.  
3.2.10.2 High resolution respirometry 
In addition to the glycolytic stress test, the mitochondrial routine respiration and the respiratory 
capacity of HUH7-WT, HUH7-R(+) and HUH7-R(-) cells were determined by high resolution 
respirometry on the OROBOROS Oxygraph-2k. For analysis, 2 x 106 HUH7-WT cells, 2 x 106 
HUH7-R(-) cells respective 4 x 106 HUH7-R(+) cells were centrifuged, resuspended in culture 
medium and added to the chamber of the oxygraph. Subsequently, cells were stimulated with 400 µM 
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oligomycin (Leak), 5 mM CCCP (ETS), 2 µM rotenone (complex II) and 500 µM antimycin A 
(ROX). The O2-flux (red curve) and the total O2-content in oxygraph chamber (blue curve) were 
assessed over time (Figure 15 D). The parameters Leak, ETS, complex II and ROX were determined 
within the red segments at the plateau phase after stimulation and normalized to the cell number. 
3.2.11 Redox-balance 
3.2.11.1 NAD+/NADH and NADP+/NADPH 
The NAD+/NADH as well as the NADP+/NADPH ratio and total content were measured using the 
commercially available NAD/NADH Glo™ and NADP/NADPH Glo™ kits. HUH7-R(+) cells were 
seeded at a density of 10,000 cells/well and sorafenib was withdrawn while cells were either left 
untreated, treated with the respective compounds or transiently gene-silenced for 72 h. Extraction 
and measurement of the reduction equivalents was performed according to the manufacturer’s 
protocol. In brief, 60 µl PBS were added to each well and plates were frozen at -80 °C for at least 
20 min. Cells were scraped off the plates and normalized in protein content using the Bradford assay 
(Bradford, 1976). Thereafter, aliquots of each sample were either left untreated (total NAD+ and 
NADH / total NADP+ and NADPH) or subjected to acid (NAD+ and NADP+), respective basic 
(NADH and NADPH) treatment. All acid- or base-treated samples were incubated for 15 min at 
60 °C on a heating shaker. Next, samples were pH-neutralized with 0.25 M tris-base (NAD+/NADP+) 
or a 0.25 M HCl/Tris-base (NADH/NADPH) buffer. For detection, the neutralized samples were 
transferred into white walled Greiner CELLSTAR® 96-well plates and measured according to the 
manufacturer’s protocol. Therefore, samples were incubated for 60 min and luminescence was 
assessed on a Spark® multimode microplate reader. 
3.2.11.2 Reactive oxygen species (ROS) 
Cells were seeded in 96-well plates as previously described, grown for 72 h and stimulated 
respectively transiently transfected for 72 h. ROS staining was performed with the ROS Detection 
Cell-Based Assay Kit (DCFDA) according to the manufacturer’s protocol. The ROS scavenger 
N-acetyl cysteine (NAC) (20 mM) was used as a negative control and fluorescence was assessed via 
dual fluorescence record at 490/530 nm on a Spark® multimode microplate reader. The obtained 
fluorescence intensities were normalized on cell number by crystal violet staining. 
3.2.12 In vivo experiments 
All experiments were performed according to German respective Austrian legislation of animal 
protection and approved by the local government authorities (approval by the government of Upper 
Bavaria, Germany: Az 55.2-1-54-2532-22-2016/ approval by the federal ministry of science, 
research and economy, Austria: BMBWF-66.019-0041-V-3b-2018). 
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3.2.12.1 Mice 
For ectopic tumor mouse xenografts, exclusively females of the albino immune-incompetent mouse 
strain „Fox Chase SCID” (CB17/Icr-Prkdcscid/IcrIcoCrl) were used. Immunodeficiency is required 
to avoid tumor cell rejection and the albino phenotype to enable in vivo bioluminescence tumor size 
measurements. All mice were purchased in an age between five to six weeks from Charles River. 
3.2.12.2 Ectopic tumor model 
Mice were shaved on the left lateral abdomen and 3 x 106 HUH7-WT or HUH7-R(+) cells were 
subcutaneously injected in the left flank of the mouse with 1 ml syringes and 27 G needles. From the 
day of tumor cell injection on, mice were treated by intraperitoneal injection with sorafenib 
(20 mg/kg), TGC (50 mg/kg, 100 mg/kg) or a DMSO control (100 μl solvent: 5% DMSO, 10% 
solutol, 85% PBS). Tumor size measurements were performed at the indicated time points, using a 
digital caliper. The tumor volume was calculated with the formula 1/6 x π x L x W x H (L=length, 
longest side of the tumor, W=width, widest side of the tumor, H=height, highest side of the tumor). 
3.2.12.3 In vivo bioluminescence imaging 
The size of HUH7-R-LUC tumors was assessed by detection of the bioluminescent signal with the 
IVIS® spectrum device. Imaging was performed at day 3 and day 6 post cell injection. Therefore, 
0.3 g/kg D-luciferin sodium salt dissolved in 100 μl PBS were intraperitoneally injected in the mice, 
prior to narcotization in 3% isoflurane in oxygen. Mice were kept under narcotization with 2% 
isoflurane and imaged in lateral position. Images were taken every minute for 20 min, 13 min after 
luciferin injection. The bioluminescence signal within the defined region of interest (ROI) was 
calculated with the Living Image 4.4 software. For quantification, the area under the curve (AUC) 
of luminescence counts was determined for each mouse. All mice were sacrificed through cervical 
dislocation. Thereafter tumors were resected and the weight and volume were determined. Tumors 
were snap frozen in liquid nitrogen, stored at -80 °C and homogenized for further analysis. 
3.2.13 Statistical analysis 
All experiments described were conducted at least three times. The data are presented as the mean 
± SEM, and statistical significance was considered at p≤0.05. Statistical analysis was performed with 
the GraphPad Prism software 7.0. For differences between two groups, an unpaired two-tailed 
Student’s t-test was used, given the assumption that both groups are sampled from a normal 
distribution with equal variances. Group comparisons (n≥3) were performed using one-way ANOVA 
with Tukey’s multiple comparison test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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4 RESULTS 
4.1 The sorafenib resistance HCC cell model 
Although sorafenib is effective in prolonging the median OS of advanced-stage HCC, acquired 
resistance has become an obstacle for increasing the life expectancy of patients. To address this 
clinically highly relevant topic, we generated sorafenib-resistant HCC cell models by exposing 
HuH-7 and RIL-175 HCC cells to increasing doses of sorafenib (Chapter 3.2.1.2). These sorafenib-
resistant HUH7-R cells, which obtained resistance up to clinically relevant peak plasma 
concentrations of 10 µM (human dose: 800 mg/day; 8.5–15.7 µM) (Strumberg et al., 2007), were 
subsequently characterized. RIL175-R cells were used to confirm the major findings of this study. 
4.1.1 Generation and characterization of the sorafenib-resistant HUH7-R cell line 
The HUH7-R cells obtained a major morphological alteration to a spindle-shaped phenotype 
(Figure 6 A) and distinct chemoresistance up to a half maximal inhibitory concentration (IC50) of 
23 µM sorafenib (Figure 6 B) that was maintained after treatment termination (Figure 6 C). This 
treatment robustness of HUH7-R cells to sorafenib compared to their parental HUH7-WT cell line 
was confirmed in vivo in an ectopic tumor mouse xenograft (Figure 7 A-B), in which decreased 
vascularization but increased invasiveness occurred in sorafenib-resistant tumors (Figure 7 C-D). 
 
Figure 6. The sorafenib resistance HCC cell model in vitro. (A) Mesenchymal phenotype induced by 
sustained sorafenib exposure. Phase contrast microscopy of wild-type (HUH7-WT) and sorafenib-resistant 
(HUH7-R) HuH-7 cells. Scale bars indicate 200 µm. (B) HUH7-R and RIL175-R cells acquired resistance to 
sorafenib up to a clinical relevant range. Dose-response curve with corresponding IC50-values and coefficient 
of determination R2 are shown. (C) Sorafenib resistance is sustained after sorafenib withdrawal for 72 h. Flow 
cytometric quantification of apoptotic cells untreated (top) vs. treated with sorafenib (10 µM) for 24 h (bottom) 
of HUH7-R vs. HUH7-WT cells. HUH7-R cells were cultured in sorafenib (10 µM) and sorafenib was 
withdrawn for 72 h prior to stimulation. Values denoted as ± SEM, n=3, ****p<0.0001 (t-test).  
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Figure 7. The sorafenib resistance HCC cell model in vivo. (A) HUH7-R cells reveal decreased sorafenib-
responsiveness in vivo. Ectopic tumor mouse xenograft with HUH7-WT and HUH7-R cells, treated with 
DMSO vs. 20 mg/kg sorafenib every second day. Assessment of tumor volume (left) and tumor weight after 
resection (right) at the indicated time points. (B) Sorafenib therapy (20 mg/kg, every second day) of ectopic 
tumor mouse model (Figure 7 A) was well tolerated. The mouse weight was assessed at the indicated time 
points. (C) Sorafenib-resistant tumors show reduced vascularization compared to HUH7-WT tumors. 
Representative resected tumors of the 4 groups are shown. (D) HUH7-R cells show highly invasive tumor 
growth in vivo. Invasive growth of HUH7-R tumors in 4/7 mice of the DMSO Control group and 3/7 mice of 
the 20 mg/kg sorafenib treated group (Figure 7 A). Values denoted as ± SEM, n=3, *p<0.05 (t-test). 
4.1.2 Sorafenib-resistant HCC undergoes relapse of tumor growth upon sorafenib therapy 
termination 
To mimic the clinical situation of advanced-stage HCC patients, in which discontinuous dosing 
schedules are common due to severe adverse events, sorafenib was retracted from this cell model 
under standardized conditions. Strikingly, after sorafenib withdrawal from the HUH7-R cells 
cultured in 10 µM sorafenib (HUH7-R(+) cells), a fast initial relapse of proliferation was observed 
within 72 h of treatment termination. In the following, these cells characterized by a rebound of 
proliferation are termed HUH7-R(-) cells (Figure 8 A-B). Notably, under sorafenib exposure, 
HUH7-R(+) cells acquired broad cross-resistance to a wide variety of clinically used 
chemotherapeutics, but resensitized after sorafenib treatment termination (Figure 8 C; Figure S1). 
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Figure 8. Rebound growth of sorafenib-resistant HUH7-R cells with chemotherapeutic resensitization. 
(A) Sorafenib withdrawal from HUH7-R cells, continuously cultured in 10 µM sorafenib (HUH7-R(+) cells) 
leads to rapid resumption of proliferation. If not mentioned otherwise, rebound growth cells are cultured 
without sorafenib for 96 h (HUH7-R(-) cells). Impedance measurements and the growth rate calculated from 
cell density (index) over 72 h are shown. (B) Schematic overview of the sorafenib-resistant rebound growth 
model. (C) HUH7-R(+) cells acquired reversal cross-resistance to the clinically applied chemotherapeutics 
cisplatin and doxorubicin. Normalized proliferation rates within 72 h of treatment are shown. Values denoted 
as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). See also Figure S1. 
4.1.3 Reversible epithelial-to-mesenchymal transition (EMT) by PI3K/AKT pathway 
activation contributes to acquired sorafenib resistance 
As sorafenib resistance has been shown to be independent of the multidrug resistance (MDR)-
machinery (Figure S2), the observed chemoresistance in HUH7-R(+) cells is suggested to be 
mediated by EMT. In fact, the HUH7-R(+) cells exhibit typical EMT features, such as decreased 
protein levels of the epithelial marker E-Cadherin, a gain of the mesenchymal marker vimentin and 
increased N-Cadherin surface localization in comparison to HUH7-WT (Figure 9 A-D). As 
previously reported in this context, EMT and malignant invasiveness can be induced by evasive 
activation of the PI3K/AKT-signaling pathway through continuous inhibition of the sorafenib-
targeted MAPK/ERK axis, as observed in sorafenib-exposed HUH7-R(+) cells (Figure 9 E) (Chen 
et al., 2011; van Malenstein et al., 2013). Both AKT phosphorylation and the mesenchymal shift in 
protein expression were found to be reversible after sorafenib withdrawal. Upon EMT, the invasive 
potential observed in vivo is largely dictated by the matrix metalloproteinases (MMPs) MMP-2 and 
MMP-9, which were both upregulated in HUH7-R(+) cells (Figure S3) (Son and Moon, 2010).  
Summarizing, in chapter 4.1 we established a robust sorafenib resistance HCC cell model that 
obtained broad chemotherapeutic cross-resistance upon sorafenib treatment and showed a rapid 
rebound of proliferation after therapy termination. Both phenomena possibly contribute to the overall 
low therapeutic benefit of sorafenib. Importantly, the resumption of tumor growth secondary to 
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sorafenib goes along with chemotherapeutic resensitization, implicating a potential strategy of 
therapeutic intervention in the second-line setting of advanced-stage sorafenib-resistant HCC. 
 
 
Figure 9. Sorafenib resistance is accompanied by partial EMT and compensatory PI3K/AKT pathway 
activation. (A) Increased surface localization of N-Cadherin under sustained sorafenib exposure. 
Immunostaining of the EMT markers E-Cadherin (green), N-Cadherin (red) as well as Hoechst33342 (blue). 
Scale bar indicates 50 µm. (B) Long-term sorafenib exposure induces partial EMT in HUH7-R(+) cells. 
Immunoblot analysis of the EMT marker E-Cadherin and vimentin, normalized to the protein load and to 
HUH7-WT. (C) E-Cadherin mRNA-expression is decreased upon sustained sorafenib exposure of HUH7-R 
cells in vitro. E-Cadherin mRNA-levels were normalized to HUH7-WT. (D) Sorafenib treatment modifies 
E-Cadherin mRNA-expression of HUH7-R cells in vivo. E-Cadherin mRNA levels of resected tumors 
(Figure 7) were normalized to the mean mRNA-expression of HUH7-WT. (E) Compensatory PI3K/Akt 
signaling pathway is upregulated in HUH7-R(+) cells. Immunoblot analysis was normalization to the protein 
load and to HUH7-WT. Values denoted as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001 (ANOVA).  
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4.2 Tumor relapse is driven by metabolic and mitochondrial alterations 
4.2.1 Mass spectrometry (MS)-based proteomics analysis of sorafenib resistance and 
rebound growth 
Sorafenib treatment abrogation accompanies with an unfavorable relapse of tumor growth, but has 
been shown to resensitize HUH7-R cells to chemotherapeutic treatment. To obtain better insight into 
the underlying mechanism of sorafenib resistance and the therapy-limiting tumor relapse, we 
performed LC-MS/MS-based proteomics screening and identified differentially expressed proteins 
in sorafenib-resistant HUH7-R cells before and after treatment termination in comparison to their 
parental HUH7-WT cell line. As sorafenib resistance was accompanied by drastic changes of the 
cellular proteome, gene set enrichment analysis (GSEA) was applied to elucidate the most prominent 
altered protein clusters (Figure 10; Figure S4). In HUH7-R(+) cells, GSEA strongly highlighted an 
elevated abundance of proteins related to mitochondrial structural components and glucose turnover, 
such as the tricarboxylic acid (TCA)-cycle, glycolysis, as well as amino and nucleotide sugar 
metabolism. In addition, higher lysosomal protein expression and suppressed transcriptional activity 
were observed when compared to HUH7-R(-) rebound growth cells. 
 
Figure 10. GSEA of the sorafenib resistance HCC cell model. (A) HUH7-R cells reveal massive alterations 
in their proteome compared to their parental HUH7-WT cell line, necessitating comparison by GSEA. Gene 
cluster analysis of MS-proteomics screen compares HUH7-WT (wt), HUH7-R(+) (Resi_pos) and HUH7-R(-) 
(Resi_neg) cells. (B) Gene sets enriched in HUH7-WT compared to HUH7-R(+) cells and (C) gene sets 
enriched in HUH7-R(+) compared to HUH7-R(-) cells are shown. Top 10 upregulated gene sets ranked 
according to their nominal p-value (NOM p-val) are listed and gene sets with NOM p-val<0.05 are highlighted. 
ES: enrichment score; FDR: false discovery rate; NES: normalized enrichment score. See also Figure S4. 
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Figure 11. Volcano blot analysis comparing the proteome of HUH7-R(+) and HUH7-R(-) cells. (A) T-test 
Difference and Log10 p-value are shown. Proteins lower and higher than the cut-off FDR 0.05, s0=2 (dashed 
green line) are highlighted with green dots. (B) Autophagic proteins and the mitochondrial complex I 
(NDUFS1) are upregulated upon rebound growth. Proteins with a t-test Difference <-0.715 (higher abundance 
in HUH7-R(-) cells) are listed according to their x-fold change. (C) Mitochondrial proteins are downregulated 
upon rebound growth. Proteins with a t-test Difference >0.715 (higher abundance in HUH7-R(+) cells) are 
listed according to their x-fold change. Proteins of mitochondrial origin are highlighted in green. Values 
denoted as ± SEM, n=5. Experiments were performed in technical duplicates. 
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Interestingly, volcano blot analysis at the single-protein level revealed a central role of the 
mitochondrial NDUF subunit 1, complex I of the respiratory chain, in HUH7-R(-) cells, as the NDUF 
was found to be almost 5-fold increased among tumor relapse (Figure 11 A-B). The mitochondrial 
ETC accounts not only for the majority of cellular ATP production, but it also supplies through its 
complex I activity mitochondria with the oxidized cofactor NAD+. This intrinsic electron acceptor, 
in turn, fuels TCA cycle activity driving biosynthesis and proliferation (Sullivan et al., 2015; Vander 
Heiden et al., 2009). In addition, we found a higher abundance of proteins involved in DNA-
replication, translation and autophagosome formation, such as Sequestosome-1 (SQSTM1; p62), in 
HUH7-R(-) compared to HUH7-R(+) cells. In contrast, mitochondrial proteins involved in protein 
import through the IMM, superoxide defense and the overall TCA cycle activity were upregulated in 
HUH7-R(+) cells (Figure 11 C). Relative quantification of the protein classes in HUH7-R cells 
before and after sorafenib withdrawal indicated an increased requirement of oxidoreductases (13%) 
and hydrolases (17%) in HUH7-R(+) cells, whereas cell adhesion molecules (0%) and chaperones 
(2%) were found to be underrepresented in comparison to HUH7-R(-) cells (Figure 12; Figure S5).  
 
Figure 12. Alterations of protein classes upon rebound growth. (A) Oxidoreductases and hydrolases are 
upregulated in HUH7-R(+) cells. Protein classes >1.5-fold upregulated in HUH7-R(+) vs. HUH7-R(-) are 
shown. (B) Chaperones and cell adhesion proteins are upregulated in HUH7-R(-) cells. Protein classes 
>1.5-fold upregulated in HUH7-R(-) vs. HUH7-R(+) are shown. The analysis of protein classes of the 
MS-proteomics screening was performed with pantherdb.org (Gene ontology database). See also Figure S5. 
4.2.2 HUH7-R(-) cells undergo a metabolic switch to increased respiratory activity 
In addition to the MS-proteomics screening, metabolic profiling by a glycolytic stress test showed 
that HUH7-R(-) cells shift towards a strongly energy-producing phenotype with a high oxygen 
consumption rate (OCR) (Figure 13 A) and a boost of ATP levels was observed upon growth 
resumption (Figure 13 B). In contrast, sustained sorafenib exposure was accompanied by an 
increased rate of lactate fermentation (Figure 13 B), an anaerobic high-flux elimination of extra-
mitochondrial pyruvate (Curi et al., 1988), which was gradually reversed after sorafenib withdrawal. 
These HUH7-R(+) cells were highly dependent on anaerobic glycolysis for ATP production, which 
was confirmed by an increased cellular glucose uptake (Figure 13 C) compared to HUH7-R(-) cells.  
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Figure 13. Metabolic profiling of the sorafenib-resistant rebound growth model. (A) Metabolic switch 
from glycolysis to respiration upon rebound growth. Oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were assessed simultaneously by a glycolytic stress test. The cells were treated with 
(1) D-glucose (10 mM), (2) oligomycin (1 µM) and (3) 2-deoxy-D-glucose (2-DG) (50 mM). Basal ECAR- 
and OCR-levels was determined at the plateau after D-glucose injection and normalized to the cell number. 
(B) Anaerobic lactate fermentation in HUH7-R(+) cells with insufficient ATP-generation. Measurements upon 
sorafenib withdrawal from HUH7-R(+) cells for 168 h every 24 h and normalization to HUH7-R(+). Mean 
(dashed line) and SEM (green area) of HUH7-WT are presented for comparison. (C) HUH7-R(+) cells are 
strongly dependent on glycolysis for energy generation. ATP levels within 72 h of glycolysis inhibition by 
2-DG were assessed and normalized to the untreated control (left). Glucose uptake within 30 min was 
determined by flow cytometry and normalized to the cellular volume (Figure S6) and to HUH7-WT (right). 
(D) HUH7-R(-) cells have a strong capacity to switch from respiration to glycolysis. The glycolytic reserve 
depicts the percentage change of ECAR before and after oligomycin treatment in a glycolytic stress test  
(Figure 13 A). Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA).  
Upon rebound growth, respiratory active HUH7-R(-) cells obtained a flexible metabolic phenotype 
and displayed the ability to switch to glycolysis after ETC inhibition (Figure 13 D). In summary, on 
the one hand, the sorafenib-resistant HUH7-R(+) cells increase their glucose metabolism and are 
dependent on glycolysis for ATP production. This so-called Warburg effect (Warburg, 1956), has 
been previously associated with acquired chemoresistance in cancer cells (Shen et al., 2012). 
However, on the other hand, the aerobic pyruvate turnover by the TCA cycle of HUH7-R(+) cells 
appears to be insufficient and results in elevated lactate excretion. Thus, the presented data suggests 
that sustained sorafenib exposure impairs the mitochondrial metabolic functionality of HCC cells. 
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4.3 Sorafenib exposure mediates mitochondrial damage 
4.3.1 Rebound growth is accompanied by dynamics in mitochondrial fission and fusion  
Prominent alterations in mitochondria and their metabolic pathways, as revealed by LC-MS/MS-
based proteomics analysis, warrant a detailed investigation of mitochondrial morphology and its 
functional dynamics upon tumor growth resumption. Mitochondria form a highly dynamic network 
undergoing constant fission and fusion to maintain functionality, adapt to environmental stressors 
and to drive metabolism (McBride et al., 2006). Fission and fusion processes are regulated by the 
GTPase dynamin-related protein (Drp1) and marked by mitofusin (Mfn-1) expression on the outer 
mitochondrial membranes (OMM) (Wong et al., 2018). A strong increase in mitochondrial mass 
(Figure 14 A) together with mitochondrial fission was observed in sorafenib-treated HUH7-R(+) 
cells compared to the parental HUH7-WT cell line (Figure 14 B). Interestingly, both morphological 
alterations were reversible in HUH7-R(-) cells upon 96 h of sorafenib withdrawal. 
 
Figure 14. Sorafenib-resistant HUH7-R(+) cells undergo mitochondrial fission. (A) Metabolic switch is 
accompanied by major dynamics in fission/fusion processes and a reversible increase of mitochondrial mass 
upon sustained sorafenib exposure. MitoTracker staining of mitochondrial network is shown. Scale bars 
indicate 20 µm. (B) Immunoblot analysis of mitochondrial fusion- respective fission-marker Mfn-1 and Drp-1 
are shown. Experiments were performed n=3 and representative images are shown. 
4.3.2 Sustained sorafenib exposure impairs mitochondrial functionality 
Sorafenib treatment impaired not only the mitochondrial network but may also have an impact on 
their functionality. First, sustained electron leakage from the ETC led to excessive production of 
mitochondrial superoxides (O2-) in HUH7-R(+) cells (Figure 15 A). This elevated electron leakage 
might be partially due to the reduced protein expression of complex I (CI-NDUFB6) and complex V 
(CV-ATP5A) respiratory chain subunits in HUH7-R(+) cells (Figure 15 B) (Murphy, 2009). In fact, 
enhanced O2- levels were found to be directly linked to sorafenib exposure and reversed upon drug 
withdrawal (Figure S7 A). Second, disrupted mitochondrial functionality was confirmed by low ETS 
capacity and routine respiration, as determined by high-resolution respirometry (Figure 15 C-D). 
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Figure 15. Sorafenib impairs composition and functionality of the ETC. (A) Sorafenib induces electron 
leakage from the ETC in HUH7-R(+) cells. Flow cytometric quantification of superoxide levels with 
normalization to the cellular volume (Figure S6) and to HUH7-WT. (B) Sorafenib impairs the protein 
expression of the nucDNA-encoded subunit CV-ATP5A and the mtDNA-encoded ETC subunit CI-NDUFB6. 
Immunoblot analysis of mtDNA- (CI-NDUFB6, CIV-MTCO1) and nucDNA-encoded ETC subunits 
(CII-SDHB, CIII-UQCRC2, CV-ATP5A). The protein expression was normalized to the protein load and to 
HUH7-WT. (C) Renewed mitochondria obtain increased ETC capacity. High-resolution O2-flux 
measurements untreated (Routine) and after oligomycin (Leak), CCCP (ETS), rotenone (complex II) and 
antimycin A (ROX) stimulation, normalized to cell number and cellular volume (Figure S6). 
(D) Representative O2-flux measurements (red curves) of 1.6 x 106 HUH7-WT, HUH7-R(-) and 3.2 x 106 
HUH7-R(+) cells are shown with the stimulation time points of oligomycin (400 µM), CCCP (5 mM), rotenone 
(2 µM) and antimycin A (500 µM). For quantitative assessment, the parameters Routine, Leak, ETS, 
complex II and ROX were determined within the red segments. Values denoted as ± SEM, n=3 for A and B, 
n=4 for C and D, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). See also Figure S7 A. 
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4.3.3 Endoplasmatic reticulum (ER)-stress links mitochondrial damage to mitophagy in 
sorafenib-resistant cells  
The origin of mitochondrial damage in HUH7-R(+) cells evoked to be closely linked to prominent 
ER-stress, as previously reported in the context of acquired chemoresistance through persistent 
sorafenib exposure (Holz et al., 2013; Ma et al., 2017). Indeed, the key-mediators of ER-stress NFκB 
and GADD 153/CHOP were strongly activated in HUH7-R cells (Figure 16 A). This implicates 
mitochondrial damage through excessing levels of free intracellular calcium (Ca2+), which is released 
from the ER. In addition, ER-stress induces, on a transcriptionally level, mitochondrial degradation 
with subsequent mitochondrial biogenesis in order to regain respiratory functionality (Figure 16 B).  
 
Figure 16. ER-stress links Ca2+-induced mitochondrial damage, activation of mitophagy and 
mitochondrial biogenesis. (A) ER-stress pathways are strongly upregulated in HUH7-R cells. Immunoblot 
analysis of CHOP and NFκB activation were normalized to the respective protein load and to HUH7-WT. 
(B) ER-stress links mitochondrial degradation and mitochondrial biogenesis upon sorafenib resistance and 
rebound growth. Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ****p<0.0001 (ANOVA). 
4.3.4 Efficient autophagy of damaged mitochondria after sorafenib withdrawal 
As mitochondria play a critical role in cellular homeostasis, they not only undergo dynamic 
reformation but also constant quality control, whereby damaged or functionally disturbed 
mitochondria are engulfed by autophagosomes that fuse with lysosomes for degradation (Pickles et 
al., 2018). Hints for the occurrence of mitophagy in HUH7-R(+) cells were obtained by the 
LC-MS/MS proteomics-based GSEA (Figure 10 C), by elevated lysosomal mass (Figure 17 A-B), 
and by the increased protein expression of TFEB and TFE3, which are transcriptional activators of 
lysosomal biogenesis (Figure 17 C). Along with mitophagy, mitochondrial proteases and ubiquitin-
mediated proteasomal degradation represent the main paradigms of mitochondrial quality control 
(Sugiura et al., 2014). In a first-line defense, mitochondrial proteases degrade unfolded and oxidized 
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proteins within the matrix and intermembrane space (Tatsuta and Langer, 2009). In a second-line 
defense, OMM proteins, such as Mfn-1 and Bcl-2 family members, tend to be ubiquitinated and 
degraded by retrotranslocation and delivery to the cytosolic proteasome (Tanaka et al., 2010). Indeed, 
proteasomal removal of the OMM proteins Bak, Bcl-2 (Figure 17 D) and Mfn-1 (Figure 14 B) was 
observed in HUH7-R cells, whereas protein expression of the cytosolic Bax persisted (Figure 17 D).  
 
Figure 17. Lysosomal biogenesis and mitophagy are upregulated in HUH7-R(+) cells. (A) Induction of 
lysosomal biogenesis upon sorafenib resistance. For LysoTracker staining, concanamycin A (1 µM) pre-
treatment for 4 h was used as negative control. Scale bars indicate 50 µm. (B) Flow cytometric quantification 
of the lysosomal mass, normalized to the cellular volume (Figure S6) and to HUH7-WT. (C) Lysosomal 
biogenesis is activated in HUH7-R cells. Immunoblot analysis of TFEB and TFE3 was normalized to the 
respective protein load. (D) Selective degradation of OMM proteins in HUH7-R cells. Immunoblot analysis of 
apoptosis regulators Bak and Bcl-2, located on the OMM as well as the cytoplasmic protein Bak was 
normalized to the protein load. (E) Strongly diminished expression of ATG5 and SQSTM-1, which contribute 
to autophagosome formation. Immunoblot analysis of proteins involved in autophagy was normalized to the 
protein load. (F) HUH7-R(+) cells have highest capacity of starvation-induced mitophagy. Cells were 
incubated with HBSS for 6 h before mitochondrial mass was assessed by flow cytometry and normalized to 
the untreated control of HUH7-WT cells. Values denoted as ± SEM, n=3, *p<0.05 (ANOVA). 
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Despite the presumably impaired autophagosome formation in HUH7-R cells (Figure 17 E), 
mitophagy remained inducible under starvation conditions prior to sorafenib withdrawal  
(Figure 17 F). Thus, starvation induced mitophagy is possibly mediated by direct translocation of 
mitochondrial cargo to the lysosomes via vesicular transport (Sugiura et al., 2014). In summary, we 
suggest that sorafenib-induced ER-stress not only contributes to the unfolding or oxidation of certain 
OMM proteins, but also leads to an overall impairment of mitochondrial function and consequent 
removal of those by the overlapping activity of different mitochondrial degradation pathways. Upon 
complete mitochondrial dysfunction, as indicated by fission or depolarization, the entire organelle is 
targeted to the autophagosome (Pickles et al., 2018). Autophagosome formation is thereby initiated 
with involvement of Beclin-1 (BECN-1), elongated by the ATG5-complex and subsequently 
conjugated to the adaptor of ubiquitinated proteins SQSTM-1 (Figure 18 A) (Kang et al., 2011). 
Nonetheless, due to insufficient levels of LC3II-positive, mature autophagosomes under sorafenib 
treatment (Figure 18 B), defective mitochondria were only efficiently degraded after 96 h of growth 
resumption. Inhibition of autophagy by 3-MA, however, was able to prevent mitochondrial 
degradation and significantly rescued superoxide levels upon rebound growth (Figure 18 C;  
Figure S7 A-B). Further, the recovery of intact mitochondrial mass in HUH7-R(-) cells indicates 
mitochondrial biogenesis after sorafenib withdrawal from HUH7-R(+) cells (Figure S7 C).  
 
Figure 18. Autophagic degradation of damaged mitochondria upon tumor relapse. (A) Illustration 
showing the involvement of BECN1, SQSTM-1, ATG5 (Figure 17 E) and LC3II in autophagosome formation. 
(B) Autophagic flux is increased in HUH7-R(-) cells. Immunoblot analysis for mature autophagosomes (high 
LC3II protein levels) was normalized to the protein load and to HUH7-WT (ANOVA). (C) Damaged 
mitochondria are degraded within 96 h of rebound growth. Mitochondrial mass was assessed by flow cytometry 
upon rebound growth for 144 h every 24 h and normalized to the cellular volume (Figure S6) and to HUH7-WT 
(left) (ANOVA). Superoxide levels were measured by flow cytometry upon 72 h of sorafenib withdrawal with 
inhibition of autophagy by 3-MA (5 mM) and normalized to the cellular volume (Figure S6) and to HUH7-WT 
(right) (t-test). Values denoted as ± SEM, n=3, *p<0.05, **p<0.01. See also Figure S7 B-C.  
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Even though sorafenib-resistant cells lack ATG5, elevated levels of mature autophagosomes were 
observed in HUH7-R(-) cells, which correlates with low levels of apoptosis (Figure 19 A). However, 
in contrast to HUH7-R(+) cells, HUH7-R(-) cells obtained reduced colocalization of mitochondria 
with lysosomes, indicating diminished mitophagy (Figure 19 B; Figure S8 A). Thus, we hypothesize 
that in addition to mitochondrial biogenesis, an ATG5-independent mechanism of autophagy 
contributes to increased cell survival upon growth resumption (Figure 19 C-D; Figure S8 B). It was 
previously reported that upon ATG5-independent autophagy, the Rab9 protein may replace the 
function of LC3 in autophagosome formation (Nishida et al., 2009). However, no alterations in Rab9 
localization were observed in HUH7-R compared to HUH7-WT cells (Figure 19 E, Figure S8 C). 
 
Figure 19. Growth resumption: Proapoptotic vs. prosurvival autophagy. (A) Increased autophagy was 
accompanied by decreased apoptosis. Flow cytometric quantification of apoptosis of HUH7-R(+) vs. 
HUH7-R(-) cells is shown (t-test). (B) Colocalization (yellow) of mitochondria and lysosomes indicates 
mitophagy in HUH7-R(+) cells. Merged images of LysoTracker (red) and MitoTracker (green) live cell 
imaging are shown (see also Figure S8 A). Scale bar indicates 50 µm. (C) Combined inhibition of 
mitochondrial biogenesis and autophagy results in additive growth inhibition. Cells were stimulated with 3-MA 
alone (control) or in combination with tigecycline (TGC), chloramphenicol (CHA) or MitoBlock-6 (MB6) for 
72 h upon rebound growth (the use of TGC, CHA and MB6 is specified in chapter 4.5 and chapter 6.1.3.1). 
The cell number was assessed by crystal violet staining and normalized to the 3-MA-treated control (for 
calculation of the Bliss value (BV) see Figure S8 B) (ANOVA). (D) ATG5 protein level of HUH7-R(-) cells 
was not regained after sorafenib withdrawal. Protein expression was assessed upon 72 h and 144 h of rebound 
growth (see also Figure 17 E). (E) Rab9 localization remained unchanged upon growth resumption. Cells were 
transiently transfected with Rab9-GFP expressing plasmid (Figure S8 C) and living cells are shown. Scale bar 
indicates 20 µm. Values shown as ± SEM, n=3, **p<0.01, ***p<0.001, ****p<0.0001. See also Figure S8. 
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4.4 Mitochondria are newly biosynthesized upon rebound growth 
4.4.1 PGC-1α-dependent mitochondrial biogenesis in sorafenib-resistant cells 
Mitochondrial quality control pathways not only eliminate damaged mitochondrial proteins, 
mitochondrial patches or the entire organelle by mitophagy but also renew components by adding 
proteins and lipids through biogenesis, collectively resulting in mitochondrial turnover (Pickles et 
al., 2018). Considering that a re-establishment of the respiratory functionality (Figure 15 C-D) and 
an initial increase in mitochondrial mass (Figure 18 C) were observed upon rebound growth, we 
hypothesized that mitochondrial biogenesis occurs in an early phase after sorafenib withdrawal. 
ER-stress was shown to increase intracellular Ca2+-levels (Figure 20 A), which despite damaging 
mitochondria, induced protein expression of the key-regulator of mitochondrial biogenesis, 
peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1α) (Figure 20 B).  
 
Figure 20. Mitochondrial damage correlates with elevated PGC-1α protein expression. (A) Free 
intracellular Ca2+ strongly increased in HUH7-R(+) cells. Flow cytometric quantification of intracellular Ca2+ 
with normalization to the cellular volume (Figure S6) and to HUH7-WT. (B) Induction of transcription and 
protein expression of PGC-1α in HUH7-R cells. mRNA (left) and protein expression (right) of PGC-1α were 
normalized to HUH7-WT. Values denoted as ± SEM, n=3, *p<0.05, **p<0.01, ****p<0.0001 (ANOVA). 
PGC-1α is a transcriptional coregulator, which is posttranslationally modified by cellular metabolic 
sensors and thereby regulates homeostasis during bioenergetic crises by integrating mitochondrial 
and fatty acid biogenesis, oxidative phosphorylation and adaptive thermogenesis (LeBleu et al., 
2014). In fact, PGC-1α is activated through phosphorylation by the mediator of cellular energy 
depletion, AMP-activated protein kinase (AMPK), and by p38 MAPK-signaling (Figure 21 A). 
Secondary to activation, PGC-1α was found to translocate to the nucleus in HUH7-R cells for 
becoming transcriptionally active (Figure 21 B-C). Elevated PGC-1α mRNA levels were also found 
in an ectopic murine xenograft in vivo, with significantly higher PGC-1α mRNA expression in 
sorafenib-resistant HUH7-R(-) tumors of mice, which were not treated with sorafenib (Figure 21 D). 
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Figure 21. Mitochondrial biogenesis occurs in a PGC-1α-dependent manner. (A) Phosphorylation of the 
metabolic sensors AMPK and p38 MAPK, required for the activation of PGC-1α and subsequent nuclear 
translocation. Immunoblots were normalized to the respective protein load and to HUH7-WT. (B) Schematic 
illustration of the PGC-1α activation cascade for induction of mitochondrial biogenesis in response to altered 
metabolic requirements and elevated cytosolic Ca2+-levels. (C) PGC-1α is activated in sorafenib-resistant cells 
and translocated to the nucleus, as revealed by immunostaining. Scale bars indicate 40 µm. (D) In contrast to 
their parental HUH7-WT cell line, PGC-1α mRNA-expression of HUH7-R is modified by sorafenib treatment 
in vivo. PGC-1α mRNA-levels in resected tumors of the previously presented ectopic mouse xenograft  
(Figure 7) are normalized to the mean of HUH7-WT expression. Values denoted as ± SEM, n=3, *p<0.05, 
****p<0.0001 (ANOVA). 
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4.4.2 Recovery of mitochondrial integrity upon rebound growth with adaptions of the 
HUH7-R(+) lipidome towards increased cardiolipin biosynthesis  
As we demonstrated the simultaneous occurrence of mitochondrial degradation and biogenesis 
pathways upon rebound growth, we suggested an overall renewal of the mitochondrial integrity and 
morphology. Indeed, TEM of sorafenib-resistant cells revealed severe mitochondrial damage in 
HUH7-R(+) cells when compared to HUH7-WT cells and complete mitochondrial recovery within 
72 h of growth resumption. In these newly biosynthesized mitochondria, prominent cristae suggested 
high respiratory activity (Figure 22 A). Mitochondrial biogenesis was also supported by a 
LC-MS/MS-based lipidomics analysis comparing HUH7-R(+) to HUH7-WT cells. On the one hand, 
lipidomics analysis confirmed the strongly reduced fatty acid (FA) metabolism as previously 
observed by proteomics screening (Figure 10 B). The reduction of FA synthesis was indicated by a 
drastic decline of activated Acyl-CoA-species (ACAs) to 4.6% of the total ACA-level in HUH7-WT 
cells, whereas the relative amount of free fatty acids (FFA) remained unchanged (Figure 22 B; 
Figure S9 A). ACAs are intermediates and products of the mitochondrial β-oxidation and essential 
for FA synthesis (Schulz, 1991). Thus, when the FA synthesis is decreased, a reduced abundance of 
various phospholipid subspecies is the consequence (Figure 22 C). However, on the other hand, 
levels of the phospholipid phosphatidylglycerol (PG) were significantly higher in HUH7-R(+) cells 
compared to HUH7-WT (Figure 22 C). PG is the precursor metabolite of cardiolipin, which is 
exclusively integrated into the IMM. In the IMM, cardiolipin acts as an essential constituent for 
cristae formation and contributes to energy conversion via respiration. Thus, cardiolipin represents a 
hallmark lipid of mitochondrial biogenesis (Dudek, 2017). Moreover, we found that sustained 
sorafenib exposure led to adaptions in lipid saturation and FA chain lengths. A significant increase 
in long chain FAs was observed for phosphatidylcholine (PC) and phosphatidylserine (PS), which 
are the main components of the cellular membrane (Figure S9 B). Importantly, intracellular ROS is 
known to attack polyunsaturated fatty acids (PUFAs), thereby initiating lipid peroxidation 
(Esterbauer et al., 1991). This results in the formation of aldehyde byproducts that diffuse from their 
site of origin and amplify the effects of oxidative stress (Browning and Horton, 2004). Interestingly, 
in a presumably protective mechanism, the abundance of PUFAs was reduced in HUH7-R(+) cells 
(Figure S9 C), whereas the activity of ROS neutralizing peroxisomes was upregulated, which is 
indicated by a massive increase of ether-phospholipids (Figure S9 D-E) (da Silva et al., 2012).   
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Figure 22. Mitochondrial renewal upon rebound growth by induction of mitochondrial biosynthesis. 
(A) Damage of mitochondrial integrity in HUH7-R(+) and regeneration after sorafenib withdrawal. TEM was 
performed for mitochondria of the HUH7 rebound cell model. Scale bars indicate 1 µm. (B) Breakdown of 
fatty acid (FA) synthesis in HUH7-R(+) cells compared to HUH7-WT. MS-based lipidomics of HUH7-WT 
and HUH7-R(+) cells is shown. The absolute amount of free fatty acids (FFA) and acyl-Co A species (ACA) 
of HUH7-R(+) cells was normalized to HUH7-WT. The heatmap of ACA subspecies is color-coded according 
to the relative abundance in HUH7-R(+) cells compared to HUH7-WT from blue (0%) to white (10%) to red 
(100%) (t-test). (C) The cardiolipin precursor PG was significantly increased in HUH7-R(+) cells. Lipidomics 
analysis of HUH7-WT and HUH7-R(+) cells with the normalized abundance of phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphaditylglycerol (PG) 
and sphingomyeline (SM) to HUH7-WT is shown (ANOVA). Values denoted as ± SEM, n=3 for A, n=5 for 
B and C, *p<0.05, **p<0.01, ***p<0.001. See also Figure S9. 
Summarizing, sustained sorafenib exposure has been shown to impair mitochondrial integrity and 
functionality, as well as the abundance of ETC subunits required to fuel tumor growth resumption. 
Given that the mitochondrial renewal upon rebound growth is essentially driven by the induction of 
mitochondrial biogenesis, targeted inhibition of the regeneration of the mitochondrial ETS aroused 
as a potential target for second-line therapeutic strategies after sorafenib therapy termination. 
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4.5 Translation-inhibiting antibiotics impair rebound growth in vitro 
According to the endosymbiont hypothesis, mitochondria descend from α-protobacteria that were 
enveloped by pre-eukaryotic cells, providing an additional energy source and thereby conferring a 
competitive advantage (Sagan, 1967). Notably, mitochondrial ETC subunits are partially encoded by 
both the nuclear (nucDNA) and the prokaryotic-derived mtDNA (Taanman, 1999). With regard to 
its clinical potential, we hypothesized that suppressing biogenesis of mtDNA-encoded subunits by 
bacterial translation inhibiting antibiotics would block the metabolic switch and consequently the 
growth resumption of HUH7-R cells when released from sustained sorafenib treatment.   
Therefore, we tested the antiproliferative potential of inhibitors of mitochondrial biogenesis in 
HUH7-R cells. In addition to the S50-ribosomal subunit binding compounds chloramphenicol (CHA) 
and linezolid (Figure 23 A), the effectiveness of translation-inhibiting antibiotics was assessed with 
the S30-subunit binder tigecycline (TGC) (Figure 23 B-C). Further, we tested the experimental 
compound MitoBlock-6 (MB6), which inhibits the endogenous retroviral sequence 1 (Erv1)-activity. 
MB6 blocks the intermembrane space import and assembly protein 40 (Mia40)/ Erv1 redox-mediated 
import pathway, which translocates proteins for translation across the OMM (Dabir et al., 2013) 
(Figure 23 D). All tested compounds revealed the strongest inhibition of proliferation in HUH7-R(-) 
cells, whereas HUH7-R(+) cells were refractory towards therapy as previously shown (Figure 8 C). 
 
Figure 23. Inhibitors of mitochondrial biogenesis have highest effectiveness in HUH7-R(-) cells. Inhibition 
of proliferation is shown for (A) the ribosomal S50-subunit binding antibiotics chloramphenicol (CHA) and 
linezolid, (B) the ribosomal S50-subunit binding antibiotic tigecycline (TGC). (C) Illustrated mode of action 
of the antibiotic compounds tested in Figure 23 A-B. (D) Proliferation of HUH7-R(-) cells was also inhibited 
by the OMM import inhibitor MitoBlock-6 (MB6). Proliferation rates within 72 h of treatment for HUH7-WT 
(white), HUH7-R(+) (grey) and HUH7-R(-) (black), normalized to the respective untreated control are shown 
for A, B and D. Values denoted as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA).  
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4.5.1 TGC prevents the biogenesis of mtDNA-encoded ETC subunits and inhibits growth 
resumption by reducing aerobic glycolysis 
As TGC is a well-tolerated, approved by the Food and Drug Administration (FDA) and has been 
previously shown to possess anticancer potential, this drug was used for subsequent mechanistic 
studies in HUH7-R and RIL175-R cells (Skrtic et al., 2011). Indeed, TGC impaired the biogenesis 
of mtDNA-encoded subunits CI-NDUFB6 and CIV-MTCO1, thereby abrogating the recurrence of 
tumor growth dose-dependently (Figure 24 A-B). At a TGC concentration (25 µM) that significantly 
impaired cell proliferation but did not induce apoptosis, concomitant reduction in NAD+-recovery 
and increased lactate fermentation were observed, whereas cellular ATP-levels remained unaffected 
(Figure 24 C). Therefore, rebound growth appears to be limited by the reduction of aerobic glycolysis 
through a diminished NAD+/NADH ratio rather than by the cell’s energetic state.  
 
Figure 24. TGC impairs tumor growth resumption by inhibition of TCA cycle activity. (A) TGC inhibits 
the biogenesis of mtDNA-encoded ETC subunits. Immunoblot analysis of HUH7-R cells treated with TGC 
upon 72 h of sorafenib withdrawal was normalized to the respective protein load and to the untreated control. 
(B) TGC prevents rebound growth of HUH7-R cells second-line to sorafenib. Proliferation rate, assessed by 
impedance measurement is shown as cell counts (cell index) over time (top). Proliferation inhibition by TGC 
upon 72 h of treatment and equal treatment conditions as in Figure 24 C was determined by crystal violet 
staining and normalized to the untreated control. (C) Inhibition of growth resumption by TGC is caused by an 
insufficient TCA cycle activity. Assessment of apoptosis (percentage of whole cell count), NAD+/NADH ratio, 
intracellular ATP and extracellular lactate levels, normalized to untreated HUH7-R cells is shown. Values 
denoted as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA).   
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Both effects, the abrogation of tumor relapse and the increase in anaerobic glycolysis were confirmed 
by the antibiotic CHA and the mitochondrial import inhibitor MB6 in HUH7-R cells upon rebound 
growth. However, the mechanism of action, especially for MB6, might deviate from that of TGC 
(Figure 25 A-B). These findings highlight the role of the TCA cycle activity in mitochondria for 
providing intermediates as substrates for de novo synthesis of lipids and nonessential amino acids 
required for rebound proliferation after sorafenib withdrawal (DeBerardinis et al., 2008).  
 
Figure 25. Rebound growth inhibiting effect of TGC confirmed by CHA and MB6. (A) CHA and MB6 
prevent growth resumption of HUH7-R cells second-line to sorafenib and promote anaerobic glycolysis. 
Proliferation inhibition, intracellular ATP, extracellular lactate (normalized to untreated control) and apoptosis 
(percentage of whole cell count) of HUH7-R cells was assessed after treatment with CHA or MB6 upon 72 h 
of rebound growth. (B) Experiments with TGC were performed in a concentration range with comparable 
efficiency to CHA and MB6. Growth rates of HUH7-R cells treated with TGC, CHA or MB6 upon rebound 
growth were calculated from the cell counts over 72 h. Growth rates of impedance measurements were 
normalized to the untreated control. For proliferation curves over time of TGC treatment see Figure 24 B. 
Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001 (ANOVA).  
4.5.2 TGC impairs rebound growth by establishing auxotrophy for electron acceptors 
To scrutinize the limiting precursors required for the growth resumption of HUH7-R cells, we 
performed rescue experiments with various TCA cycle intermediates and precursor metabolites of 
related anabolic pathways. Surprisingly, among the metabolites tested, only pyruvate (PYR), 
α-ketoglutarate (AKG) and oxaloacetate (OAA) sufficiently restored rebound proliferation by 
reversing NAD+-depletion, whereas no rebound growth rescue was observed with Acetyl-CoA 
(ACoA), malate (MAL), citrate (CIT), cysteine (CYS) and aspartate (ASP) (Figure 26). We 
hypothesized a structural causality of successful growth rescue, as the alpha-ketoacids PYR, AKG 
and OAA are substrates of NAD+-regenerating dehydrogenases (Figure 27 A). 
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Figure 26. TGC prevents rebound growth by limiting NAD+-recovery. Rebound growth rescue upon TGC 
treatment was only obtained for alpha-ketoacids. HUH7-R cells upon 72 h of rebound growth were left 
untreated, treated with TGC, treated with PYR, AKG, OAA, α ketobutyrate (AKB), ACH, MAL, CIT, CYS, 
ASP or a combination of TGC and the respective metabolite. The viability was normalized to the respective 
untreated control. Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). 
To uncouple the role of TCA cycle intermediates as NAD+-regenerating electron acceptors from their 
role as carbon sources for cellular biogenesis, we supplemented TGC-treated HUH7-R cells after 
sorafenib withdrawal with the four-carbon metabolite α-ketobutyrate (AKB), which is not part of the 
TCA cycle. As shown previously, AKB acts as a substrate of dehydrogenases and oxidizes NADH 
to NAD+, while supplying cells neither carbon nor ATP (King and Attardi, 1989; Sullivan et al., 
2015). Indeed, AKB successfully restored rebound proliferation of HUH7-R cells to a similar extent 
as the electron accepting TCA cycle intermediates PYR, AKG and OAA (Figure 27 B-C). 
Altogether, this data suggest that inhibited biogenesis of mtDNA-encoded respiratory chain subunits 
upon TGC treatment leads to an impaired NAD+-recovery by the NDUF, further diminishing aerobic 
glycolysis in HUH7-R cells upon sorafenib withdrawal. Although a partial recovery of NAD+ by 
cytosolic lactate fermentation is possible, cells suffer reductive stress. Thus, mitochondrial NAD+ 
depletion renders the exogenous electron acceptor supply a limiting requirement for restoring growth 
resumption, which cannot be met by TCA cycle intermediates that only donate carbon. 
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Figure 27. AKB rescues rebound growth proliferation by restoring NAD+-levels. (A) Illustration of the 
impact of TGC on NAD+-turnover and TCA cycle activity. The ETC is constantly powered by NADH-turnover 
of the TCA cycle. A decreased biogenesis of mtDNA-encoded complex I subunits by TGC impairs NADH-
oxidation, leading to decreased TCA cycle activity and extracellular lactate fermentation. Substitution with 
extracellular electron acceptors (EAs) restores intracellular NAD+-levels and rescues rebound growth, as EAs 
are substrates of intracellular dehydrogenases. (B) Exogenous substitution with NAD+-regenerating EAs 
rescues rebound growth. Determination of viability of HUH7-R cells untreated, treated with TGC only or TGC 
in combination with PYR, AKG, OAA or AKB by subtraction of the metabolite specific toxicity when applied 
as single-treatment (Figure 26). The viability was normalized to the untreated control. (C) The cellular 
reductive stress upon TGC treatment is displayed by the NAD+/NADH ratio (left) and the NADP+/NADPH 
ratio (right). Both ratios were assessed in HUH7-R cells after sorafenib withdrawal and normalized to the 
untreated control. Values shown as ± SEM, n=3, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA).  
In order to substantiate the rebound growth inhibiting effect of TGC second-line to sorafenib, which 
was so far restricted to the HUH7-R cell model, key-experiments were additionally performed with 
sorafenib-resistant RIL175-R cells. RIL175-R cells obtained resistance to 10 µM sorafenib in the 
growth medium (Figure 6) and revealed a resumption of proliferation upon sorafenib withdrawal 
comparable to HUH7-R cells (Figure S10). Importantly, the effect of TGC and the rebound growth 
rescue by AKB were confirmed by this alternative HCC rebound growth cell model (Figure 28). 
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Figure 28. RIL175 cells confirm the inhibition of rebound growth by TGC through electron acceptor 
depletion. (A) TGC inhibits the biogenesis of mtDNA-encoded ETC subunits in RIL175-R cells. Immunoblot 
analysis of RIL175-R cells treated with TGC upon 72 h of sorafenib withdrawal was normalized to the 
respective protein load and to the untreated control. (B) TGC highly efficiently prevents rebound growth of 
RIL175-R cells second-line to sorafenib. For proliferation curves over time of TGC treatment see Figure 24 B. 
(C) HUH7-R cells are more susceptible to the inhibition of rebound growth by CHA then RIL175-R cells. For 
proliferation curves over time of CHA (25 µM) treatment see Figure 25 B. (D) AKB rescues rebound growth 
upon TGC treatment in RIL175-R cells. For proliferation curves over time of TGC and AKB treatment see 
Figure S10. For (B), (C) and (D) proliferation rates, which were assessed by impedance measurement are 
shown as cell counts (cell index) over time (top). Growth rates of HUH7-R and RIL175-R treated upon rebound 
growth were calculated from the cell counts over 72 h and normalized to the untreated control (bottom). Values 
shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). See also Figure S10. 
 
Summarizing, we could demonstrate that translation-inhibiting antibiotics, such as TGC, efficiently 
prevent growth resumption of HUH7-R and RIL175-R cells after sorafenib withdrawal in vitro. 
Importantly, approved antibiotic compounds are generally characterized by favorable safety profiles 
with low incidence of adverse side-effects and good experience on dosing schedules. Thus, inhibiting 
the biogenesis of mitochondrial respiratory chain subunits by the antibiotic TGC may constitute a 
promising second-line therapeutic approach for advanced-stage HCC patients after sorafenib failure. 
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4.6 TGC promotes sustained mitochondrial damage 
Next, we aimed to investigate in detail how the diminished NAD+/NADH recovery under TGC 
treatment affects oxidative processes and prevents HUH7-R cells from undergoing rebound growth. 
It is known that despite the presence of glucose, glutamine is one of the most consumed nutrients to 
fuel oxidative TCA cycle activity. Thus, glutamine essentially contributes to cellular energy 
generation and biosynthesis, thereby driving tumor growth (Fan et al., 2013; Zielke et al., 1984). 
4.6.1 TGC abrogates tumor relapse-fueling oxidative glutamine metabolism 
To analyze the contributions of glucose and glutamine to tumor relapse after sorafenib withdrawal, 
we transiently silenced oxoglutarate dehydrogenase (OGDH) downstream of glutamine-derived 
AKG in the oxidative pathway, respectively isocitrate dehydrogenases (IDH2) downstream of 
glucose, but upstream of glutamine oxidation, with an efficiency of 81.2% and 90.5% (Figure 29).  
 
Figure 29. The role of glutamine oxidation in tumor relapse and the maintenance of cellular superoxide 
defense. (A) Transient gene silencing of the TCA cycle enzymes isocitrate dehydrogenases (IDH2) and 
oxoglutarate dehydrogenase (OGDH) upon rebound growth of HUH7-R cells. Immunoblot analysis of IDH2 
upstream and OGDH downstream of oxidative glutamine metabolism of the TCA cycle were normalized to 
the respective protein load and to the siLUC-transfected control. (B) Schematic illustration of the impact of 
IDH2- and OGDH silencing on the glucose and glutamine metabolism as well as the redox-mediated ROS 
production. Values denoted as ± SEM, n=3, ****p<0.0001 (t-test). 
Interestingly, suppression of OGDH expression impaired rebound growth and diminished the 
NAD+/NADH ratio upon sorafenib withdrawal comparable to 25 µM TGC. In contrast, both rebound 
growth and the NAD+ ratio remained unaffected by IDH2 silencing (Figure 30 A-B). In addition, 
OGDH protein levels, which were not directly regulated by TGC treatment (Figure 30 C), were 
significantly increased in HUH7-R(-) cells, whereas IDH2-abundance was reduced upon sorafenib 
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withdrawal (Figure 30 D). Thus, both the dependency of proliferation on OGDH activity and the 
increased OGDH protein abundance support an essential role of glutamine oxidation as a driving 
force for rebound growth. In turn, the ETS is substantially powered by NADH, which is provided by 
the glutamine-fueled oxidative TCA cycle (Fan et al., 2013). Therefore, NDUF activity is not only 
impaired by TGC but also by impairment of the TCA cycle through transient OGDH silencing. 
 
Figure 30. OGDH silencing impairs viability and NAD+ recovery upon rebound growth comparable to 
25 µM TGC. (A) Inhibited glutamine oxidation by OGDH silencing prevents tumor relapse whereas IDH2 
silencing per se has no effect on viability. Viability of HUH7-R cells was determined upon 72 h of rebound 
growth. Cells were transfected with siLUC, siOGDH, siIDH2 and left either untreated or treated with TGC. 
(B) OGDH silencing reduces NAD+ recovery by the NDUF. The NAD+/NADH ratio was assessed upon 72 h 
of rebound growth in HUH7-R cells, transfected with siLUC, siOGDH or siIDH2 and left either untreated or 
treated with TGC. Both viability (Figure 32 A) and the NAD+/NADH ratio were normalized to the siLUC-
transfected, untreated control. (C) TGC has no effect on IDH2 and OGDH protein levels. Immunoblot analysis 
of IDH2 and OGDH upon tumor relapse, untreated vs. treated with TGC is shown. (D) Increased protein 
expression of OGDH in HUH7-R cells. Immunoblot analysis of IDH2 and OGDH of the sorafenib-resistant 
HUH7 cell model is shown. Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001 (ANOVA). 
4.6.2 Oxidative glutamine metabolism provides intermediates for aspartate biosynthesis 
Herein, we demonstrated that abrogation of the oxidative TCA cycle critically impairs the NAD+ 
turnover by the NDUF, which is required for rebound proliferation of HCC cells. In a bidirectional 
manner, the NDUF oxidizes NADH to NAD+, thus, providing electron acceptors required to drive 
oxidative TCA cycle activity in order to generate biosynthetic intermediates for lipids, amino acids, 
and nucleotides. Among these precursor metabolites, especially aspartate was reported to be limiting 
for proliferation upon ETC deficiency or complex I inhibition (Birsoy et al., 2015; DeBerardinis et 
al., 2007; Sullivan et al., 2015). Although we confirmed that TGC hinders aspartate production, we 
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found that aspartate levels were not equally rescued by exogenous electron acceptors, and that no 
rebound growth rescue occurred by aspartate supplementation (Figure 31; Figure 26). Thus, 
aspartate alone was not limiting for growth resumption of HUH7-R cells after sorafenib retraction.  
 
Figure 31. Aspartate levels are not restored upon rebound growth rescue. (A) TGC treatment decreases 
the aspartate abundance. The intracellular aspartate level of HUH7-R cells was assessed upon TGC treatment 
with subsequent normalization to the untreated control. (B) AKG rescues growth resumption (Figure 27 B) 
independent of aspartate levels. Intracellular aspartate was assessed for HUH7-R cells untreated, treated with 
TGC or a combination of TGC with PYR, AKG or OAA. Aspartate levels were normalized to the untreated 
control. Values shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). 
4.6.3 Translation-inhibiting antibiotics disturb glutamine-dependent redox-balance and 
promote sustained mitochondrial damage 
Although aspartate does not directly limit rebound growth of HUH7-R cells, TCA cycle-derived 
aspartate or malate is exported to the cytosol, where it is converted to pyruvate to replenish NADPH. 
We found that the measured NADP+/NADPH ratio remains constant upon OGDH and IDH2 
silencing. However, no prediction on the mitochondrial and cytosolic distribution could be made. A 
diminished cytosolic NADP+/NADPH ratio may be partially covered by a high mitochondrial 
NADPH abundance. High mitochondrial NADPH levels, in turn, may reflect a low NDUF activity 
due to the enzymatic hydride transfer from NADH to NADP+ (Figure 32 A-B; Figure 27 C) (Altman 
et al., 2016). While the generation of NADH is dependent on NDUF activity, NADPH is an electron 
donor for biosynthetic processes that can transfer its reducing potential to glutathione (GSSG) for 
ROS elimination (Murphy, 2009). In fact, ROS levels were elevated by both OGDH silencing as well 
as TGC treatment and rescued by the ROS scavenger N-acetyl cysteine (NAC) (Figure 32 C-D). 
Moreover, impaired maintenance of redox homeostasis by inhibiting the biogenesis of the ETS was 
confirmed by CHA and MB6 treatment upon growth resumption (Figure 32 E). Thus, defective 
elimination of ROS by TGC treatment or abrogation of glutamine oxidation via OGDH silencing 
alters the integrity of mitochondrial cristae (Figure 32 F). This might not only prevent rebound 
proliferation of tumor cells but may also contribute to a long-term treatment benefit. 
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Figure 32. ROS-induced mitochondrial damage by OGDH silencing and antibiotic treatment upon 
rebound growth. (A) The NADP+/NADPH ratio remains constant upon OGDH-silencing. HUH7-R cells upon 
72 h of rebound growth were transfected with siLUC (Control), siOGDH or siIDH2 respectively treated with 
TGC. The NADP+/NADPH ratio was normalized to the siLUC transfected, untreated control. (B) Biogenesis 
of NADP is sensitive to TCA cycle inhibition. Total NAD and NADP levels of Figure 30 B and Figure 32 A 
were assessed and normalized to the siLUC transfected, untreated control. (C) Abrogation of glutamine 
oxidation increases ROS production. ROS levels were assessed for HUH7-R cells transfected with siLUC 
(Control), siOGDH or siIDH2 respectively treated with TGC. The ROS scavenger N-acetyl cysteine (NAC) 
was used as a negative control and ROS levels were normalized to the untreated, siLUC transfected control. 
(D) Increased ROS production confirmed by TGC treatment, and by (E) treatment of HUH7-R cells with CHA 
and MB6 for 72 h upon rebound growth is shown. NAC was used as a negative control (for Figure 32 D) and 
ROS levels were normalized to the DMSO-treated control. (F) TGC treatment and OGDH silencing increases 
ROS-mediated mitochondrial damage upon rebound growth. TEM images of HUH7-R cells untreated, treated 
with TGC or transiently transfected with siOGDH upon 72 h of rebound growth are shown. Scale bars indicate 
1 µm. Values denoted as ± SEM, n=3, *p<0.05, **p<0.01 (ANOVA).   
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4.7 TGC impairs resumption of tumor growth as second-line therapy 
to sorafenib in vivo 
4.7.1 TGC prevents tumor relapse and NDUF biosynthesis in short-term therapy in vivo 
The translation-inhibiting antibiotic TGC was previously shown to prevent rebound growth after 
sorafenib retraction in vitro by limiting the electron acceptor turnover, required for proliferation-
fueling glutamine oxidation. To assess TGC as a second-line therapy in vivo, we established an 
ectopic tumor mouse xenograft with stably luciferase-expressing HUH7-R-LUC cells, cultured in 
sorafenib prior to injection. We could confirm that TGC treatment also significantly prevented tumor 
relapse upon sorafenib withdrawal in vivo, with a tumor size as well as growth rate comparable to 
that of persistently sorafenib treated mice. Both sorafenib and TGC therapy were well-tolerated 
(Figure 33). The excised tumors were visually smaller in the TGC treated group, with a mean weight 
of 58.4 mg/tumor compared to 246.7 mg/tumor of the untreated group (Figure 34 A-B). 
 
Figure 33. TGC prevents rebound growth second-line to sorafenib in vivo. (A) TGC prevents tumor relapse 
in an ectopic tumor mouse model of HUH7-R(+)-LUC cells. Cells were cultured in sorafenib prior to injection. 
Mice were treated with 20 mg/kg sorafenib (Control), DMSO (Relapse) or 50 mg/kg TGC daily for 6 days. 
DMSO #2 was excluded from statistical analysis as no tumor was detected until day 6 post cell injection. Tumor 
volume and mouse weight were assessed by digital Caliper measurements at the indicated time points. 
(B) Growth rate determined as x-fold change of in vivo bioluminescence imaging performed at day 3 and day 
6 after HUH7-R(+)-LUC cell injection. The area under the curve (AUC) of luminescence counts was assessed 
for 20 min after 13 min of 0.3 g/kg luciferin injection for each mouse. (C) Images of in vivo bioluminescence 
imaging were taken 20 min after 0.3 g/kg luciferin injection (binning 4, min=150 counts; max=3000 counts). 
Values denoted as ± SEM, n=11 (n=10 for DMSO Control), **p<0.01, ****p<0.0001 (ANOVA). 
Results 
77 
 
 
Figure 34. TGC diminished CI-NDUFB6 expression of respected tumors in vivo. (A) Size of resected 
tumors at day 6 post cell injection of ectopic tumor mouse model (Figure 33). (B) Weight of resected tumors 
(Figure 33). (C) Significantly reduced protein expression of mtDNA-encoded CI-NDUFB6 subunit upon TGC 
treatment in vivo. Quantitative immunoblot analysis of ETC subunits respectively TCA cycle enzymes IDH2 
and OGDH from resected tumors (Figure 34 A). (D) Immunoblot analysis of resected tumors for the protein 
abundance of the ETC subunits, respectively (E) protein levels of the enzymes IDH2 and OGDH. The 
immunoblots were normalized to the protein load and to the mean band intensity per blot. Values denoted as 
± SEM, n=11 (n=10 for DMSO Control), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). 
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The impact of TGC on the biogenesis of mtDNA-encoded subunits in vivo was supported by a 
significantly reduced CI-NDUFB6 protein expression in resected tumors, whereas protein levels of 
nucDNA-encoded subunits remained unaffected (Figure 34 C). Sorafenib withdrawal increased the 
abundance of nucDNA-encoded CV-ATP5A subunit, as demonstrated in vitro, but had no effect on 
CI-NDUFB6 expression in vivo (Figure 34 D). In contrast to previous in vitro studies, tumor relapse 
accompanied with elevated levels of the TCA cycle enzymes OGDH and IDH2 (Figure 34 E).  
4.7.2 TGC shows effectiveness in long-term treatment second-line to sorafenib in vivo 
A comparable ectopic tumor mouse xenograft implemented over 14 days, showed a strong initial 
effect of TGC treatment (Figure 35 A-B; Figure S11 A), though no alterations were observed in 
expression patterns of the ETC subunits, OGDH or IDH2, at the time of tumor excision  
(Figure 35 C-D; Figure S11 B-C). We suggest that protein expression of these proteins underlies 
regulatory dynamics over the time of therapy with the strongest effectiveness of TGC in an early 
phase after sorafenib withdrawal. Altogether, these in vivo results are consistent with the in vitro 
findings presented above, indicating the biogenesis of mtDNA-encoded ETC subunits as a selective 
and potent target for therapeutic intervention in a second-line setting of sorafenib-resistant HCC.  
 
Figure 35. TGC shows strongest inhibition of tumor relapse in initial phase. (A) TGC prevents tumor 
relapse under long-term treatment in ectopic tumor mouse xenograft of HUH7-R(+) cells. Mice were treated 
with a DMSO or 100 mg/kg TGC every second day for 14 days. Tumor volume and mouse weight were 
assessed at the indicated time points. (B) Tumor weight after resection is decreased in tendency. For images of 
the resected tumors at day 14 see Figure S11 A. (C) TGC has no effect on biogenesis of ETC subunits under 
long-term treatment. Immunoblot quantification (Figure S11 B) is shown for mtDNA- (CI-NDUFB6, 
CIV-MTCO1) and nucDNA-encoded subunits (CII-SDHB, CIII-UQCRC2, CV-ATP5A). (D) TGC has no 
effect on IDH2 and OGDH protein levels under long-term treatment. Immunoblot quantification of  
Figure S11 C is shown. Values denoted as ± SEM, n=11, *p<0.05 (t-test). See also Figure S11. 
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5 SUMMARY 
In the following, the key findings of this study are summarized in brief: 
1. We established a robust sorafenib resistance HCC model, revealing partial EMT and broad 
chemotherapeutic cross-resistance upon sorafenib exposure. Importantly, sorafenib withdrawal 
resensitized cells but was accompanied by an unfavorable relapse of tumor growth. 
2. MS-based proteomics and metabolic profiling of this cell model indicated that tumor growth 
resumption is driven by metabolic and mitochondrial alterations towards high ETS activity. 
3. By means of TEM and high resolution respirometry we found that sorafenib therapy mediates 
mitochondrial impairment. These damaged mitochondria are efficiently degraded upon 
rebound growth. Thus, mitophagy contributes to regeneration of the mitochondrial functionality. 
4. In addition to autophagic pathways, mitochondria are newly biosynthesized upon rebound 
growth due to starvation-induced activation of PGC-1α. Mitochondrial biogenesis was 
confirmed by increased biosynthesis of cardiolipin, which is a hallmark lipid of the IMM. 
5. The translation inhibiting antibiotic compound TGC impairs biogenesis of mtDNA-encoded 
ETC subunits, limiting the electron acceptor turnover by the NDUF and establishing auxotrophy 
for NAD+. TGC thereby prevents the therapy-limiting tumor relapse in vitro. 
6. The electron acceptor turnover is required for the proliferation-fueling glutamine oxidation. TGC 
impairs the cellular redox balance and promotes sustained mitochondrial damage. 
7. By demonstrating that TGC significantly impairs tumor relapse in vivo, we present a 
promising therapeutic approach for advanced-stage HCC second-line to sorafenib therapy.  
 
Figure 36. Overview of the key results obtained in this study.  
 
 
  
DISCUSSION 
Discussion 
81 
 
6 DISCUSSION 
Since the 1970s, the epidemic of HCC has spread beyond Eastern Asia, with almost a doubling of 
cases reported in the United States and Canada within the following two decades (El-Serag et al., 
2003). To date, sorafenib is still a standard of care first-line therapy for advanced-stage HCC. 
Nonetheless, with only 2% of patients showing a partial response, sorafenib resistance and 
consequent tumor relapse represent a serious challenge for prolonging the OS. In this study, we aimed 
to unravel unknown mechanistic features of sorafenib resistance with a special focus on tumor 
growth resumption after sorafenib withdrawal. Both sorafenib resistance and rebound growth 
contribute to the low therapeutic benefit of this drug as well as to the frequent failure of first-line and 
second-line therapeutic approaches in clinical trials (Kudo, 2017). Thus, clarifying the molecular 
basis of acquired sorafenib resistance and tumor relapse could help to find innovative therapeutic 
options for advanced-stage HCC patients. In the following, the contributions of evasive pathway 
signaling and autophagy to acquired resistance are discussed. Further, the role of metabolic 
reprogramming and mitochondrial biogenesis in rapid tumor relapse is highlighted and the rationale 
using translation-inhibiting antibiotics as second line therapy after sorafenib failure is reviewed. 
6.1 The mechanistic interplay conferring sorafenib resistance 
In this study, we developed a human HCC cell line with acquired resistance to sorafenib in a range 
equivalent to the serum concentration of patients on a recommended sorafenib intake of 400 mg, 
twice daily (Al-Rajabi et al., 2015). We showed that these sorafenib-resistant HUH7-R(+) cells were 
highly refractory to all tested chemotherapeutics when cultured in sorafenib but that they regained 
sensitivity when therapy was withdrawn. We suggest that acquired sorafenib resistance constitutes 
an interplay of diverse survival mechanisms, promoted by sustained MAPK pathway inhibition, 
ER-stress and lysosomal drug sequestration, which will be outlined in the following. 
6.1.1 Evasive PI3K/AKT signaling promotes EMT and glycolysis but prevents autophagy 
6.1.1.1 Invasive tumor growth triggered by PI3K/AKT-mediated EMT 
Preclinical and clinical observations indicate that limited sorafenib responsiveness may be caused by 
acquired therapy evasion in which EMT plays a decisive role (van Malenstein et al., 2013). EMT is 
triggered by compensatory PI3K/Akt-pathway activation upon sustained inhibition of the 
MAPK/ERK axis and was therefore reversible after sorafenib withdrawal (van Malenstein et al., 
2013). Nonetheless, HUH7-R(+) cells undergo only partial EMT with low but maintained 
E-Cadherin expression (Figure 9), suggesting that EMT does not solely mediate sorafenib resistance. 
However, cancer cell invasion, tumor malignancy and the OS of patients may be guided by the 
acquisition of EMT features (Marcucci and Rumio, 2018; Thiery, 2002). Thereby, matrix 
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metalloproteinases (MMPs) are involved in the spreading of metastasis via enzymatic degradation of 
extracellular matrix components (Son and Moon, 2010). The invasive potential is mainly dictated by 
MMP-2 and MMP-9, which were upregulated in HUH7-R(+) cells (Figure S3). In order to adapt to 
the microenvironment upon secondary tumor formation, metastasizing tumors are capable of 
reversing mesenchymal cells to epithelial derivatives via mesenchymal-to-epithelial transition 
(MET) (Kalluri and Weinberg, 2009). We found that upon sorafenib withdrawal HUH7-R(-) cells 
regained and even increased their epithelial phenotype (Figure 9 A-B), while resensitizing towards 
chemotherapy (Figure 8 C; Figure S1). However, in contrast to previous findings, HUH7-R(-) cells 
did not reverse their mesenchymal plasticity neither regain MMP-2 protein levels (van Malenstein et 
al., 2013). In summary, we hypothesize that EMT contributes to chemotherapeutic resistance of 
HUH7-R(+) cells and conveys an elevated invasive potential via MMPs.  
6.1.1.2 Sorafenib alters tumor microenvironment and promotes ER-stress 
ER-stress is the consequence of cellular adaptive mechanisms towards intrinsic and extrinsic 
stressors, such as oncogene activation, nutrient deprivation or chemotherapy (Avril et al., 2017). 
Thereby, the tumor microenvironment contributes to the limited cellular oxygen supply through 
inadequate vascularization, which was observed upon sorafenib therapy in vivo (Figure 7 C). The 
cancer cell adaptions to such milieu of hypoxia, pH variation and nutrient depletion include the 
unfolded protein response (UPR) and selection of drug-resistant cells, which circumvent the 
amplification of microenvironmental stress by anticancer agents (Mann and Hendershot, 2006). 
Thus, we hypothesize that HUH7-R cells induce secretion of MMPs and the EMT-associated 
transcription factors NFκB and interleukin-6 in the course of ER-stress, to sustain their metabolic 
demands and to adapt to a challenging environment. In turn, these transcription factors promote an 
EMT-like phenotype and may therefore increase the invasive potential of HUH7-R cells (Sheshadri 
et al., 2014). To date, the clinical evidence of ER-stress-mediated drug resistance is limited to breast 
cancer (Avril et al., 2017). Herein, we reveal a possible involvement in acquired sorafenib resistance 
of HCC by integrating EMT, autophagy and reprogramming of the glucose metabolism. 
6.1.2 Lysosomal sorafenib sequestration 
Besides promoting EMT and anaerobic glycolysis, evasive PI3K/AKT pathway signaling activates 
mTOR, which exerts an inhibitory effect on autophagy induction (Zhai and Sun, 2013). Indeed, 
HUH7-R(+) cells were found to possess low levels of mature autophagosomes (low LC3II lipidation) 
(Figure 18 B), which contributes to an insufficient mitochondrial degradation by macroautophagy 
and results in an accumulation of dysfunctional mitochondrial structures (Figure 15 C; Figure S7 C). 
In addition, sustained sorafenib exposure was found to drive lysosomal biogenesis. However, the 
accumulation of lysosomal mass in HUH7-R(+) cells implicates impaired autophagosomal 
degradation (Figure 17 A-C). Consequently, due to this perturbed autophagic flux, lysosomes that 
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are not fused with autophagosomes may be involved in drug sequestration and inactivation, thereby 
conferring sorafenib resistance (Abdel-Aziz et al., 2017). Previous studies indicated that 
P-glycoprotein (P-gp)-positive cytoplasmic vacuoles of lysosomal origin sequester the multikinase 
inhibitor sunitinib in HCC (Colombo et al., 2014). This process of drug entrapment describes the 
enrichment of hydrophobic weak base chemotherapeutics, such as doxorubicin and vincristine, in the 
lysosomal compartment. These drugs accumulate due to the highly acidic luminal pH of the 
lysosomes and are consequently prevented from reaching their therapeutic targets (Duvvuri et al., 
2005). To date, the lysosomal lumen alkalizers chloroquine and its derivate hydroxychloroquine are 
the only clinically available autophagy-inhibiting drugs. Both were shown to neutralize the lysosomal 
pH, block the fusion of autophagosomes with lysosomes and enhance tumor cell sensitivity of HCC 
to various chemotherapeutic agents in vitro and in vivo (Sheng et al., 2018; Shimizu et al., 2012). 
Thus, preventing lysosomal acidification independently of P-gp (Figure S2) evoked as a promising 
target for resensitizing HUH7-R cells towards sorafenib therapy and will therefore be subject of 
further investigations (Mueller et al., unpublished data). 
6.1.3 The choice between autophagy and apoptosis 
Importantly, autophagy is not solely controlled by the PI3K/AKT-axis as a panoply of other growth 
factors act upstream of mTORC1 and activate the ribosomal S6 kinase (RSK), protein kinase B 
(PKB), AKT and ERK. They all ultimately feed into the tuberous sclerosis complexes 1 and 2 (TSC1 
and TSC2), which are critical integrators of growth factors, nutrients and stress signals (He and 
Klionsky, 2009; Paquette et al., 2018). In the presence of nutrients or growth factors mTORC1 is 
activated and abolishes autophagy through phosphorylation and inhibition of TFEB and TFE3. In 
addition, mTORC1 inhibits the UNC-51-like kinases 1 (ULK1) complex, which acts with BECN-1 
and LC3 in the induction of autophagosome formation. In contrast, AMPK prevents mTORC1 
activation and promotes autophagy when the ATP/AMP ratio is low or upon activation of the 
DNA damage-induced p53 signaling (Paquette et al., 2018; Prieto-Domínguez et al., 2016). Thus, in 
response to the same selection of stress mediators, cells can preferentially undergo apoptosis or 
autophagy, a choice that is dictated by the intensity of the respective stimulus (Figure 37). 
Those stimulants of apoptosis and autophagy comprise ROS, the elevation of cytosolic Ca2+ and 
BH3-only proteins, such as BIM and BID (Maiuri et al., 2007). As shown previously, the PI3K/AKT 
signaling to mTORC1 is induced in HUH7-R(+) cells (Figure 9 E), but mTORC1 activation might 
be counter-regulated by phosphorylation of the AMPK (Figure 20 C) due to energy depletion 
(Figure 13 B) and excessive mitochondrial ROS production (Figure 15 A). In addition, sustained 
sorafenib exposure was found to promote lysosomal biogenesis by elevating TFEB/TFE3 protein 
levels (Figure 17 C) and the ER-stress-mediated Ca2+ release to the cytoplasm (Figure 16 B; 
Figure 20 A). Further, the abundance of the antiapoptotic Bcl-2 protein was reduced, possibly due to 
increased proteasomal degradation (Figure 17 D). Thus, sorafenib strongly intervenes with the 
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regulation of both apoptosis and autophagy in HUH7-R cells. Notably, Bcl-2 has drawn attention in 
regulating prosurvival autophagy by interacting with BECN-1 through a BH3-domain (Abdel-Aziz 
et al., 2017). However, competitive disruption of this inhibitory interaction by the BH3-only proteins 
BID and BIM, which activate the proapoptotic mediators Bax and Bak, can also stimulate autophagy 
(Maiuri et al., 2007). This switch from apoptosis to autophagy might play a decisive role in the 
growth resumption secondary to sorafenib withdrawal, as HUH7-R(-) cells reveal a decrease of 
cytosolic Ca2+ and mitochondrial ROS (Figure 15 A; Figure 20 A), resulting in reduced apoptosis 
but elevated levels of mature autophagosomes (Figure 19 A; Figure 18 B). Given that sorafenib 
retraction from HUH7-R cells promotes a switch from apoptosis to autophagy, a combinational 
treatment of antibiotics with autophagy inhibitors might be beneficial to increase the effect of TGC. 
 
Figure 37. The crosstalk of autophagy and apoptosis. In response to the same panoply of stressors cells can 
either undergo apoptosis or autophagy. Thereby, mTORC1 and Bcl-2 play a key role in the regulation of both 
processes, which are dependent on PI3K or MAPK pathway signaling and the cellular energy status.  
6.1.3.1 Combinational therapy of antibiotics with autophagy inhibitors 
Short-term sorafenib treatment has been previously shown to induce autophagy in various HCC cell 
lines, which is attained by increased LC3II lipidation and expression of the autophagy mediators 
Beclin-1, ATG5, ATG7 or LC3 (Shi et al., 2011; Shimizu et al., 2012). Thus, silencing of key 
autophagy genes or the combinational use of autophagy inhibitors could enhance the cytotoxic effect 
of sorafenib on HCC cells (Sheng et al., 2018). In fact, HUH7-R(+) cells obtained an increased 
colocalization of mitochondria with lysosomes, indicating autophagic sequestration of damaged 
mitochondria and subsequent fusion with lysosomes for degradation (Figure 19 B; Figure S8 A). 
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However, 3-MA was not capable of sensitizing HUH7-R(+) towards sorafenib treatment, suggesting 
that autophagosome formation was not induced in these cells and that conventional autophagy is not 
the key-mechanism of acquired sorafenib resistance (Figure S7 C). Nonetheless, LC3II lipidation 
and autophagic removal of damaged mitochondria were strongly induced upon growth resumption 
(Figure 18 B-C). Thus, we hypothesized that the inhibition of autophagy might constitute a possible 
adjuvant therapy to translation-inhibiting antibiotics, as both mitophagy and mitochondrial 
biogenesis contribute to the tumor relapse after sorafenib therapy termination. In fact, the 
combinational use of TGC with 3-MA obtained additive growth inhibition in HUH7-R(-) cells 
(Figure 19 C; Figure S8 B). However, autophagy inhibitors are solely recommended for acute 
application, as long-term use of those agents is limited due to intolerance and toxicity (Weinberg and 
Chandel, 2015). In summary, autophagy inhibitors additively enhance the effect of antibiotics as 
second-line therapy to sorafenib, but possess inferior relevance for clinical translation. 
6.1.3.2 Autophagy protein 5 (ATG5)-independent autophagy 
Autophagy is a tightly regulated process contributing to mitochondrial quality control with critical 
involvement of the ATG proteins. Among those, ATG5 was long thought to be indispensable for 
autophagy induction and vesicle formation (Sugiura et al., 2014). In addition to its role in autophagy, 
ATG5 can be cleaved by calpain cysteine proteases, thereby losing its proautophagic property and 
becoming a proapoptotic molecule (Maiuri et al., 2007). Surprisingly, although ATG5 silencing was 
shown to sensitize Mhcc97-L and PLc/PRF/5 HCC cells towards sorafenib therapy (Shi et al., 2011), 
HUH7-R cells lack ATG5 protein expression (Figure 17 E), which was not recovered upon sorafenib 
withdrawal (Figure 19 D). We hypothesized that degradation of the ATG5 protein might be the result 
of increased ER-stress in HUH7-R cells, which leads to elevated cytosolic Ca2+ levels that activate 
the ATG5-cleaving cysteine protease calpain and induce the UPR in these cells (Figure 16; 
Figure 20 A). The UPR aims at limiting the accumulation of misfolded proteins in the ER by 
transiently attenuating protein translation, by enhancing the ER folding capacity through enhanced 
transcription of local chaperones and by promoting protein clearance from the ER via increasing its 
degradation capacity (Avril et al., 2017). As damaged mitochondria were efficiently degraded upon 
rebound growth, HUH7-R cells were suggested to undergo ATG5-independent autophagy, which 
allows the degradation of organelles and formation of autophagosomes in the absence of ATG5 and 
ATG7 (Nishida et al., 2009). It has been previously reported that upon ATG5-independent 
autophagy, the Rab9 protein may replace the function of LC3 in autophagosome formation (Nishida 
et al., 2009). In conventional, ATG5-dependent autophagy, Rab9 mediates protein traffic between 
late endosomes and the trans-Golgi network (Lombardi et al., 1993). Nonetheless, no alterations in 
Rab9 localization were observed in HUH7-R compared to HUH7-WT cells (Figure 19 E; 
Figure S8 C). Thus, the mechanism of ATG5- and Rab9 independent autophagy of HUH7-R cells 
remains elusive and requires further investigations.  
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6.2 Metabolic reprogramming – a new hallmark of cancer malignancy? 
The acquisition of resistance and growth resumption following sorafenib therapy termination have 
been previously described (Ebos et al., 2009; van Malenstein et al., 2013), though the underlying 
metabolic mechanism has not been investigated thus far. In this study, we provided evidence that 
upon sustained sorafenib exposure, severe mitochondrial damage and ETC dysfunction render 
HUH7-R(+) cells dependent on glucose metabolism for ATP homeostasis and NAD+ recycling. In 
contrast, tumor rebound growth upon sorafenib withdrawal was accompanied by increased ETC 
activity and glutamine turnover to drive precursor metabolite biosynthesis by the oxidative TCA 
cycle. Herein, we emphasize renewal of the ETC and metabolic reprogramming as a driving force 
behind tumor relapse and as a potential target for therapeutic intervention second-line to sorafenib. 
6.2.1 Mitochondria as gatekeepers for sorafenib responsiveness 
Mitochondria are integral organelles required for cellular stress sensing and for conveying 
bioenergetic adaptation to environmental alterations. Recently, multiple studies have highlighted that 
mitochondria are not only indispensable for energy production and survival of the eukaryotic cell, 
but also play a role in malignant transformation (Vyas et al., 2016). Moreover, they are crucial 
regulators of the intrinsic (mitochondrial) pathway of apoptosis (Fulda et al., 2010).  
6.2.1.1 Bak-deficiency of HUH7-R cells might convey resistance to intrinsic apoptosis 
Proteins of the Bcl-2 family control apoptosis at the mitochondria through regulation of OMM 
permeabilization by the pore-forming proteins Bax and Bak. These proteins promote the release of 
cytochrome c and smac/DIABLO to the cytosol, leading to caspase activation and rapid cell death. 
Thus, OMM permeabilization is tightly regulated by the Bax/Bak activating BH3-only proteins BID 
or BIM, which are induced upon the ER-stress-mediated UPR (Glab et al., 2017). In addition, a 
changing ratio of Bcl-2 activators and repressors may result in cell death or in the appearance of drug 
resistance, as reported for sorafenib and regorafenib in the therapy of HCC (Tutusaus et al., 2018). 
Interestingly, both Bak and Bcl-2 protein levels were diminished in HUH7-R cells, whereas 
Bax-levels persisted (Figure 17 D). Evidence is given that activation preferences exist upon which 
BID preferentially activates Bak, while BIM preferentially activates Bax. Thus, cells lacking Bak, 
such as HUH7-R cells, are expected to be resistant towards agents that require BID activation for the 
induction of mitochondrial apoptosis. Those include DNA damaging chemotherapeutics and other 
agents that activate cell surface death receptors by the ligands FasL, TNF and TRAIL (Sarosiek et 
al., 2013). However, the MS-proteomics screening revealed that protein levels of the apoptosis 
executioner caspase-3 (CASP3), which is activated by both intrinsic and extrinsic pathways, were 
strongly increased in HUH7-R cells (22-fold higher in HUH7-R(-) vs. HUH7-WT; 4-fold higher in 
HUH7-R(-) vs. HUH7-R(+)) (Figure 11 A-B). This might be a regulatory consequence of the reduced 
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activation of intrinsic and extrinsic apoptosis due to Bak-deficiency. We hypothesized that 
HUH7-R(+) cells possibly undergo an alternative route of programmed cell death, termed ferroptosis, 
which is regulated by iron or ROS and induced by sorafenib treatment and ER-stress (Galluzzi et al., 
2018). Ferroptosis is morphologically characterized by mitochondrial abnormalities, involving the 
reduction of crista, increased mitochondrial membrane density and OMM rupture (Xie et al., 2016). 
In addition, ferroptosis leads to the accumulation of lipid peroxidation products and lethal iron 
metabolism-derived ROS, which are characteristics found in high abundance in HUH7-R(+) cells 
(Figure 15 A; Figure S4 B, D; Figure S9 D). 
6.2.1.2 The metabolic component in acquired drug resistance 
As mentioned above, the mitochondrial regulation of programmed cell death may involve a large 
metabolic component and also the overall therapeutic response may be influenced by the cellular 
metabolism and mitochondrial reprogramming upon chemotherapeutic treatment (Porporato et al., 
2017). Notably, evasive activation of the PI3K/Akt pathway by sorafenib physiologically promotes 
glucose uptake and turnover, promoting rapid but inefficient anabolism and lactate fermentation 
(Elstrom et al., 2004; Pfeiffer et al., 2001). Cancer cells partially adapt their metabolic demands under 
these conditions of nutrient deprivation, microenvironmental stress by the UPR, through activation 
of the hexosamine biosynthetic pathway. Thereby, glucose is converted to substrates for the O- and 
N-glycosylation of proteins, which improve protein folding, stability and cell adhesion (Avril et al., 
2017; Shental-Bechor and Levy, 2008). Indeed, the MS-proteomics screening revealed enhanced 
amino sugar metabolism in HUH7-R(+) cells possibly caused by sorafenib-induced ER-stress or 
nutrient depletion (Figure 10 C). In addition, previous metabolomics studies reported a higher 
demand for glucose in sorafenib-resistant leukemia cells (You et al., 2019) and an increased glucose 
flux into the PPP of sorafenib-resistant HCC cells. The study further reports elevated glutamine-
derived lipid biosynthetic pathways in these resistant HCC cells with a high tolerance to oxidative 
stress due to an elevated glutamine turnover (Kim et al., 2017). This observed phenotype therefore 
combines metabolic key-characteristics of sorafenib-resistant HUH7-R and RIL175-R cells upon 
sorafenib treatment respectively drug withdrawal conditions. Notably, the impact of the metabolism 
on resistance in vitro, may be amplified in patients by the antiangiogenic effects of sorafenib therapy, 
which reduces microvessel density and promotes intratumoral hypoxia and HIF-mediated cellular 
responses. Hypoxia favors the selection of resistant cells that are adapted to the oxygen-deficient 
microenvironment by their enhanced glucose turnover (Avril et al., 2017; Méndez-Blanco et al., 
2018; Zhai and Sun, 2013). Moreover, nutrient deprivation, growth factor withdrawal, hypoxia, 
ER-stress or ROS accumulation not only promote metabolic adaptions but have the ability to induce 
or modify autophagy via the nutrient sensor AMPK, which may also contribute to acquired drug 
resistance (He and Klionsky, 2009; Prieto-Domínguez et al., 2016).  
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6.2.2 The oncogenic potential of metabolic reprogramming 
As reviewed above (chapter 2.3.2) tumor suppressors and oncogenes have been reported to regulate 
the Warburg effect, which acts in cancer cells concurrently to respiration (Koppenol et al., 2011). 
Interestingly, mutations in metabolic enzymes appear to have vice versa oncogenic potential and 
specifically citric acid cycle enzymes, such as IDH1 and IDH2, are causally linked to familial and 
spontaneous cancers (Dang et al., 2009; Koppenol et al., 2011). Thereby, an IDH1 gain-of-function 
mutation catalyzes the NADPH-dependent reduction of AKG to the oncometabolite 2-hydroxy-
glutarate, which accumulates and contributes to the malignant progression of gliomas (Dang et al., 
2009). Further, a variety of studies proofed that isoforms of metabolic enzymes, which are 
preferentially expressed in cancer cells, are involved in metabolic reprogramming upon 
tumorigenesis by enhancing the glycolytic flux due to deviating enzymatic kinetics (Cassago et al., 
2012; Christofk et al., 2008). Thus, it is suggested that metabolites themselves can be oncogenic by 
altering cell signaling and blocking cellular differentiation (Ward and Thompson, 2012). 
6.2.2.1 Metabolic rewiring and tumor growth resumption 
Conceptual progress in the last decade has added the emerging neoplastic traits “reprogramming of 
energy metabolism” and “evading immune destruction” to the six commonly known hallmarks of 
cancer (Hanahan and Weinberg, 2011). Thereby, oncogenic activation may increase the 
mitochondrial metabolism to generate ATP and TCA cycle intermediates. These are redirected into 
anabolic pathways in order to accumulate cellular building blocks required for rapid tumor growth 
(Weinberg and Chandel, 2015). Given that TGC enhanced CV-ATP5A expression (Figure 24 A) and 
intracellular ATP levels at high concentrations (Figure 24 C), we conclude that mitochondrial ATP 
generation may not be crucial for rebound growth of HUH-R and RIL175-R cells. Among the TCA 
cycle metabolites provided by the mitochondrial metabolism, citrate is exported to the cytosol and 
supports lipid synthesis via ACoA, whereas nucleotide synthesis is driven by OAA (Weinberg and 
Chandel, 2015). It has been previously shown that following TKI withdrawal, tumor cells undergo a 
metabolic shift to de novo lipogenesis, which is associated with rapid tumor regrowth and accelerated 
metastatic dissemination (Sounni et al., 2014). This growth resumption involved upregulation of the 
fatty acid synthase (FASN), herein confirmed by volcano plot analysis through a 2.6-fold increase 
of this enzyme in HUH-R(-) cells in comparison to HUH-R(+) cells (Figure 11 A-B). To sufficiently 
supply tumors with TCA cycle intermediates, cells utilize glutamine, which is stepwise oxidized to 
AKG and OAA, subsequently (DeBerardinis et al., 2007). Therefore, glutamine is replenished by 
autophagy, a cellular process that supplies cancer cells with additional energy by degrading protein 
aggregates or damaged organelles, to sustain the mitochondrial metabolism and fast proliferation 
(Altman et al., 2016). It is assumed that, on the one hand, mTOR and EMT, which are active in 
HUH7-R(+) cells and, on the other hand, AMPK and autophagy negatively regulate each other 
(Marcucci and Rumio, 2018). Thus, sorafenib treatment impairs the initiation of autophagy, but 
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withdrawal conditions might reverse this phenotype, promoting glutamine supply and rapid growth 
recurrence (He and Klionsky, 2009; Zhai and Sun, 2013). In addition to the contribution of glutamine 
to the biogenesis of macromolecular building blocks, this amino acid is required to recycle reducing 
equivalents by the TCA cycle to drive ETC activity and to maintain ROS homeostasis (DeBerardinis 
et al., 2007; Sun, 2010). In fact, upon rebound growth, HUH7-R cells essentially rely on both ETC 
activity and glutamine oxidation (Figure 24; Figure 30 A). In summary, this study provided evidence 
that mitochondrial alterations are the key-drivers of tumor relapse following sorafenib treatment 
abrogation. Thus, we presented the inhibition of ETC renewal, which impairs glutamine oxidation, 
and consequently the supply of TCA cycle-derived anabolic metabolites as efficacious second-line 
therapy for HCC patients.  
6.2.2.2 Mitochondria confer metabolic requirements for aggressive tumor growth 
Complementing the role in energy generation, biosynthesis, signal transduction and the initiation of 
programmed cell death, it has been established that mitochondria are crucially involved in the 
regulation of stem cell identity and differentiation. In contrast to their differentiated counterparts, 
stem cells rely on glycolysis for ATP production and undergo a shift toward OXPHOS upon 
dedifferentiation (Margineantu and Hockenbery, 2016). In addition, dedifferentiation is accompanied 
by mitochondrial structural remodeling from fragmented organelles with poorly developed cristae, 
towards mature elongated mitochondria forming tubular networks (Skoda et al., 2019). This tendency 
of mitochondria to undergo fission by upregulation of Drp-1 and reduction of Mfn-1 has been 
associated with a high invasive potential, drug resistance, tumor recurrence and an overall poor 
prognosis in many human cancers (Anderson et al., 2018; Skoda et al., 2019). As these characteristics 
strongly resemble the mitochondrial morphology of HUH-R(+) cells and the dedifferentiating 
phenotype upon sorafenib withdrawal, we hypothesize that sustained treatment may induce stem 
cell-like properties in these cells (Figure 13 A; Figure 14; Figure 22 A). Of note, despite imbalances 
in mitochondrial dynamics, defective mitophagy and elevated respiration have also been linked to 
ROS overproduction and consequent metastatic dissemination (Porporato et al., 2017). Moreover, 
phosphorylation of the AMPK upon energy depletion, which was observed in HUH7-R(+) cells, 
promotes mitochondrial biogenesis via the transcriptional coactivator PGC-1α, thereby enhancing 
respiration and oxygen consumption (Figure 20 C-E). PGC-1α expression strongly correlates with 
the malignant potential of cancer cells and the formation of distant metastases, whereas silencing of 
PGC-1α suspends their invasive potential and attenuated metastasis without affecting proliferation, 
primary tumor growth or EMT (LeBleu et al., 2014). In summary, the aggressive growth of HUH7-R 
cells in vivo may be an interplay of PI3K/AKT induced EMT, hypoxia and the invasive potential 
conferred by mitochondrial fission, ROS overproduction and the metabolic activation of PGC-1α 
upon sorafenib exposure (Figure 7 D).  
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6.3 Antibiotics for anticancer therapy 
In this study, we efficiently prevented the growth resumption secondary to sorafenib by the bacterial 
translation-inhibiting antibiotic TGC, which suppresses the biogenesis of mtDNA-encoded ETC 
subunits. To date, the use of antibiotics has not been investigated in HCC or as a second-line therapy 
for any other type of cancer. Thus, we presented an innovative treatment approach for advanced-
stage HCC, which holds tremendous promise for clinical translation. In the following, the 
mechanistic background of TGC as a second-line therapy for sorafenib-resistant HCC is reviewed 
and the potential of a possible evaluation of new designation in this setting is discussed. 
6.3.1 Translation-inhibiting antibiotics impair glutamine oxidation 
The endosymbiotic theory hypothesizes, that mitochondria descended from α-protobacteria that were 
engulfed by eukaryotic cells, proving an additional energy source and thereby conferring a 
competitive advantage (Sagan, 1967). Thus, the respiratory chain is a relic of evolution and the ETC 
subunits are encoded by both eukaryotic (nuclear) and prokaryotic (mitochondrial) DNA. 
Translation-inhibiting antibiotics are known to suppress the biogenesis of mtDNA-encoded ETC 
subunits, which account in total for 13 essential subunits of the respiratory chain complexes I 
(7 subunits), III (1 subunit), IV (3 subunits), and V (2 subunits) (Scarpulla, 2006; Taanman, 1999). 
Given this broad involvement, we sought to determine which product of the mitochondrial 
metabolism was rate-limiting for growth resumption of HUH7-R cells after sorafenib withdrawal. 
6.3.1.1 The effect of TGC on aspartate biosynthesis  
In addition to producing ATP, the ETC oxidizes NADH to NAD+, which is required for driving 
aerobic TCA cycle activity to generate biosynthetic intermediates for lipids, amino acids, and 
nucleotides (Birsoy et al., 2015; DeBerardinis et al., 2007). The substitution experiments presented 
herein clearly demonstrated that TGC treatment established auxotrophy for exogenous electron 
acceptors that restore the proliferation-limiting glutamine oxidation by regenerating the oxidized 
cofactor NAD+ (Figure 27 B-C). Among the TCA-cycle derived precursor metabolites, aspartate has 
been previously reported to be limiting for proliferation in ETC-deficient cells (Birsoy et al., 2015; 
DeBerardinis et al., 2007; Sullivan et al., 2015). This amino acid plays an essential role in nucleotide 
biosynthesis and can be generated directly from glutamate via transamination and from AKG via 
both glutamine-dependent reductive carboxylation and oxidative pathways. Thus, aspartate 
production is limited by the electron acceptor NAD+ and the overall glutamate respectively AKG 
abundance (Fendt et al., 2013; Mullen et al., 2014). Indeed, TGC limited the carbon requirement of 
the TCA cycle for sufficient maintenance of aspartate synthesis (Figure 31 A). Nonetheless, aspartate 
substitution per se did not rescue the effect of TGC (Figure 26) and aspartate levels are mostly 
restored by pyruvate, which can form aspartate independently of NAD+ via carboxylation to OAA 
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and subsequent transamination (Figure 31 B; Figure 3) (Altman et al., 2016; Sullivan et al., 2015). 
Thus, aspartate depletion is not rebound growth limiting and might therefore occur independently of 
inhibited glutamine oxidation. It has been previously shown that the glutamine consumption may 
exceed the nitrogen demand of cancer cells, because glutamine also supports the use of glucose-
derived carbon for biogenesis (DeBerardinis et al., 2007). Thus, we hypothesize that HUH7-R(-) 
cells preferentially drive metabolism by glutamine oxidation. However, these cells also engage 
glucose derived OAA in biosynthetic pathways and aspartate depletion might be obtained by 
impaired aerobic glycolysis independently of the NDUF activity. 
6.3.1.2 TGC disturbs redox balance upon growth resumption 
Although the amino acid aspartate does not directly confer the growth inhibiting effect of TGC, it 
essentially contributes to redox homeostasis via the malate-aspartate shuttle, which exchange 
transfers reducing equivalents across the mitochondrial membrane without translocating carbon or 
nitrogen. Further, aspartate replenishes mitochondrial and cytosolic OAA for precursor metabolite 
biosynthesis (Figure 3) (DeBerardinis et al., 2007; Greenhouse and Lehninger, 1977). Cytosolic 
OAA is then metabolized via malate to pyruvate and NADPH, which provides the reducing power 
to maintain reduced glutathione pools for the antioxidant defense (Cairns et al., 2011). Thus, 
depleting cancer cells of aspartate and disrupting their malate-aspartate shuttle, damages 
mitochondria, results in the accumulation of ROS and consequently increases the genomic instability 
(Cheng et al., 2018). In general, glutamine metabolism provides an essential nitrogen source for 
nucleotide synthesis or the maintenance of nonessential amino acid pools. Among those, the amino 
acids glutamate, cysteine and glycine, which are required for synthesis of the ROS-neutralizing 
tri-peptide glutathione, are all critically dependent on glutamine input (Altman et al., 2016). In 
addition, abrogation of glutamine oxidation diminishes pools of malate and NADPH, both of which 
contribute to ROS elimination (DeBerardinis et al., 2008). The mitochondrial NADP+/NADPH ratio 
thereby reflects NDUF impairment via enzymatic hydride transfer from NADH to NADP+  
(Figure 27 C), which is possibly compensated by evasive NADPH-consuming reductive 
carboxylation in OGDH-silenced HUH7-R cells (Mullen et al., 2014). In contrast, cytosolic NADPH 
levels essentially rely on TCA cycle-dependent malate turnover (Figure 29 B) (DeBerardinis et al., 
2008). In summary, we could show that TGC treatment leads to electron acceptor depletion, which 
limits glutamine oxidation, required to promote tumor relapse and to generate directly ROS-
controlling products. Notably, elevated ROS levels are able to promote metabolic reprogramming, 
tumor growth and malignant progression, which might contribute to the rebound growth phenotype 
in HUH7-R and RIL175-R cells (Panieri and Santoro, 2016). Therefore, we conclude that disabling 
antioxidant defense mechanisms by TGC may constitute an efficient second-line approach to prevent 
tumor growth resumption after sorafenib retraction.  
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6.3.2 Up-to-date research and clinical experience 
As mitochondria descent from bacteria, a multitude of FDA-approved antibiotic classes target in 
addition to the bacterial also the mitochondrial biogenesis and therefore confer mild side-effects. 
However, antibiotics are well-tolerated in most patients and may be harnessed as therapeutic tools to 
address biogenesis and metabolic reprograming of mitochondria, which promotes malignant tumor 
progression. To date, there is scant knowledge on the therapeutic benefit of antibiotics in cancer, as 
most studies focus on administration for cancer-associated infections. Cancer patients are prone to 
acquire infections due to intensive myelosuppressive chemotherapy and surgical site infections that 
indicate the use of broad-spectrum antibiotics (Razzouk et al., 2006). Thereby, growing clinical 
evidence demonstrated that besides eradicating chemotherapy-related infections, antibiotics may 
have anticancer potential per se. In initial endeavors, TGC was shown to selectively induce cell death 
in a panel of leukemia cell lines (Skrtic et al., 2011), to target sub-forms of lung- and breast cancer 
(Jia et al., 2016; Jones et al., 2016) and to eradicate cancer stem cells, which were resistant to the 
TKI imatinib (Kuntz et al., 2017). Moreover, recent work demonstrated that the inhibition of 
mitochondrial translation by TGC, effectively targets renal cell carcinoma and sensitizes cells to 
chemotherapy (Wang et al., 2017). So far, studies with TGC have been performed on 15 solid or 
hematologic tumor types, resulting in reduced ETC activity while inducing intrinsic apoptosis, 
autophagy and oxidative damage (Table 27) (Dong et al., 2019).  
Table 27. TGC used for the treatment of different solid tumors. 
Cancer Type Biological phenotypes Target/ Signaling pathways 
Breast cancer* ATP↓, OXPHOS↓ Mitochondrial translation↓ 
Cervical SCC intrinsic apoptosis↑ Wnt/β-catenin↓ 
Gastric cancer autophagy↑ AMPK-mTOR↑ 
Glioma/ Neuroblastoma cell cycle arrest↑ AKT-FOXO3a↓ 
HCC/ NSCLC ATP↓, OXPHOS↓, ROS↑ Mitochondrial translation↓ 
Melanoma cell cycle arrest, invasion↓ Cytoplasmic p21↓ 
Multiple myeloma cell cycle arrest↑, autophagy↑ AMPK-mTOR↑ 
Oral SCC cell cycle arrest↑ CDK4-CCNE2↓ 
Ovarian cancer OXPHOS↓, ROS↑, cell cycle arrest↑,  
intrinsic apoptosis↑ 
Mitochondrial translation↓ 
Renal cell carcinoma intrinsic apoptosis↑ Mitochondrial translation↓, 
PI3K/AKT-mTOR↓ 
Retinoblastoma intrinsic apoptosis↑, angiogenesis↓, ATP↓ - 
*retinoblastoma susceptibility gene (RB-1)-deficient triple-negative breast cancer; NSCLC, non-small cell 
lung cancer; SCC, squamous cell carcinoma (Dong et al., 2019). 
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Until now, anticancer potential has been confirmed for the four mitochondria-targeting antibiotic 
classes, erythromycins, tetracyclines, glycylcyclines and chloramphenicol (Dong et al., 2019; Lamb 
et al., 2015). Further, combination therapies of TGC with the chemotherapeutics daunorubicin or 
cytarabine were found to exhibit an additive respectively synergistic cytotoxic effect on acute 
myeloid leukemia cells (Jaras and Ebert, 2011) and to enhance cisplatin efficiency in HCC (Tan et 
al., 2017). A first phase I dose-escalation study with TGC was performed in acute myeloid leukemia 
patients (Reed et al., 2016) and a clinical pilot study supported therapeutic success of the tetracycline 
doxycycline in targeting cancer stem cells of early breast cancer patients (Scatena et al., 2018). The 
possible usage of antibiotics in cancer therapy drew increasing scientific attention within the last 
years; however, mechanistic insights on their mode of action remain sparse.  
6.3.3 The rationale behind antibiotics as chemotherapeutic agents 
To date, a panoply of antibiotic classes are already clinically harnessed as chemotherapeutic agents, 
including the anthracyclines doxorubicin and daunorubicin (Hortobagyi, 1997), dactinomycins 
(Langholz et al., 2011), mitomycins (Volpe et al., 2010), bleomycins (Blum et al., 1973) and 
macrolides (Lagler et al., 2019). In addition, recent reports implicate that the modulation of the 
microbiome with antibiotics may affect the success of cancer immunotherapies (Dong et al., 2019; 
Luke and Pal, 2018). This study, however, focuses on the effect of antibiotics on mitochondria, which 
has been previously suggested to modulate energy production and apoptosis of cancer cells (Lamb 
et al., 2015). TGC is a low-cost FDA-approved antimicrobial agent, which belongs to the class of 
glycylcyclines and is used to treat complicated skin- and intraabdominal infections with a low 
incidence of side-effects (Bradford et al., 2005). TGC targets the S30 small ribosomal subunit, blocks 
the binding of aminoacyl-tRNAs to the A-site of the ribosome and exhibits broad spectrum anti-
bacterial activity against gram-positive and gram-negative bacteria (Thaden et al., 2017; Xu et al., 
2016). In contrast, CHA selectively binds to the S50 subunit and inhibits the activity of the peptidyl-
transferase, thereby preventing peptide bond formation and protein chain elongation (Figure 23 C). 
Importantly, both antibiotics prevent the translation of essential mitochondrial ETC subunits (Lamb 
et al., 2015). So far, a problem of targeting the mitochondrial metabolism in patients was that immune 
effector cells, in particular CD8+ cytotoxic T-lymphocytes, display remarkable metabolic similarities 
to malignant cells (Porporato et al., 2017). However, TGC specifically targets the mitochondrial 
ribosome (Skrtic et al., 2011; Wang et al., 2017) and impairs translation of the NAD+-recycling 
NDUF, which evoked to be a sensitive target for controlling tumor cell proliferation (King and 
Attardi, 1989; Wheaton et al., 2014). Moreover, TGC impairs the antioxidant defense of cancer cells 
and, thus, in adjuvant use, sensitizes tumors to chemotherapy (Panieri and Santoro, 2016). TGC may 
have additional direct targets that contribute to its biological phenotypes upon anticancer treatment 
that, however, remain still unknown. 
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6.3.4 Clinical relevance of this study 
6.3.4.1 Is the era of sorafenib ending? 
Sorafenib has evolved as the only systemic treatment for unresectable HCC, until 2018, when data 
from the phase III REFLECT trial revealed non-inferiority of the multikinase inhibitor lenvatinib in 
terms of OS (Table 28) (Kudo et al., 2018a). Further, lenvatinib increased the TTP from 3.7 to 7.4 
months (hazard-ratio (HR): 0.61; P<0.0001) and the PFS (Table 28). The overall safety profile was 
similar with both drugs, but patients treated with lenvatinib had a higher rate of hypertension (42% 
versus 30%) and a lower rate of hand-foot syndrome (27% versus 52%) than patients treated with 
sorafenib (Kudo et al., 2018a). Overall, the incidence of grade ≥3 treatment-emergent adverse events 
(57% versus 49%) was higher in the lenvatinib arm compared to sorafenib (Reig et al., 2018).  
Encouraging efficacy was also reported by a phase I/II trial of the immune checkpoint inhibitor 
nivolumab (CheckMate-459) in the first-line setting of unresectable HCC (Table 1), and most 
recently, synergism has been postulated for VEGFR-2 inhibitors and immunotherapy (El-Khoueiry 
et al., 2017; Personeni et al., 2019). Even though, a phase III trial with nivolumab failed to achieve 
statistical significance in terms of OS, improvement was observed, and further immunotherapy-based 
trials have been launched challenging first-line sorafenib (Table 1) (Liu et al., 2019). To date, the 
ongoing phase III trial, IMbrave150, compares a combination of atezolizumab (anti-PD-L1) and 
bevacizumab (anti-VEGF) to sorafenib in patients with advanced or metastatic HCC, who have not 
received prior systemic therapy. In fact, a preliminary outcome reported significantly prolonged OS 
and PFS with a comparable prevalence of grade 3-5 adverse events (Table 28) (Cheng et al., 2019). 
Table 28. Study endpoints of the REFLECT and the IMbrave150 phase III clinical trials. 
Study endpoints REFLECT trial IMbrave150 trial (ongoing) 
Treatment lenvatinib sorafenib atezolizumab + 
bevacizumab 
sorafenib 
 12 mg/day ≥60 kg or 
8 mg/day <60 kg; 
1x daily 
400 mg;  
2x daily 
atezo.1.2 g and 
bev. 15 mg/kg; 
21-day cycles 
400 mg;  
2x daily 
Group size n = 478  n = 476 n = 336  n = 165 
Median OS (95% CI)* 13.6 (12.1-14.9) 12.3 (10.4-13.9) NE 13.2 (10.4-NE) 
HR (95% CI) of OS 0.92 (0.79-1.06) 0.58 (0.42-0.79) 
P-value OS not significant 0.0006 
Median PFS (95% CI)* 7.3 (5.6-7.5) 3.6 (3.6-3.9) 6.8 (5.7-8.3) 4.3 (4.0-5.6) 
HR (95% CI) of PFS 0.65 (0.56-0.77) 0.59 (0.47-0.76) 
P-value PFS <0.0001 <0.0001 
*atezo., atezolizumab; bev., bevaciumab; CI, confidence interval; HR, hazard ratio; NE, non-estimable; PFS, 
progression-free survival; median OS and PFS are shown in months (Cheng et al., 2019; Kudo et al., 2018a). 
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In summary, lenvatinib evoked as first-line treatment alternative to sorafenib in unresectable HCC 
and also immunotherapy has the potential to be practice changing. However, an optimal treatment 
strategy that includes lenvatinib has still to be defined and the impact of different regional etiologies 
and ethnicities on treatment success remains elusive. The REFLECT trial enrolled 33% of patients 
from western countries and 67% from the Asia-Pacific region. As already shown for sorafenib in the 
SHARP (Llovet et al., 2008) and AP-trial (Cheng et al., 2009), therapeutic success may yield locally 
discrepant outcomes. Thus, major efforts are ongoing in order to identify molecular biomarkers that 
may guide the choice of a preferable first-line treatment strategy (Capozzi et al., 2019).  
Notably, as for sorafenib, most HCC patients also develop resistance to lenvatinib and, so far, there 
is no information on the mechanistic background. We hypothesize that the mechanisms of sorafenib 
resistance presented herein might be applicable for various multikinase inhibitors and, therefore, 
provide the basis for ongoing studies on lenvatinib resistance (Ardelt, M. A., unpublished data).  
Most recently, also novel second-line treatment options were developed for advanced-stage HCC, 
which, however, have been proven effective only in sorafenib-experienced patients. Although the 
spectrum of kinase inhibition generated by lenvatinib and sorafenib is overlapping, lenvatinib more 
potently inhibits VEGFR than sorafenib and additionally targets fibroblast growth factor receptors 
(FGFRs) (Yamamoto et al., 2014). Thus, post-study survivals and the efficacy of second-line 
therapies might differ when applied after first-line lenvatinib, which supports a favorable role of 
sorafenib until clinical evidence on the optimal drug sequencing after lenvatinib is provided. 
6.3.4.2 Second-line therapeutic options for sorafenib-experienced patients 
In 2017, the TKI regorafenib was granted approval as the first second-line therapy to sorafenib in 
advanced-stage HCC. The mechanism of action of both drugs is similar due to their structural 
similarity, but not identical. In comparison to sorafenib, regorafenib shows more potent activity 
against VEGFR, c-Kit, and partially blocks TIE2, which is not a target of sorafenib (Wilhelm et al., 
2011). Notably, the RESORCE trial only included patients who tolerated at least 400 mg/day of 
sorafenib (Bruix et al., 2017; Reig et al., 2018). However, it has been previously reported that the OS 
of patients who discontinued sorafenib because of adverse events is better than that of patients who 
discontinued sorafenib because of tumor progression (Figure 38) (Iavarone et al., 2015). Thus, 
regorafenib is not only limited to a subset of patients, but its efficiency may be overestimated by 
recruiting a biased study cohort with particularly poor OS. We suggest that this poor survival after 
treatment discontinuation indicates rapid tumor regrowth upon sorafenib retraction, making these 
patients potential candidates for a second-line therapy with translation-inhibiting antibiotics.  
Unfortunately, most of subsequent phase III trials failed to demonstrate improvement in OS or were 
successful only for a predefined subset of patients, such as REACH-2 (Table 1; chapter 2.1.2.2.2). 
In 2018, the phase III trial CELESTIAL was announced positive as the small molecule TKI 
cabozantinib significantly improved OS of both patients with progressive disease and sorafenib-
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intolerant patients. However, regarding safety, 62% of patients in the cabozantinib arm required dose 
reduction and 16% of patients discontinued therapy due to treatment-related hand-foot syndrome 
(17%), hypertension (16%), fatigue (10%) or diarrhea (10%) (Abou-Alfa et al., 2018a).   
Almost simultaneously, the immune checkpoint inhibitors nivolumab and pembrolizumab were 
conditionally approved by the FDA as second-line therapies for sorafenib-experienced HCC (El-
Khoueiry et al., 2017; Zhu et al., 2018a). Both drugs achieved durable responses, long-term survival, 
and favorable safety profiles in phase I/II trials (Capozzi et al., 2019). Although a phase III trial of 
second-line pembrolizumab (KEYNOTE-240) failed to reach significance, PFS was prolonged and 
mortality reduced by 22% (Figure 38) (Liu et al., 2019). Based on these promising results and 
positive preliminary endpoints of a CHECKMATE-040 cohort with 49 patients, the FDA further 
approved the combination of nivolumab and ipilimumab for HCC in march 2020 (FDA, 2020).   
Besides numerous recent approvals, immunotherapy for HCC is still in its infancy and yet faces 
limitations. Resistance is complex and involves mutations affecting immunogenicity of cancers 
(Wnt/CTNNB1 mutation in ~37% of patients), defective cytokine signaling, and upregulation of 
evasive immune checkpoint pathways (Xu et al., 2019). In addition, reports of hyperprogressors upon 
immunotherapy of advanced-stage malignancies have emerged (Champiat et al., 2017). Thus, the 
identification of biomarkers remains an area of active research to predict nonresponders and 
hyperprogressors, in order to provide personalized therapeutic strategies in the future. 
 
Figure 38. Overall survival of patient cohorts that were enrolled in clinical phase III trials of approved 
second-line treatment options after sorafenib discontinuation. The median overall survival (in months) 
with corresponding 95% confidence intervals (95% CI) for each experimental and placebo arm are illustrated.  
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6.4 Conclusion 
Acquired sorafenib resistance occurs frequently during therapy of HCC and is accompanied by a 
rapid recurrence of tumor growth after sorafenib treatment termination. In this study we aimed to 
characterize the underlying mechanism of sorafenib resistance and the unfavorable resumption of 
cancer cell proliferation to provide the basis for a potential second-line therapeutic approach.   
We provided evidence that sorafenib-resistant HCC exhibits mitochondrial dysfunction and chemo-
therapeutic cross-resistance, but resensitized upon sorafenib withdrawal. This suggests that a second-
line therapy following sorafenib retraction may be beneficial in comparison to an adjuvant treatment. 
Importantly, we found that a drastic renewal of mitochondrial structures and a metabolic switch 
toward high respiratory chain activity resulted in a relapse of tumor growth upon sorafenib 
withdrawal. Inhibition of the biogenesis of mtDNA-encoded ETC subunits using the antibiotic TGC 
impaired mitochondrial translation, the cellular antioxidant defense and limited the electron acceptor 
turnover required for proliferation-fueling glutamine oxidation. Thereby, TGC efficiently prevented 
the therapy-limiting tumor growth resumption in vitro and in vivo.  
So far, numerous alternative molecular-targeted agents have been developed and tested in clinical 
trials; however, all have failed to prolong OS compared to sorafenib in a systemic first-line setting. 
An improved OS was obtained with both regorafenib and ramucirumab second-line to sorafenib, but 
its applications are restricted to sorafenib-tolerant patients for regorafenib and patients with elevated 
AFP levels for ramucirumab, respectively. As second-line cabozantinib is associated with severe 
adverse-events, a second-line therapy to sorafenib with a reliable safety profile for sorafenib-
intolerant HCC patients still remains an urgent need. Thus, the results presented herein offer a novel 
promising second-line therapeutic approach for both sorafenib-resistant and sorafenib-intolerant 
advanced-stage HCC patients. Approved bacterial translation-inhibiting antibiotics are characterized 
by favorable safety profiles with low incidence of adverse side-effects and good experience on dosing 
schedules, therefore holding tremendous promise for clinical translation. In contrast to other 
available second-line options, tigecycline counteracts the metabolic origin of tumor relapse and may, 
thus, be a promising therapeutic option for sorafenib-experienced patients with progressive disease. 
In summary, we encourage a clinical evaluation of TGC for a new designation in advanced-stage 
HCC, to prevent tumor relapse and prolong the life expectancy after sorafenib failure. 
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7 SUPPLEMENTARY 
 
7.1 EMT-mediated reversible cross-resistance of HUH7-R cells 
 
Figure S1. Broad chemoresistance and resensitization after sorafenib withdrawal. (A) Cross-resistance of 
HUH7-R(+) cells upon sorafenib-exposure was also obtained for: chemotherapeutics as the microtubule-
binding alkaloid vincristine, the PARP-inhibitor ABT-888, the topoisomerase I inhibitor SN-38, (B) the 
mTOR-inhibitor everolimus as well as the MET-, respective EGF-receptor inhibitors tivantinib and gefitinib. 
Proliferation rates within 72 h of treatment were normalized to the untreated control. Values denoted as ± SEM, 
n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). Figure is related to Figure 8.  
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Figure S2. The MDR-proteins P-gp and MRP are not involved in the broad resistance spectrum of 
HUH7-R(+) cells upon sorafenib exposure. Calcein retention was assessed by flow cytometry and MDR-
positive vincristine-resistant CEM/VCR-R cells (Haber et al., 1989) were used as a positive control. Verapamil 
and cyclosporine A block MDR-transporters causing a shift in intracellular calcium retention. 
 
 
 
Figure S3. Matrix metalloproteinase (MMP)-2 and MMP-9 might be involved in conferring invasive 
potential to HUH7-R cells in vivo (Figure 7). (A) Immunoblot analysis of MMP-2 and (B) MMP-9, 
normalized to the protein load and to HUH7-WT. Values shown as ± SEM, n=3, *p<0.05 (ANOVA). 
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7.2 MS-proteomics screening and GSEA 
 
Figure S4. GSEA of the sorafenib-resistant rebound growth model. (A) Gene sets enriched in HUH7-R(-) 
cells compared to HUH7-R(+), (B) Gene sets enriched in HUH7-R(+) cells compared to HUH7-WT, (C) Gene 
sets enriched in HUH7-WT cells compared to HUH7-R(-) and (D) Gene sets enriched in HUH7-R(-) cells 
compared to HUH7-WT. The top 10 upregulated gene sets, ranked according to their nominal p-value 
(NOM p-val) are shown. Gene sets with NOM p-val<0.01 are highlighted. ES: enrichment score, NES: 
normalized enrichment score, FDR: false discovery rate. Figure is related to Figure 10. 
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Figure S5. Composition of protein classes largely maintained upon sorafenib resistance. (A) Similar 
distribution of protein classes obtained in HUH7-R(+) cells compared to HUH7-WT. Protein classes that are 
>1.5-fold altered are shown. (B) Decreased abundance of hydrolases is associated with the sorafenib resistance 
phenotype. Protein classes that are >1.5-fold altered in HUH7-R(-) cells vs. HUH7-WT are shown. Analysis 
was performed with pantherdb.org (Gene ontology database). Figure is related to Figure 12. 
7.3 Normalization of the cellular volume of HUH7-R cells 
 
Figure S6. Determination of normalization factor for cellular volume. (A) HUH7-R cells have a 
significantly decreased cellular volume compared to HUH7-WT cells. The cellular diameter of HUH7-WT and 
HUH7-R cells (left) was assessed via image analysis by the ViCell cell counter and used for calculation of the 
cellular volume (right). (B) The ratio of cellular volume of HUH7-WT and HUH7-R cells results in a correction 
factor used for normalization of cellular fluorescent intensities obtained by flow cytometry, cellular ATP levels 
and cellular oxygen consumption. Values shown as ± SEM, n=4, ****p<0.0001 (t-test). 
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7.4 Autophagy upon rebound growth 
 
Figure S7. Damaged mitochondria are degraded upon rebound growth. (A) Sorafenib causes excessive 
superoxide production in HUH7-R(+) cells. Superoxide levels were assessed by flow cytometry upon rebound 
growth at the indicated time points and normalized to the superoxide abundance of HUH7-R(+) cells. 
(B) HUH7-R(-) cells show highest susceptibility towards autophagy inhibition by 3-MA. Proliferation rates 
within 72 h of treatment were assessed for HUH7-WT, HUH7-R(+) and HUH7-R(-) cells and normalized to 
the untreated control. (C) Localization of MitoTracker dye indicates mitochondrial biogenesis in HUH7-R(-) 
cells. Membrane potential-dependent staining (MitoTracker, green) and immunostaining (COX4, red) of the 
mitochondrial network after fixation are shown. Cell nuclei were stained with Hoechst33342 (blue). Scale bar 
indicates 50 µm. Values denoted as ± SEM, n=3, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA). Figure is 
related to Figure 18.  
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7.5 ATG5-independent autophagy in HUH7-R cells 
 
Figure S8. Mitophagy of HUH7-R cells might be independent of autophagosome fusion to lysosomes. 
(A) No colocalization of mitochondria and lysosomes upon rebound growth. Colocalization (yellow) of 
MitoTracker (green) and LysoTracker (red) live cell staining indicates mitophagy and was assessed in 
HUH7-WT, HUH7-R(+) cells and over the course of rebound growth. Scale bar indicates 50 µm. 
(B) Synergism of 3-MA and inhibitors of mitochondrial biogenesis was calculated using the Bliss 
Independence model (Berenbaum, 1989). (C) Map of the Rab9-GFP plasmid. Figure is related to Figure 19.
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7.6 LC-MS/MS-based lipidomics analysis 
 
Figure S9. Adaption of the lipidome to the excessive ROS exposure in HUH7-R(+) cells. (A) The 20:3 
FAA subspecies was reduced in HUH7-R(+) cells. The abundance of FAA subspecies in HUH7-R(+) cells 
compared to HUH7-WT is shown. The heatmap (relative abundance in HUH-R(+) cells) is color-coded from 
blue (50%) to white (100%) to red (200%). (B) Increase of long-chain FAs as compensation for reduction of 
20:3 FFAs. The 18:0/16:0 ratio of FAs was normalized to the total level of phospholipids (PLs), comparing 
HUH7-R(+) cells to HUH7-WT cells. (C) Reduction of the 20:3 PL subspecies causes overall reduction of 
polyunsaturated fatty acids (PUFAs). PUFAs and 20:3 PL subspecies were normalized to the total abundance 
of PLs, comparing HUH7-R(+) cells to HUH7-WT cells. (D) High abundance of ether-phospholipids in 
HUH7-R(+) cells. Ether-PL subspecies were normalized to the total abundance of PLs, comparing HUH7-R(+) 
cells to HUH7-WT cells. (E) Overview of the saturation of all measured PLs in HUH7-R(+) cells in comparison 
to HUH7-WT is shown. The heatmap is color-coded from blue (0%) to white (100%) to red (200%).Values 
denoted as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001 (ANOVA). Figure is related to Figure 22. 
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7.7 The rebound growth model with sorafenib-resistant RIL175-R cells 
 
Figure S10. The sorafenib-resistant HCC rebound growth model with RIL175 cells. (A) RIL175 cells do 
not alter their morphology upon acquired sorafenib resistance. Phase-contrast microscopy of wild-type 
(RIL175-WT) and sorafenib-resistant (RIL175-R) RIL-175 cells. Scale bars indicate 200 µm. (B) Sorafenib 
withdrawal from RIL175-R cells continuously cultured in 10 µM sorafenib (RIL175-R(+)) leads to 
significantly increased resumption of proliferation. Cells upon rebound growth were cultured, as already 
described for HUH7-R cells, without sorafenib for 72 h before seeding (RIL175 R(-)). Proliferation rates, 
which were assessed by impedance measurement are shown as cell counts (cell index) over time (left). Growth 
rates of HUH7-R and RIL175-R treated upon rebound growth were calculated from the cell counts over 72 h 
(right). For proliferation curves over time of HUH7 cells see Figure 8 A. (C) Protein expression of NDUF is 
impaired in RIL175-R(+) cells and relapses upon sorafenib withdrawal. Immunoblot quantification of mtDNA- 
(CI-NDUFB6, CIV-MTCO1) and nucDNA-encoded ETC-subunits (CII-SDHB, CIII-UQCRC2, CV-ATP5A) 
was normalized to RIL175-WT (ANOVA). (D) Rebound growth rescue for the electron acceptors PYR, OAA 
and AKB confirmed in HUH7-R cells by impedance measurements. The calculated growth rates over 72 h for 
AKB are shown in Figure 28 D (bottom). Values are shown as ± SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 (ANOVA). Figure is related to Figure 6 and Figure 28. 
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7.8 In vivo long-term treatment with TGC second-line to sorafenib 
 
Figure S11. TGC has no impact on the protein expression of ETC subunits, IDH2 or OGDH upon 
long-term treatment (14 days). (A) The size of resected tumors (Figure 35 B) was decreased in tendency in 
the TGC treated group. (B) Immunoblot analysis of resected tumors for the ETC subunits and (C) the TCA 
cycle enzymes IDH2 and OGDH is shown. For quantification (Figure 35 C-D), immunoblots were normalized 
to the protein load and to the mean band intensity of the respective blot. Figure is related to Figure 35. 
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9 APPENDIX 
9.1 Abbreviations 
Table 29. List of abbreviations 
Abbreviation Full name 
2-DG 2-deoxy-D-glucose 
3-MA 3-methyladenine 
90Y yttrium-90 
ACA acyl-CoA-species 
ACoA acetyl-coenzyme A 
AKB α-ketobutyrate 
AKG α-ketoglutarate 
AMPK 5′ adenosine monophosphate-activated protein kinase 
AP Asia-pacific 
APS ammonium persulfate 
ASP aspartate 
ATG5/7 autophagy protein 5/7 
ATP adenosine-5’-triphosphate 
AUC area under the curve 
BCLC Barcelona Clinic Liver Cancer 
Bcl-X B-cell lymphoma X 
BECN-1 beclin-1 
BSA bovine serum albumin 
BV Bliss value 
CCCP carbonyl cyanide 3-chlorophenylhydrazone 
CHA chloramphenicol 
CI confidence interval 
CLT; LDLT cadaveric liver transplantation; living donor liver transplantation 
CoQ (Q) coenzyme Q (or ubiquinone) 
CST Cell Signaling Technologies 
CTB CellTiterBlue® 
CYP3A4 cytochrome P450 3A4 
CYS cysteine 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA; mt/nucDNA deoxyribonucleic acid; mitochondrial/ nuclear DNA 
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Drp-1 dynamin-related protein-1 
DTT dithiothreitol 
ECAR extracellular acidification rate 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EMT epithelial-to-mesenchymal transition 
ER endoplasmatic reticulum 
ERK extracellular signaling-regulated kinase 
ES enrichment score 
ETC/ ETS electron transport system/ electron transport chain 
FA; FFA fatty acid; free fatty acid 
FACS fluorescence activated cell sorter 
FAD; FADH2 oxidized flavin adenine dinucleotide; reduced flavin adenine dinucleotide 
FCS fetal calf serum 
FDR false discovery rate 
FGF(R) fibroblast growth factor (receptor) 
Flt-3 FMS-like tyrosine kinase-3 
FOCM folate one-carbon metabolism 
FS fluorochrome solution 
GIDEON global investigation of therapeutic decisions in HCC and of its treatment with 
sorafenib 
GLU glutamate 
GSEA Gene Set Enrichment Analysis 
GSSH; GSH reduced glutathione; oxidized glutathione 
HAIC hepatic arterial infusion chemotherapy 
HBV; HCV hepatitis B virus; hepatitis C virus 
HCC hepatocellular carcinoma 
HEPES 4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFSR hand–foot skin reaction 
HIF-1α hypoxia-inducible factor-1α 
HRP horseradish peroxidase 
HUH7-R sorafenib-resistant HUH7 cell line 
HUH7-R(-) HUH7-R cell line cultured without sorafenib for 96 h 
HUH7-R(-/X h) HUH7-R cell line cultured without sorafenib for X h 
HUH7-R(+) HUH7-R cell line persistently cultured in 10 µM sorafenib 
HUH7-R-LUC stable luciferase transfected HUH7-R cell line 
HUH7-WT wild type HuH-7 cell line 
IC50 half maximal inhibitory concentration 
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IDH1; IDH2 isocitate dehydrogenase 1; isocitate dehydrogenase 2 
IMM inner mitochondrial membrane 
JCRB Japanese Collection of Research Bioresources 
KEGG Kyoto Encyclopedia of Genes and Genomes 
MAL malate 
MAPK mitogen-activated protein kinase 
MB6 MitoBlock-6 
Mcl-1 myeloid cell leukemia 1 
MDR multidrug resistance 
MET mesenchymal-to-epithelial transition 
Mfn-1 mitofusin-1 
MMP matrix metalloproteinase 
MS mass spectrometry 
mTOR(C) mammalian target of rapamycin (complex) 
NAC N-acetyl cysteine 
NAD(P)+/ NAD(P)H oxidized/ reduced nicotinamide adenine dinucleotide (phosphate) 
NDUF NADH-ubiquinone oxidoreductase 
NNT nicotinamide nucleotide transhydrogenase 
NOM p-val nominal p-value 
OAA oxaloacetate 
OCR oxygen consumption rate 
OGDH oxoglutarate dehydrogenase 
OMM outer mitochondrial membrane 
OS overall survival 
OXPHOS oxidative phosphorylation 
PBS phosphate buffered saline 
PC; PE; PG; PI; PS phosphatidyl-choline; -ethanolamine; -glycerol; -inositol; -serine 
PCA; PDH pyruvate carboxylase; pyruvate dehydrogenase 
PDGF(R) platelet-derived growth factor (receptor) 
PEI percutaneous ethanol injection 
PFA paraformaldehyde 
PFS progression-free survival 
PGC-1α peroxisome proliferator activated receptor gamma coactivator-1 alpha 
P-gp P-glycoprotein 
PI propidium iodide 
PI3K  phosphatidylinositol-4.5-bisphosphate 3-kinase 
PMSF phenylmethylsulfonyl fluoride 
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PPP pentose phosphate pathway 
PST performance status test 
PUFAs polyunsaturated fatty acids 
PYR pyruvate 
qPCR quantitative polymerase chain reaction 
R2 coefficient of determination 
REFLECT clinical phase III trial: lenvatinib vs. sorafenib (Table 1; Table 28) 
RESOURCE clinical phase III trial: regorafenib vs. placebo (Table 1) 
RF(A) radiofrequency (ablation) 
RNA ribonucleic acid 
ROS reactive oxygen species 
rpm revolutions per minute 
RT room temperature 
SDS(-PAGE) sodium dodecyl sulfate (polyacrylamide gel electrophoresis) 
SEM standard error of the mean value 
SHARP sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol 
SIRT selective internal radiation therapy 
SM sphingomyeline 
SQSTM-1 sequestosome-1 (or: p62) 
T/E  trypsin/EDTA 
TACE transarterial chemoembolization 
TBS-T tris-buffered saline with tween20 
TCA tricarboxylic acid cycle 
TEM transmission electron microscopy 
TEMED N’, N’, N’, N’ tetramethylethylene diamine 
TGC tigecycline 
TGFβ transforming growth factor β 
THF tetrahydrofolate 
TKI tyrosine kinase inhibitor 
Tris trishydroxymethylaminomethane 
TSC1/2 tuberous sclerosis complex 1/ 2 
TTP time to progression 
ULK1 UNC-51-like kinases 1 
UPR unfolded protein response 
VEGF(R) vascular endothelial growth factor (receptor) 
WHO World health organization 
*abbreviations of clinical trials that are not used repeatedly are not listed (see Table 1). 
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